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ABSTRACT
TIMOTHY LEE TICKLE. Data mining the serous ovarian tumor transcriptome.
(Under the direction of DR. M. TAGHI MOSTAFAVI AND DR. JENNIFER
WALSH WELLER)
Ovarian cancer is the most lethal gynecologic cancer in the United States. If
caught in early stages, patient survival rate is 94%, late stage survival rates drop to
28%. It is because most cases are caught in late stages that high mortality is seen.
Correct diagnosis is dependent on the presence of symptoms: ∼90% of diagnosed ovar-
ian cancers are symptomatic. These symptoms tend to be unfocused and not acute.
The goal of this project is to develop a transcript-level data set measuring ovarian
tumor expression and associated paracrine signaling for later biomarker research. To
this end, laser capture microdissection was used with exon based oligonucleotide ar-
rays to measure the transcriptome of benign and malignant (Type II) serous ovarian
surface epithelial-stromal tumors. In addition to profiling tumor, surrounding stro-
mal tissue expression was measured to examine potential paracrine signaling. In total,
∼270 million measurements were performed using 50 microarrays. An initial analysis
was performed to measure quality, and to compare our measurements against known
ovarian cancer properties as established in the molecular genetics literature. Using
ontological annotation and de novo pathway generation methods, major trends were
defined in the data set including the following: apical surface and tight junction ac-
tivity, mitotic activity, tumor suppression in benign tumors, epithelial-mesenchymal
transitioning, known ovarian tumor oncogene activity, and evidence of paracrine sig-
naling. A list of differentially expressed transcripts was defined which may be explored
as biomarkers. The potential for meaningful future analysis is diverse. This data set
will contribute to the capacity of the cancer genetics community to perform high
resolution exploration of serous ovarian epithelial-stromal surface tumors, aiding in
developing better diagnostics and therapeutics.
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CHAPTER 1: INTRODUCTION
One may expect a cancer derived from a small organ not essential to living to
be easily managed. Although removal of the ovary requires invasive surgery and
maintaining physiological balance necessitates hormone therapy, both oopherectomies
(specifically in conjunction with abdominal hysterectomies) and hormone therapy are
common-place medical therapies, reinforcing the notion that this is a non-essential
organ. Indeed, when diagnosed as a stage 1 tumor, 5 year survival rates for patients
are at 90% [1]. Yet, 20,000 cases were estimated to occur in 2008 with 15,000 asso-
ciated deaths [1]. Why is ovarian cancer the most lethal gynecologic cancer in the
United States?
1.1 Ovarian Tumor Clinicopathologic Features
Ovarian cancer is elusive because the organ is inaccessible and early symptoms
are mild, if distinguishable at all. The reality of any cancer is grim; ovarian cancers
subtle symptoms and complex nature magnify its lethal potential. Empirical medicine
is based first on diagnosis through family history and patient symptoms and only
secondarily on diagnostic tests. For this disease, direct observation is not possible,
only symptoms remain to suggest further investigation, which is currently comprised
of exploratory surgery, carrying its own risks.
Women with ovarian cancer do not necessarily present symptoms, with perhaps
20% of diagnosed ovarian cancers being asymptomatic [2] [3]. Despite this, most
asymptomatic ovarian cancers are discovered at an early stage, with the exception of
serous cancers. Asymptomatic serous cancers are found to be in late stages in 55%
of diagnoses [4]. There is evidence that asymptomatic cancers are found as late stage
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not because of lack of detection but because of a separate trend, where late-stage
serous carcinomas have a shorter symptom duration than early-stage cancers [4].
Although deemed a “silent killer”, ovarian cancer usually does present symptoms,
but these are often so generic that they go unrecognized [5] [6] [7]. One retrospective
study of 200 ovarian cancer patients indicated that 90% of all cases present symptoms,
and 100% of advanced stages present one or more symptoms [8]. The National Can-
cer Institute (NCI) booklet on epithelial ovarian cancer defines common symptoms
as “pressure or pain in the abdomen, pelvis, back, or legs”, “a swollen or bloated ab-
domen”, “nausea, indigestion, gas, constipation, or diarrhea”, and “feeling very tired”
[9]. Although intended to increase awareness of ovarian cancer and prevention, these
symptoms are vague, and so often associated with other common illnesses, including
bladder infection and irritable bowel syndrome [6] that their impact is doubtful. Pa-
tients frequently self-diagnose symptoms as arising from age, menopause, or a benign
condition [3], and do not seek any clinical advice at all.
Evaluation of the above symptoms as predictors of diagnosis have shown some to
be marginally predictive [10]. The most predictive individual symptoms were found to
be unusual bleeding, masses, and “distended and hard abdomens”. When combining
these symptoms with the occurrence of pain, the index had a 74% sensitivity and 77%
specificity in prediction. More specifically, if stratified by histology, each epithelial
tumor histology has specific symptoms [4]. Patients with mucinous tumors most
commonly presented swollen abdomen (60%); patients with endometrioid tumors
presented bleeding (19%); patients with serous tumors presented abnormal bowel
symptoms (47%). All of these differences were significant statistically [4]. Still, it is
clear that ovarian cancer symptoms are vague, unspecific, and vary with histological
type, lending little help to diagnosis.
A peripheral molecular signature detectable in circulating fluid would be advan-
tageous, and considerable resources have been invested in discovering such markers.
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For a small cohort of patients, there appears to be an inherited genetic component;
BRCA-linked inheritance has been the most studied. This group is distinguished
by the mean age of diagnosis, 54 years rather than 62 years for sporadic cancer.
Pathological features of the tumors in those with the inherited predisposition were
not found to differ from sporadic tumors [11], but their advanced stage tumors had
a lower recurrence (50% less) and a better prognosis (p=0.004). This has sometimes
been ascribed to the inability of BRCA mutants to repair DNA damage, making
post-surgical remnants of tumors more susceptible to chemotherapy [11].
1.2 Ovarian Tumor Histology
According to the World Health Organization, primary ovarian tumors are sep-
arated into the following histological subtypes: surface epithelial-stromal tumors,
sex cord-stromal tumors, germ cell tumors, miscellaneous tumors, and lymphoid
and haematopoetic tumors [12]. The most common histological subtype is surface
epithelial-stromal tumors (occurring 90% of the time) [13]. Within this category
several subcategories exist, including serous, mucinous, endometrioid, clear cell, and
several less common types of tumors. A fascinating characteristic of these tumors
is their disparate histological features. Many of these tumors more closely resemble
tissues from other parts of the peritoneal cavity than they do normal ovarian surface
epithelium. For example, serous carcinomas most closely resemble the fallopian tube
epithelium, while endometrioid carcinomas resemble the uterine corpus; mucinous
tumor cells exhibit intracellular mucin and resemble endocervix cells, as well as the
gastric pylorus and intestine [14].
The differences in histopathological subtypes are mirrored by differences in clini-
copathological symptoms, and these extend from the phenotype to the genotype. A
study of the expression of 21 protein biomarkers in 500 ovarian carcinomas of a range
of subtypes (high-grade serous, clear cell, endometrioid, mucinous, and low-grade
serous) showed characteristic signatures for each subtype. The expression level dif-
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ferences were more effective in survival analysis predictions when treated as discrete
histological subtypes [15]. This heterogeneity raises serious questions about whether
the origin and progression of diseases classified as ovarian cancers truly belong in the
same disease category [15].
The study described here focused on a single subtype. Serous surface epithelial-
stromal tumors were selected, since they are the most commonly observed form (oc-
curring approximately 32% of the time) and are the most deadly (5 year relative sur-
vival rate of 42%) [13]. In addition to normal tissue the study included samples from
benign (neoplastic) serous tumors, which typically occur as cystadenomas and cyade-
nofibromas; these may be large unilocular cysts or multilocular cysts surrounding
pockets of serous fluid. Malignant tumors occur as adenocarcinomas, adenocarcinofi-
bromas, cystadenocarcinomas, and cystadenocarcinofibromas. Most predominantly,
as high grade carcinomas, these tumors have papillary structures, but a minority exist
as glandular structures or solid sheets of cells [14]. Malignant tumors may also be
composed of poorly differentiated cells [14]. An intermediate group exists, borderline
tumors, which resemble benign neoplasms but are a multilayer tissue structure with
infrequent evidence of proliferation [16]; they may be a step in progression between
neoplastic and malignant tumors since they sometimes exhibit stromal invasion, but
they do not necessarily progress to malignancy [14].
Staging is an additional method of classifying serous ovarian tumors, reflecting
the location of the tumor as noted during surgery. Stages range from I to IV, with
stage I indicating that the tumor was restricted to the ovary, II indicating pelvic
extension, III indicating metastasis to the peritoneal cavity beyond the pelvis, and
stage IV indicating metastasis outside of the peritoneal cavity [14]. Of the major
ovarian surface epithelial-stromal tumors, serous tumors are the only type in which
staging is least likely to be reported as stage I, with only 13% of cases reported as
belonging to that category, while mucinous, endometroid, and clear cell tumors are
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reported as stage I in 71% , 48% , and 63% of cases, respectively [16].
1.3 Serous Ovarian Surface Epithelial-Stromal Tumorigenesis
The events that set the stage for the initiation of tumorigenesis in ovarian surface
epithelial-stromal tumors are currently not known. Several mechanisms have been
proposed and are described here. While appearing contradictory at first, additional
information has revealed an unexpected common root, and there is reason to believe
that the initiating events will soon be understood.
Early evidence suggested that ovarian surface epithelial-stromal tumors originated
from the ovarian surface epithelium (hence the name). This came from studies in the
aged domestic hen (Gallus gallus, female) [17]. Domestic hens are known to suffer
naturally from a high incidence of ovarian cancer [18], leading to the addition of
restricted ovulator chickens (and mutant types) to the short list of approved model
animals for ovarian tumor research [19].
A plausible contributing factor for the susceptibility to ovarian cancers of aged
domestic hens is their state of near constant ovulation. Ovulation is the production
of a cell that forms the basis of a new life, but ironically, the ovum itself arises in
an act of destruction. Follicles develop in the ovarian stroma, which lies directly un-
derneath the ovarian surface epithelium. Yet, unlike many other organs that develop
biological products, there are no ducts or vessels for the secretion of the ovules. Each
productive cycle of ovulation ruptures the ovary, releasing the ovule to travel into
the fallopian tubes and on to the uterus. This breaking free damages the ovarian
surface causing a wound that must heal. The damage from ovulation is dramatically
clear when comparing the ovaries of younger and older individuals: young females
exhibit a relatively smooth ovarian surface, while ovaries of mature females have
a heavily scarred surface. This irregular surface lends itself to the development of
invaginations, which may either be consumed by the ovary or persist as cysts. In
this “incessant ovulation” model, the cysts are required to initiate the tumorigene-
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sis process. The incessant ovulation model does not explain the similarity between
some serous ovarian surface epithelial-stromal tumors with the fallopian tube ep-
ithelium. Some explanation is required here: while the ovarian surface epithelium
is continuous with the mesothelial lining of the peritoneal surfaces, and shares many
histological features with those cells, ovarian epithelial carcinomas themselves are not
mesothelioma-like. Instead they are Müllerian-like, meaning that they resemble the
organs of the Müllerian system, which includes the fallopian tubes, uterus, cervix and
the upper portion of the vagina, but not the ovary. The simplest explanation for this
observation is that serous ovarian surface epithelium-stromal tumors are secondary
site tumors, originating from epithelial cells in the Müllerian system [20].This is cur-
rently a minority view, with most researchers preferring a model in which the ovarian
surface epithelium undergoes a metaplastic transformation during the initial steps of
tumorigenesis, causing it to resemble Müllerian-derived cells [20]. If a metaplastic
transformation occurs one would expect to find precursor epithelial lesions, but no
unambiguous examples have been found [21] [22]; thus a de novo event is sought as
the source of this etiology [23].
With respect to the minority view that these tumors are secondary lesions whose
source is the fallopian tubes, several arguments are advanced. One is that early
studies did not consider the fallopian tubes, so the absence of evidence is not evidence
of absence [23]. With a rising interest in the secondary-Müllerian system, fallopian
tubes were inspected for associated precursor lesions and tumors [24] [25] [26] [27].
These studies found tubal carcinomas and similarities with ovarian carcinomas were
noted, although a limitation of the studies is that they focused on individuals with
BRCA mutations [28]. Specifically, when microscopically examining serial dissections
of fallopian tubes, 60%-70% of ovarian and peritoneal high grade serous carcinomas
showed evidence of tubal involvement [29] [30]. A study examining gene expression
using microarrays showed a greater similarity between high-grade serous carcinomas
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and fallopian tubes than to the ovarian surface epithelium [31].
Given this dichotomy in models for etiology, some investigators now divide ovarian
epithelial serous carcinomas according to molecular profile and speed of progression
[32], rather than stage or histopathology type. This avoids any presumptions about
cause that might preclude considering associations of potential merit. For example,
in one study, carcinomas were assigned, across histological subtypes, to one of two
classes. Type I carcinomas were defined as low-grade serous carcinomas, muscinous
carcinomas, endometroid carcinomas, clear cell carcinomas, and malignant Brenner
tumors (which show urothelial differentiation). Within this class, serous carcinomas
predominantly exhibit KRAS and BRAF mutations and follow the classical tumor
progression from benign adenomas/adenofibromas through proliferative tumors and
noninvasive carcinomas to invasive low-grade carcinomas [32]. Type II tumors were
defined to contain high-grade serous carcinomas, undifferentiated carcinomas, and
malignant mixed mesodermal tumors or carcinosarcomas. Within this second class,
serous tumors exhibit p53 mutations and HLA-G expression [32]. Tumors in this
second class did not, however, have a known initiating event, and so were classified
as “de novo” [33] [34]. There is considerable effort being invested in understanding
the ramifications of previous studies of high-grade serous carcinomas if they are now
cast as secondary tumors [35]. One proposal is that tubal intraepithelial carcinomas
are shed from the fimbrial epithelium of the oviduct and then implant on the ovary
surface, where molecular changes that are affected by the new environment continue
an adapted tumorigenesis process (much like retrograde menstruation can initiate
endometriosis) [23]. It is even suggested that this could be the initiation mechanism
for type II serous tumors, with the outcome depending on the first molecular changes
[23]. However there is as little hard evidence for this, as for the initial steps in cortical
cyst transformation, so experts remain uncommitted to either at this time [23].
Two schools of thought now surround the pathogenesis of serous ovarian surface
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epithelial-stromal tumors. The initiation and tumorigenesis of type I serous tumors
is less controversial, particularly as molecular events and intermediate forms can be
observed. However, the initiation and progression of type II serous tumors is subject
to much debate; Nelly Auersperg recently suggested a theory that may resolve some
of the disagreement [36]. Her argument is that, given that the fimbrial and the
ovarian surface epithelium both develop from the embryonic coelomic epithelium, the
epithelia of the ovaries and fallopian tube ampullae may not be fully developmentally
committed, and thus are susceptible to neoplasia. Auersperg has used epithelial and
mesenchymal cell molecular markers to show the existence of an overlapping region
of ovarian surface and fimbrial epithelium. This region is classified as a “transitional
epithelium of common origin”, giving advocates of both the ovarian surface epithelial-
derived genesis and the secondary-Müllerian fimbrial-derived genesis common grounds
for their evidence for their respective tumorigenesis models [36].
1.4 Tumors and the Surrounding Stroma
Paracrine signaling (signaling between cells) is an important part of cellular func-
tionality that has been, thus far, largely ignored in the tumor research community
[37]. However, cells communicate with and affect one another, performing as units in
a complex network; evidence exists that this occurs in tumors [38]. Many studies be-
gin by dissecting cells of interest from their environment, in order to enhance signals
specific to those cell types. Other studies macrodissect cells of interest and stroma
elements together, confounding signals in down-stream analysis. We were interested
in measuring not only expression in tumorigenic cells but surrounding stroma cells
which may exhibit associated paragrine signaling. Thus, we collected cells from the
surrounding stromal environment of ovarian serous carcinomas.
While a relative recent focus, several studies have looked at characteristics of
stroma surrounding endothelial cells, pericytes, leukocytes, and fibroblasts. Carcinoma-
associated fibroblasts (CAFs) are the most frequently encountered element of tumor
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exposed stroma [39] [40], and may contribute to what are considered the “hallmarks
of cancer” [38] based on their: self-sufficiency in growth signals, evasion of apoptosis,
sustained angiogensis, and capacity for tissue invasion/metastasis [37].
In normal environments, cells influence others with mitogenic signaling, sending
growth signals to surrounding cells. CAFs express a number of specific mitogenic
factors, including hepatocyte growth factor (HGF), fibroblast growth factor (FGF)
and Wnt pathway signaling molecules [41]. Several studies in mice show that aberrant
signaling in just one factor can induce a tumor, including notch signaling in epidermal
keratinocytes and TGFβ functionality in fibroblasts [42] [43].
A requirement in all cancers is the suppression of the apoptotic pathway, by
which cells suicide. Stroma cells produce survival signals that surrounding cells use
to counter the initiation of apoptosis. More specifically, CAFs express insulin-like
growth factor-1 and -2 (IGF1/2) [44] [45]. Additionally, increases in collagen in
the extracellular matrix (produced by CAFs), have been shown to increase integrin
signaling [46].
Angiogenesis, or the growth of a blood supply to nourish tumors, is important to
sustain tumor growth. In one study covering a panel of known angiogenic factors,
all were more highly expressed in stroma cells than the actual tumor [47], with the
exception of VEGF. It was shown in mice that the VEGF promoter was more active
in CAFs at the onset of primary site and metastic tumors [48]. CAFs have been
shown to have a role in recruitment of cells for MCF-7-ras human breast carcinoma
vascularization [49].
Lastly, with respect to the role of CAFs in metastasis, tumors must invade sur-
rounding tissue: CAFs secrete TGFβ and facilitate the epithelial-mesenchymal tran-
sition needed for tumor invasion of surrounding cells [41]. CAFs secrete proteases,
required to degrade fibers tethering tumor cells in their current environment, permit-
ting mobility [37].
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1.5 Ovarian Tumor Epidemiology
Without a well-defined pathogenesis model, uncovering epidemiological factors
contributing to steps in the initiation and progression of ovarian tumors is difficult.
Some risk factors have been defined but their biological bases are not understood. Pro-
tective and risk factors span biological, medical, environmental, and genetic sources.
Few reproductive factors appear to reduce the risk of ovarian surface epithelial-
stromal tumors. Parity and pregnancy, being biological functions directly associated
with ovaries, have been shown to have some association, with higher parity reducing
the risk of ovarian cancer. In one study, one birth gave patients a 40% risk reduction
with an additional 14% per additional birth [50]. This protective effect seems to
hold for all ovarian surface epithelial-stromal tumors excluding mucinous tumors [51].
Incomplete pregnancies provide a slightly lower protective rate [52] [53]. An associated
process, lactation, is marginally preventive, seen most clearly between women who
have never breastfeed and those who have breastfed for 18 months or more (2% risk
decrease per month) [54].
Oral contraceptives have been found to reduce the risk factor of ovarian cancer
onset in almost all studies [55]. Although reduction in risk has been associated with
less than 1 year of use, it appears that greater risk reduction occurs with more exten-
sive use. One study reported a 50% reduction in risk after 5 years of use [56], even if
use was 15 years previously [57].
If incessant ovulation is a primary risk, it would seem that ovulation-stimulation
treatments would carry an increased risk. Indeed, two studies claimed fertility drugs
produced an increased risk of developing ovarian tumors [58] [59], but to date only
weak, or nonexistent, associations have been found between ovarian cancer and drugs
causing superovulation [60] [61] [62]. The need for larger studies with longer follow-up
has been expressed to better clarify this potential risk factor [63].
A bilateral oophorectomy is the most extreme preventive factor known, but the
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procedure carries serious consequences, including sterility, changes in hormone pro-
duction and psychological effects [55]. Interestingly, as much as an 80% reduction of
risk of ovarian cancer has been shown following tubal ligation alone, carrying forward
as much as 20 years post-surgery [64] [65]. A hysterectomy also is preventive although
less so than tubal ligation, with a decrease of 33% [66].
Other reproductive system events increase ovarian cancer risks.
Endometriosis, in which uterine endometrial tissue implants outside the uterus
(typically through retrograde menstruation), is one such risk factor for ovarian cancer
onset. Endometriosis has most specifically been linked to clear cell and endometrioid
tumors, with evidence showing significant co-occurrence with ovarian cancers [67]
and increased ovarian tumor risk correlating with a history of endometroisis [68].
Research is currently being conducted to understand at what level endometriosis
may be a causative factor for ovarian tumors [55].
Several environmental factors have been shown to affect the chance of ovarian
tumor occurrence. Use of talcum powder in the genital region can increase risk by
30% [69]. Serous histopathology may specifically have a stronger percent influence [70]
[71]. The structural similarity of talcum powder to asbestos may play some role in this
risk [72]. Additionally, drinking green and black teas have shown a dose-responsive
protective capacity [73]. Obesity in early adulthood correlated to a general increase in
ovarian tumor occurrence [74]. Other environmental factors are under study including
smoking, alcohol use, and caffeine, but have conflicting bodies of evidence on their
relative associated risk [55].
The most significant known risk factor for ovarian tumors is genetic. In particular,
BRCA1/2 mutations increase the risk of ovarian tumors, specifically serous tumors.
Of the 10% of ovarian tumors which for which a genetic component is implicated,
90% map to BRCA1/2 mutations [55]. An individual with a BRCA1/2 mutation has
a 15% to 66% increase in risk of developing an ovarian tumor in her lifetime [75].
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1.6 Ovarian Cancer Biomarkers
An ideal diagnostic biomarker has several characteristics: it is stable in biological
fluids, easy to purify and detect, always discrete between the conditions to be tested
and only between those conditions, occurs in a medium that is safely and readily
available, it is produced from the very beginning of the condition and continues to
be produced by all offspring cells. Ideally, ovarian cancer cells from the very first
transformation would produce a unique and stable protein or nucleic acid that was
shed into the blood or urine, and this molecule would never be produced by healthy
cells or those with other pathologies. The reality is that cancer seems to be due to
disregulation of several large neighborhoods of genes that are used in healthy cells,
often with increasingly chaotic signals over time [38]. Thus an effective test will
likely be based on one or more panels of transcripts (or their products) with readout
comprising characteristic changes but not on/off phenotypes.
Currently, some cancers have biomarkers which are used in a clinical environment.
Several clinical tests, including BRACAnalysis®, measure for genes with a known as-
sociation with inherited ovarian and breast cancer (BRCA1/2 mutations). Agendia®
provides several gene expression products that are FDA-cleared for use in clinical set-
tings. MammaPrint® is a 70 gene expression panel which measures risk of metastasis
and recurrence in early stage breast cancer [76]. BluePrint is an 80-gene expres-
sion product used to classify breast tumors into subtypes of clinical importance [77].
Additionally Pathwork® Diagnostics has created a “Tissue of Origin Test” based on
a 1,550 gene expression signature that is focused on indicating the primary site of
poorly-differentiated and undifferentiated primary tumors, and metastatic tumors in
general[20].
Given the successful translation of gene expression panels to diagnostics in breast
cancer research, it is reasonable to hope for a similar outcome for correctly identi-
fied ovarian tumor biomarkers. Genes with favorable characteristics for inclusion in an
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ovarian cancer diagnostic biomarker panel include: CA-125, BRACA1/2, HER2/NEU,
AKT2, c-fms, BCL-2, FGF3, MET, p53, SPARC, nm23, and KRAS, some of which
are described in more detail below.
Historically, CA-125 (cancer antigen 125 or MUC16) was the first notable ovarian
tumor biomarker [78]. CA-125 expression is consistently exhibited in serous carci-
noma. When immunohistochemistry was performed on 43 serous papillary ovarian
carcinomas 37 samples indicated CA-125 expression [79]. CA-125 levels are currently
monitored in clinical settings, but only after onset of ovarian tumors is confirmed.
CA-125 changes are not specific enough to indicate tumorigenesis and are also trig-
gered by other changes in the peritoneal cavity, including endometriosis. It has been
suggested that screening based on CA-125 levels, ultrasound, or serum protein tests
alone do not produce the sensitivity or specificity needed for screening. An approach
combining modalities should be investigated [80].
Although made famous for associations with inherited breast cancer, BRCA1 and
BRCA2 (Breast Cancer Gene 1 and 2) are also biomarkers for inherited ovarian
cancer. BRCA1/2 mutation is also a strong factor in tubal serous epithelial tumors
originating in the fallopian tubes [81]. Depending on how type II serous ovarian
tumorigenesis is defined to be derived (from the fallopian tube or ovarian surface
epithelium), inclusion of BRCA1/2 mutations may be complicated, since BRCA1/2
disregulation is not specific to ovarian tumors (since it is inherited in breast cancer)
[82] [83]. If tubal serous carcinoma is defined as a different tumor type from ovarian
serous tumors, two BRCA1/2-expressing tumors may be difficult to distinguish.
When immortalized (non-tumorous) ovarian epithelial cell lines (T29 and T80)
were transduced with HER2/NEU and exposed to subcutaneous and intraperitoneal
environments, undifferentiated and papillary carcinomas arose. Papillary carcinomas
from the T29 line injected intraperitoneally matched human papillary serous carci-
noma in immunophenotype and histologically [84]. Although this is not evidence that
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singly mutating HER2/NEU would produce carcinomas (particularly given the im-
mortalizing of the cell lines and the apparent need of the peritoneal environment), this
is strong evidence of potential activity in human papillary serous ovarian carcinoma
tumorigenesis.
Protein 53 (p53) is an important part of a cell’s response to damage arising in
the cell-cycle, which can affect apoptosis. P53 is expressed in approximately 50% of
human tumors [85]. Prolific expression in cancer has made p53 a well studied tumor
suppressor. Specific to the peritoneal cavity, p53 is known to express in tumors
of the ovary, the fallopian tube, and the peritoneum [86] [87] [88]. Such ubiquitous
expression in tumors is useful in developing markers for therapeutic success[89] but not
for specific diagnostic markers. That is, if p53 products can be detected peripherally,
p53 will not be a marker of a specific tumor type but, coupled with ovarian specific
biomarkers, may increase sensitivity to a tumor positive condition.
Ras, a small GTPase superfamily member, exhibits mutations in many tumors.
In relation to serous ovarian tumors, K-Ras mutations are found in >70% of low
malignant potential serous ovarian tumors but only in 12.5% of serous ovarian car-
cinomas in general [90]. When serous carcinomas are defined as type I and type II,
KRAS mutations are expressed in type I but not type II carcinoma [91]. Patients with
type I carcinoma have a better prognosis than type II, KRAS and genes with similar
expression could be candidates on a biomarker panel targeted at defining (better)
prognosis.
1.7 Alternative Splicing and Tumorigenesis
Alternative splicing is the process where multiple mature mRNA transcripts can
be derived from one pre-mRNA transcript. Alternative splicing is estimated to occur
in 70% of genes (referred to as transcript-clusters) [92]. Alternative splicing has been
associated with several diseases including: Frasier syndrome, frontotemperal demen-
tia, Parkinsonism, atypical cystic fibrosis, retinitis pigmentosa, and spinal muscular
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atrophy [93]. Given the increased potential for functional transcription, cancer has
been documented as associated with such splicing. Many transcript-clusters recog-
nized to be associated with cancer exhibit alternative splicing including MUC1 [94],
VEGF [95], p53 [96], and BRCA1 [97]. Alternative splicing was measured in a study
of mixed ovarian surface epithelial-stromal tumors using a high-throughput RT-PCR
system (LISA) on 600 transcript clusters [98]. Carcinoma and normal samples could
be separated by the expression of 46 transcript isoforms under unsupervised cluster-
ing. Affymetrix Human Exon 1.0 ST microarrays were also shown to be effective in
measuring transcript level expression and alternative splicing in cancer (colon) [99].
The success of the colon cancer study, depending on the density of oligonucleotide
microarrays that can measure differential expression, our ovarian tumors, were mea-
sured with these Affymetrix Human Exon 1.0 ST microarrays. If successful, this could
document exact transcript association with tumors without the confounding effects
of transcript-cluster level analysis.
1.8 Microarray Technology
The seminal manuscript “Molecular Structure of Nucleic Acids: A Structure for
Deoxyribose Nucleic Acid” by Watson and Crick concluded by alluding to the compli-
mentary nature of DNA strands [100]. As our understanding of nucleotide polymers
has matured, modern molecular biology has defined a multitude of techniques exploit-
ing the complimentary nature of double-strand nucleic acid bonding. Hybridization
assays go back to the “blotting” techniques of Southern [101], but have been refined
by miniaturization and advances in DNA synthesis technology to produce highly
parallel platforms called microarrays or chips [102]. Oligonucleotide microarray tech-
nology combines sequences known to occur in target genomes with circuit fabrication
techniques to make a device that allows one to interrogate, or probe, nucleic acids
characteristic of a genome. The target pool that comes from the sample may either
be the genomic DNA, which is amplified and labeled for hybridization for a genetic
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screen, or the mRNA, which is first transformed to cDNA and then amplified and
labeled for hybridization in an expression screen [103].
Commercial arrays vary by oligonucleotide density and length. Those used in
most biomedical studies are from the manufacturing company Affymetrix, which lays
down 25-mer oligonucleotides that are complementary to targeted regions of the model
genome. Our interest was in the class of chips that reports on all defined exons in
the human genome.
Specifically, Human Exon 1.0 ST microarrays (Affymetrix, Inc.) were used to
measure the expression of genes in samples from patients with benign and malignant
serous ovarian surface epithelial-stromal tumors. These microarrays are designed
to have multiple (ideally 4) probes for every exon (probes are aggregated to give a
ProbeSet defining the exon) belonging to a transcript cluster associated with a gene.
Approximately 5.4 million probes are employed in exon microarrays to interrogate
approximately 1 million exons [104]. These exons define 300,000 different transcript
clusters (90,000 express multiple transcripts). Almost 800,000 probes sets of the
1.4 million ProbeSets are supported by evidence from EST and GENSCAN sources
[104]. However, for a large number of computationally predicted genes, no evidence
for expression has ever been found. It may be that the correct conditions for eliciting
a response has never been imposed, or these may be pseudogenes, whose promoters
and other regulatory elements no longer function. Similarly, detailed work on the
gene models that describe intron and exon boundaries and alternative splice forms is
only slowly increasing, so some of the probes may respond in unexpected ways. The
manufacture process is described briefly below, with emphasis on factors that affect
analysis of the signal.
The oligonucleotide probe design process is key to all subsequent steps. The
confidence that the Affymetrix array designers consider that an analyst can place
in a probe response is provided in the annotation files. Each ProbeSet is given an
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“evidence level”: ProbeSets with the strongest support are considered “Core”, the
biological contextualization and design of these ProbeSets are supported by Refseq
evidence and full-length mRNA GenBank entries (with full CDS data) [105]. The next
level of evidence is defined as “Extended”: these are supported by other biological
proof such as GenBank mRNA entries not associated with full-length CDS data,
ESTs, microRNA registry entries, vegaGene and vegaPseudoGene entries, as well as
others. Next, “Full” ProbeSets are supported by in silico gene prediction (algorithms
encompassed in GeneScan, GenScanSubOptimal, exoniphy, RNAGene, sgpGene, and
TwinScan). Finally, “Free” ProbeSets are composed of probes which, when combined
into ProbeSets, do not have annotations that comment on the full ProbeSet, and
“Ambiguous” ProbeSets can be assigned to multiple transcript clusters [105] and
thus signal from these ProbeSets live up to their label.
Once probes have been designed, the physical molecules are created using pho-
tolithography. An inert surface, typically a glass or silicon wafer, is coated with
an ultraviolet light reactive chemical. A series of masks directs the building of the
probes, one base with UV-sensitive reactive groups at a time. Masks have small holes
allowing the UV light to reach regions to be activated so that the next base can be
added. When complete, the inert surface has chains of nucleotides of 25 base in a
length which have an explicit design based on the targets of the chip (Figure 1.1
left). The chemistry used is not highly efficient, so a large number of incomplete
probes surround each full-length probe. Hybridization conditions are recommended
that limit non-specific binding to these shorter probes, but false signals are always a
risk.
Once chips have been created, patient samples can be prepared for hybridization
on GeneChips. Sample preparation methodologies are tuned to the molecule type of
interest and aim of the project. Although many parts of the sample preparation have
been commercialized as kits, this step is known to introduce a great deal of variation
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into the final measurements. In gene expression experiments the common threads
are: isolation of RNA from the biological material, cDNA conversion, reamplification
of the strand of interest, fragmentation of the amplification product (50 - 100 bases
in this study), and attachment of a biotin-based label [103]. Many quality control
measures are associated with the process.
Fragmented and labeled cDNA is combined with a hybridization solution that is
added to GeneChips so that probes are exposed to the targets in the solution. Under
correct conditions, only target that is fully complementary to a probe will bind stably,
an association persisting through all subsequent processing steps (Figure 1.1 middle).
After 18 hours of hybridization, all sample cDNA not hybridized to GeneChip probes
are washed out of the chip, and a detection dye is added to biotinylated target that
remains. At this point GeneChips are scanned by a laser to induce fluorescence from
the detection dyes (Figure 1.1 right) [103]. Software integrated with the scanner
assigns the photon flux detected per pixel to a specified spot (reported as the spot
intensity). Subsequent quality control steps are used to make sure the scanner and
chip were correctly aligned, that the signal was above a noise threshold, that the
conformation of the spot met expected standards, etc. Those spots that pass the
criteria for acceptability are averaged (most probes are present at multiple locations)
and then aggregated according to some rule (generally weighted, not simply added
before averaging) to yield a ProbeSet value that is the starting point for all further
bioinformatics analysis. The specific details of our protocol are given in the Wet Lab
Methods section of Materials and Methods chapter, to follow.
1.9 Prior Studies
The combined experimental model and transcript-level resolution of this experi-
ment will be unique in ovarian surface epithelial-stromal tumor research. The first
principles which will generate this data set do, however, apply to other oligonucleotide
based arrays. Although the analysis reported in literature is based on transcript-
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Millions of DNA strands built up in each location
A
1.28 cm
1.28 cm
RNA fragment hybridizes with DNA on GeneChipfi array
RNA fragments with fluorescent tags from sample to be tested
Figure 1.1: Human Exon 1.0 ST microarray chip synthesis. Photolithography is used
to create oligonucleotide probes (left). Single-stranded oligonulcleotide probes hy-
bridize to biotin-labeled, complementary sample cDNA (middle). After washing,
lasers scan chips to excite biotinylated dye, measuring hybridized cDNA (right).
(Source Affymetrix.com)
cluster level data, this does not mean some similarity in results between platforms
will not be found. At a minimum, given proper design, transcript-clusters that do not
exhibit alternative splicing should have similarity. As well, in future work, it may be
possible to reconstruct transcript-level array results and attempt to combine similar
published data sets with this data set. With this potential, some prior studies are of
interest to consider here.
The potential for biomarker identification was immediately realized by early ovar-
ian tumor oligonucleotide microarray studies (starting in approximately 2000). Stan-
dardized and specialized microarrays were developed for analysis of transcript-cluster
expression. Researchers struggled with producing adequate input sample, especially
normal epithelium. Two approaches were used to amplify starting material [106].
One method, attempting to transform samples (control and test) and then allow-
ing the cell culture to grow before RNA extraction could increase RNA yield but
required non-tumorous control tissue and led to modifications in tumor expression
through cell line transformation [107] [108]. Immunomagnetic-enrichment of normal
epithelium nucleic-acid was also attempted but exposed RNA to the risk of degra-
dation [109] [110]. Other limitations were already recognized at this time, including:
the lack of standards, the sparse use of microdissection, the difficulty in obtaining
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required starting material quantities, and the practical limitation of the features of
the microarray; if the transcript-cluster does not have an associated probe on the
microarray, it is not measured [106].
Learning from initial experimentation, the microarray community developed stan-
dards. Minimum Information About a Microarray Experiment (MIAME) [111], Mi-
croarray Gene Expression Markup Language (MAGE-ML) [112], and the Gene Ex-
pression Omnibus (GEO) [113] were defined to standardize experiment annotation
and information, data storage, data sharing, and centralize expression data stor-
age. The capacity of measurement for microarrays increased. Considering Affymetrix
GeneChips, the original chip capacity used 18µfeatures grouped in >8,700 ProbeSets
to measure ∼8,5000 transcripts; (Human Genome Focus Array), currently the Human
Genome U133 Plus 2.0 microarrays use 11µfeatures grouped into >54,000 ProbeSets
to measure ∼47,400 transcripts [114].
Unfortunately, the experimental model of earlier OSE studies did not control for
histopathological subtype. Typically histopathology of all carcinomas were viewed as
one highly variable pathology, and the group was treated as one cohort. Efforts to
define panels of genes associated with prognostics, response to chemotherapy, early
detection, and tumor characterization were performed. Studies often did not perform
tumor microdissection [115] [116] [117] [118] [119] [120]. Due to the frequency of onset,
serous carcinoma often comprised the majority of samples in these studies, but other
major subtypes were included, leading to mixed expression signals. Although laser
cutting/capture microdissection (LCM) was not performed, microscopic inspection of
tissues was performed and percentage tumor counts were given as a measure of tissue
heterogeneity and expected levels of signal mixing. This is only useful if baseline
signals are known. Some studies quoted as low as a median of 64% percent tumor
cells in samples. Not surprisingly, these studies produced non-overlapping or minimal
common content[121].
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With the emerging focus on stratification by histopathology, recent studies have
become more specific. The research community continues to lack commitment to
standardizing LCM as a microarray experiment process, perhaps due to cost or ex-
pertise.
Large consortiums have been funded to profile ovarian tumors. One such project,
the Cancer Genome Atlas project, includes a repository of 588 ovarian cystadeno-
macarcinomas (tumor and associated controls) that have been measured by various
high-throughput methods including Copy Number Variation (genes and miRNAs),
gene expression, miRNA expression, DNA methylation, and somatic mutation. Al-
though not microdissected, samples were carefully controlled for sample tumor ratio
and RNA quality. These large, public projects provide data freely, allowing smaller
experiments to combine data with theirs and gain additional power in analysis [122].
Certainly, next efforts in ovarian cancer biomarker detection will need to combine
and make sense of the varied studies already performed. The combination of prior
studies with new transcript-level studies and high through-put sequencing data will
require highly integrated approaches in order to leverage this data.
1.10 Experimental Design
The recent understanding that ovarian surface epithelial-stromal tumor histopatho-
logical subtypes are separate diseases puts prior studies into question. By stratifying
the design to account for subtype, analysis power will increase and more accurate
measurements of expression may be performed. Changing ideas about tumorigenesis
lead to questions about basic experimental models. This study takes the opportu-
nity to apply these changing concepts and include higher resolution of measurement
offered by exon-based oligonucleotide chips.
Serous ovarian surface epithelial-stromal tumors are the most common and most
deadly histopathological subtype and were the focus of this experiment. Both tradi-
tionally accepted benign and malignant tumors may offer clues to biomarker selection.
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In an attempt to select categories that fit both tumorigenesis theories, the malignant
tumor cohort was Type II serous tumors. Benign tumors are not accepted to be the
sole progenitor of malignant tumors. The tumorigenesis theories offer alternative nar-
ratives (in situ genesis and fallopian tube metastasis). A common control will need to
be used, to provide an unambiguous reference. At the same time we are restricted to
the material the surgeons can collect and that our IRB approval permits. Tradition-
ally, tumorigenesis theories assume ovarian surface epithelial-stromal tumors to be
derived from normal ovarian surface epithelium (NOSE). Therefore, NOSE was used
as a control in this study. The alternative to NOSE, fimbrial epithelium, is related
to NOSE through the embryonic coelomic epithelium. This relatedness and the hy-
pothesis of the ‘transitional epithelium of common origin’ gives support for using the
traditional NOSE control. Paracrine signaling will also be explored as an additional
facet to this study. Stroma in proximity of tumors and distant from tumors will be
compared in samples with both benign and malignant tumors.
1.11 Summary
Unfortunately, the answer to the question “Why is ovarian cancer the most lethal
gynecologic cancer in the United States?” is that we dont know...yet. We are unsure
of the epidemiology and etiology of the tumors, we are unclear in our understanding of
the tumorigenesis model. Ovarian tumor mechanisms are as vague as the symptoms.
Progress is occurring. While few epidemiological factors are agreed upon (in-
cluding BRCA1/2 genes, a history of parity, lactation, and oral contraceptive use),
molecular mechanisms have begun to define the heterogeneity of ovarian tumors as a
diversity of separate diseases.
Candidate biomarkers have been identified by a number of groups but do not
exhibit the specificity and sensitivity needed for tumor detection. The discovery of
biomarkers suitable for early diagnostics, using noninvasive techniques for sample
acquisition (ideally a peripheral blood draw) was the idealized long term application
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for this data set. This requires that products of early events in a few cells be secreted
and stable, features not addressed in this study.
CHAPTER 2: MATERIALS AND METHODS
2.1 Rationale for the Key Features of the Wet Lab Methods
Several concepts were essential to the development of the series of wet lab protocols
used in this study. Before protocols are presented, the rationale is given for the
choices made, which are grounded in our experimental design and best practices as
established in the literature. Firstly, we used LCM because macrodissected samples
exhibit several levels of heterogeneity; there is already natural heterogeneity in the
ovary and there are many histological subtypes as well as the possibility of polyclonal
tumors. Next, since the mechanism of tumorigenesis of ovarian tumors is under
debate, normal ovarian cancer epithelium was included as a common baseline. Since
signaling may explain some of the history as well as the current activity of the tumor,
stromal cells in the surrounding environment (both proximal and distal to the tumor)
were profiled.
2.1.1 Laser Capture Microdissection
One of sources of complexity associated with ovarian tumors is the heterogeneity
of samples. Diversity in samples can be due to any number of factors including but
not limited to natural elements occuring in the organ (for example stroma, follicles,
and tunica albuginea), distinct histopatholgical subtypes, polyclonal tumors, necrosis,
immune response, and bleeding. Laser Capture Microdissection (LCM) allows specific
subpopulations of tissues to be identified, separated and collected for further analysis.
Microscopic identification of target cell populations is followed by placement of an
LCM cap with thermoplastic film over the cells, after which a low-power infrared
laser beam is focused on the film over the cells. When the film physically contacts
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the cells, it attaches to them. When the cap is removed, the cells attached to the film
are removed at the same time while non-attached cells are left on the slide [123]. The
infrared-laser, although it activates the film and sticks it to the cells is low enough
energy that it does not compromise the integrity of the biological material. Material
on the cap can then be removed with extraction reagents.
2.1.2 Microdissection Schema
The experimental plan was to LCM-purify four categories of cells from every
sample in one of the two class types, benign or malignant serous ovarian surface
epithelial-stromal tumors. The four categories were normal epithelium, tumor cells,
proximal stroma cells and distal stroma cells. Benign tumors represent early, possibly
non-progressive events for Type I tumors, and the malignant tumors represent some
stage of the Type II tumors, since they were further selected to match the high grade
classification. The following labels are used for the samples: NE is normal ovarian
surface epithelium, T is tumor, TS is proximal tumor-stroma microenvironment, and
S is distal stroma. Figures 2.1 and 2.2 illustrate the microdissection schema, in a
benign sample and malignant sample respectively. Not all samples yielded high-
quality material in all 4 subsets of cells; in particular NE was difficult to obtain in
sufficient quantity.
2.2 Wet Lab Methods
The following summarizes the main steps for preparing samples for microarray
hybridization. It follows the recommendations of LCM experts and the microarray
suppliers; deviations are noted where they occurred. The time line from tissue har-
vesting to hybridization typically required 2-3 weeks. This complex protocol used a
diversity of techniques with multiple points of failure and thus quality control was
essential (Figure 2.3).
Several check-points were incorporated into the wet-lab protocol to insure a level
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Figure 2.1: Microdissection of benign sample. The green arrow indicates normal
surface epithelium, red indicates tumor, purple indicates stroma adjacent to tumor,
and blue indicates stroma distant from tumor.
of quality and consistency Figure 2.4. The initial two checks performed on sam-
ples were based on controlling for the histopathology of the tumor sample. Certified
pathologists evaluated biopsies from patients to diagnose tumor histology. Serous
tumors were flagged for this study. Cryosectioned, hemotoxylin and eosin stained
samples were evaluated microscopically. The histopathology of the lab sample was
checked for consistency with the pathology report (to remove issues involving incon-
sistent macrodissection of tissue). Additionally, the presence of normal epithelium,
tumor, stroma and stroma adjacent to tumors was indicated.
When samples passed microscopic histopathology checks, several checks were pe-
riodically performed enforcing quality of product. Initially, the quality of RNA from
samples was measured from most samples. An Agilent 2100 Bioanalyzer was used
to measure RNA integrity numbers (RIN). Although limited samples were available,
the samples offering the best RIN numbers were used. This check focused the study
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Figure 2.2: Microdissection of malignant sample. The green arrow indicates normal
surface epithelium, red indicates tumor, purple indicates stroma adjacent to tumor,
and blue indicates stroma distant from tumor.
on samples that would, by report, be most efficient to use in the study and give the
best quality products. A Nanodrop spectrophotometer was used to measure cDNA,
and ST-cDNA quality as per Nugen recommendations (having a 260/280 >1.8 and a
respective quantity of 3µg and 5µg).
2.2.1 Patient Sample Harvesting
Ovaries were harvested by a clinician and placed in gamma radiation-sterilized
60 ml tubes with approximately 7.5 ml of Hanks Balanced Salt solution (Invitrogen
Co., Carlsbad, CA). Ascities was collected in an empty gamma radiation-sterilized 60
ml tube (Invitrogen Co., Carlsbad, CA). Blood was collected in sterile vials. Upon
receipt of sample, collected blood and ascities fluids were spun at 2,500 rotations
per minute (rpm) or 1,430 relative centrifugal fields (rcf) for 15 minutes in a Beck-
man GS-6 centrifuge (Beckman Coulter, Inc., Fullerton, CA). During this time, ovary
samples were cut into representative halves. One half was placed in a 1.5 ml cry-
ovial (Fisher Scientific, Pittsburgh, PA), immediately placed in liquid nitrogen, and
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later stored in a Taylor-Wharton K Series Cryostorage System (Taylor-Wharton-
Cryogenics, Theodore, AL) with a Rees Scientific environmental monitoring system
(Rees Scientific, Trenton, NJ). The other half was placed in a standard sized cryomold
(Sakura Finetek USA, Inc., Torrance, CA), covered with Optimal Cutting Tempera-
ture (OCT) compound (Sakura Finetek USA, Inc., Torrance, CA), frozen on dry ice,
and later stored at -80°C. Serum and buffy coat from centrifuged blood were each
separately stored in 1.5 ml cryovials at -80°C. The ascities cell pellet formed after
centrifuging was placed in a 1.5 ml cryovial and stored in the K Series Cryostorage
System. Ascities was stored in 1.5 ml eppendorf tubes at -80°C.
2.2.2 Hemotoxylin and Eosin staining (Histopathology Confirmation)
Cryomold samples were serially sectioned into one 5µm and multiple 8µm sections
using Extremus Microtome Knives (C. L. Surkey, Inc, Lebanon, PA) in a Leica CM
1850 UV Cryostat (Leica Microsystems Inc., Bannockburn, IL). Sections were placed
on precleaned Fisherbrand Superfrost®*/Plus Microscope slides (Fisher Scientific,
Pittsburgh, PA), cooled on dry ice and later stored at -80°C. 8µm sections were stored
for Laser Capture Microdissection. 5µm sections were used to guide capturing and
were exposed to Hemotoxylin and Eosin staining. More specifically, 5µm sectioned
tissue samples were exposed to the following reagents: 95% ethanol for 1 minute,
Harris’ Hemotoxylin (Hemotoxylin 7211, Richard-Allan Scientific, Kalamazoo, MI)
for 1 minute, distilled H2O for 20 seconds, weak ammonium H2O for 1 second, distilled
H2O for 20 seconds, 95% ethanol for 10 seconds, 50% Eosin (Sigma-Aldrich, St.
Louis, MO) and 50% 95% ethanol for 1 second, 95% ethanol for 10 seconds 95%
ethanol for 10 seconds, 100% ethanol for 10 seconds, 100% ethanol for 10 seconds,
and xylene (Sciencelab.com, Inc, Houston, TX) for 10 seconds. After air-drying, VWR
Micro cover glasses (VWR Scientific Inc, Media, PA) were affixed to the slides using
permanent mounting media (Vector Laboratories, Inc., Burlingame, CA). Pathology
was performed using a VistaVision microscope (VWR Scientific Inc, Media, PA).
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Microscopic images were captured by an Olympus BX60, DP71 using the Olympus
DPController and Manager (Olympus America, Inc., Center Valley, PA). Light was
set to default for camera (or ‘9’). One touch auto-whitening was used which, on
average, adjusted color composition as follows: red 0.6, green 1.0, and blue 1.2.
2.2.3 HistoGene Staining
The HistoGene LCM Frozen Section Staining kit (MDS Analytical Technologies,
Toronto, Canada) was used according to the suppliers instructions to prepare fresh
frozen, cryosectioned samples for LCM. Sample slides cut at 8µm were briefly thawed
and subjected to 75% ethanol for 30 seconds, nuclease-free distilled H2O for 30 sec-
onds, HistoGene Staining solution for 20 seconds, nuclease-free distilled H2O for 30
seconds, 75% ethanol for 30 seconds, 95% ethanol for 30 seconds, 100% ethanol for
30 seconds, and Xylene for 5 minutes.
2.2.4 Laser Capture Microdissection
After staining, samples were immediately microdissected: the first samples with
a PixCell IIe instrument and the final samples with an ArcturusXT Laser Microdis-
section instrument (Applied Biosystems, Life Technologies, Co., Carlsbad, CA). Mi-
crodissection was performed on precleaned Fisherbrand Superfrost®*/Plus Micro-
scope slides (Fisher Scientific, Pittsburgh, PA) using CapSure® HS LCM caps. When
available, normal epithelium, tumor, stroma, and stroma adjacent to tumor were sep-
arately collected. The capturing period was limited to 30-45 minutes (for all cell types
combined from a single slide) after the Xylene HistoGene staining kit step, with a
small number of samples requiring one hour.
2.2.5 RNA Extraction
After the microdissection of each cell type ExtracSure devices (C. L. Surkey,
Inc., Lebanon, PA) were attached to the caps and 10µl of PicoPure® RNA Isolation
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kit extraction buffer (Applied Biosystems, Life Technologies, Co., Carlsbad, CA)
was applied to the dissected tissues. ExtracSure devices were each capped with
a 0.5 ml microcentrifuge tube (USA Scientific, Inc., Ocala, FL) and incubated in
a mini-incubation oven (Bio-Rad Laboratories, Inc., Hercules, CA) at 42°C for 30
minutes. After incubation, ExtracSure devices with attached microcentrofuge tubes
were centrifuged at 800xg for 2 minutes. ExtractSure devices were then removed,
10µl of 70% ethanol was added to each tube and tubes were stored at -20°C.
2.2.6 Tissue Scraped RNA Extraction
After the microdissection of each tissue type but before incubation, tissue scrapes
from residual slide material were also performed for each patient sample, to provide
additional material for inferring the RNA quality. Approximately 50µl of PicoPure®
RNA Isolation kit extraction buffer (Applied Biosystems, Life Technologies, Co.,
Carlsbad, CA) was applied to slides after microdissection was complete to remove
residual tissue. Extraction buffer with suspended tissue scrape material was pipet-
ted into a cap with attached ExtracSure® device and capped with a 0.5 ml micro-
centrifuge tube (VWR Scientific Inc, Media, PA), and co-incubated with the other
samples from that slide. After centrifugation 50µl of 70% ethanol was added to the
tissue scrape solution before being stored at -20°C.
2.2.7 RNA Purification
The PicoPure RNA Isolation kit (Applied Biosystems, Life Technologies, Co.,
Carlsbad, CA) was used for the steps outlined below, according to the supplier’s
instructions. After column purification, 5µl of RNase-free DNase I stock solution
(Qiagen, Inc., Valencia, CA) was mixed with 35µl Buffer RDD per column and added
to each purification column, then allowed to incubate for 15 minutes at room temper-
ature. After washing away the enzyme and any nucleotides resulting from its activity,
samples were eluted in 11µl of Elution Buffer.
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2.2.8 RNA Integrity Measurements
For assessing RNA integrity we used an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Inc., Santa Clara, CA), and the standard RNA 6000 Nano Assay protocol,
as described by the manufacturer. The RNA 6000 Nano Marker was used in each well
and ladders were used in each chip as positive technical controls. 1.5µl of sample plus
RNA ladder was heated at 70°C, then 1µl was added to each well of an RNA Nano
chip which was loaded into the Bioanalyzer. Subsequent to the run the Eukaryote
Total RNA Nano electrophoresis assay was performed, yielding a quality score and
mass per sample.
2.2.9 Complementary DNA Generation
Due to the nature of the samples the amount of starting material was extremely
limited, so amplification was necessary to produce sufficient mass to drive the hy-
bridization. Complimentary DNA (cDNA) generation and amplification was per-
formed using the Whole Transcriptome WT-Ovation Pico RNA Amplification Sys-
tem Kit (NuGEN Technologies Inc, San Carlos, CA) recommended by Affymetrix.
The kit was used according to the supplier’s instructions. Before cDNA amplification,
cDNA was purified using Agencourt® RNAClean® Beads, according to the suppliers
instructions.
2.2.10 SPIA Amplification
Following the instructions supplied with the kit, the SPIA Amplification Master
mix was created; 160µl was added to each tube of dried beads and sample, subdivided
and amplified using the recommended thermoprofile for an ABI 9600 thermocycler.
After removal of the beads, the amplified cDNA was further purified either with a
Zymo DNA concentration and purification kit (Zymo Research Corporation, Irvine,
CA) or the QIAquick PCR Purification Kit (Qiagen, Inc., Valencia, CA), accord-
ing to each suppliers instructions. In each case the column elute was subjected to
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Nanodrop quantification prior to ST-cDNA generation.
2.2.11 Nanodrop Amplified Complementary DNA Quantification
2µl of purified SPIA amplified cDNA was aliquotted for Nanodrop quality and
quantification analysis. The Nanodrop 1000 (Thermo Fisher Scientific, Inc., Wilm-
ington, DE) stage was initialized and blanked with nuclease-free H2O. After blanking,
a sample of nuclease-free H2O (negative technical control) was used to verify that
readings were within the prescribed ±0.6 ng/ml range of error of the instrument.
After samples were analyzed, quality and quantification scores were recorded. Due
to material limitations replicates of the samples were not measured. To continue to
ST-cDNA conversion a quantity of 3µg of SPIA amplified cDNA with an absorbence
ratio of 1.8 ≤ x ≤ 2.0 was required. (Nanodrop measurements were also performed
for ST-cDNA protocol products requiring 5µg of ST-cDNA with an absorbency ratio
of >1.8 before proceeding to fragmentation and labeling steps).
2.2.12 ST-Complementary DNA Conversion
The ST-cDNA is a stable intermediate of the mRNA, but does not provide the
single-stranded complement to probes in sufficient quantity to drive the hybridiza-
tion reaction. The asymmetric amplification was performed using the WT-Ovation
Exon Module (NuGEN Technologies Inc, San Carlos, CA), according to the suppli-
ers instructions, using x µg of qualified ST-cDNA from the above procedure. The
single-stranded cDNA so generated was then purified, with either a Zymo DNA con-
centration and purification kit or a QIAquick PCR Purification Kit, according to the
suppliers instructions. The column eluates were again qualified using the Nanodrop
1000 spectrophotometer, as described above (or in the Supplementary Materials).
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2.2.13 Fragmentation and Labeling
The single-stranded DNA target material is fragmented to normalize the diffusion
of all targets in the hybridization reaction, and labeled to allow detection of the target.
The FL-Ovation cDNA Biotin Module V2 (NuGEN Technologies Inc, San Carlos,
CA) was used according to the suppliers instructions to perform these steps, starting
with 5µg of qualified material. Samples were then stored at -20°C until hybridization
could be performed.
2.2.14 Exon Microarray Hybridization Recipe
The hybridization cocktail recommended by Affymetrix for use in their stations
and on these chips was modified by Nugen, specifically with respect to the use of
Human Exon 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA) and Nugen’s Ova-
tion products (FL-Ovation cDNA Biotin Module V2 Users Guide, Appendix A.1)
[124]. This modified cocktail was used for all samples. The Affymetrix hybridization,
staining, washing and scanning were performed at the Microarray Core facility at
Carolina’s Medical Center’s Cannon Research Center by certified technicians. With
the exception of modifications to the hybridization cocktail noted, all reagents for
these steps are included in the Affymetrix’s Hybridization, Wash, and Stain (HWS)
kit (Affymetrix, Inc., Santa Clara, CA). After scanning, data was burned to DVDs
for later analysis. The hybridization solution was reserved and stored as a precaution
against Genechip failure.
2.3 Analysis Pipeline
2.3.1 In Silico Quality Control
Two primary-level quality control features are built into exon chips: one is based
on a handful of non-human transcripts (spike-in controls) and the second uses the
distribution of all intensities on a chip [125] [126] and compares that to what is typi-
34
cally seen. These rudimentary quality control steps were performed immediately upon
scanning of the arrays, using the Expression Console software (EC) from Affymetrix
provided for the purpose. Briefly, the quality control report included data from the
core probes, which were compared for expected intensity; the distributions of core
transcript intensities of exon chips was plotted as a series of boxplots (one per chip)
to identify outlier intensity distributions. Additionally, the mean intensity of Core
probes (using very high-confidence probe design) and their background probes was
independently assessed. Finally, Pearson and Spearman correlations were performed
on the Core and Extended ProbeSet (transcript) measurements in order to identify
unusual chip correlations (primarily to indicate batch effects). These measures were
used to indicate whether a sample or chip had failed and needed to be replaced. Once
acceptable arrays were identified more sophisticated measures were used for validating
assumptions in our experimental model or more subtle batch effects using algorithms
available in the Partek® Genomics Suite(Partek, Inc., St. Louis, Missouri).
2.3.2 Initial Data Generation
Exon-level arrays create a very large body of data that can be recombined in a
number of meaningful ways. This is a benefit as it expands the number of models
that can be tested, but it can easily lead to a sensation of drowning in data. As
a first pass, microarray analysis was performed at the transcript cluster (gene) and
transcript levels. As a first step the probe signal must be estimated (relative to
noise), and we used the widely-accepted algorithm GC-RMA[127], as implemented
in the Partek software environment. We focused on transcripts defined as “Core”,
since the genes of interest, described in the Introduction, are all included in this
category. The probes’ values are combined into ProbeSets for each exon, and exons
are combined according to gene models for each transcript, and the set of transcripts
is combined for each transcript cluster or gene. When performing transcript cluster
level analysis, probes were combined using a Winsorized mean (truncating the top
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and lowest 10 percent intensities).
2.3.3 Inferential Statistics: Gene-level
Our initial goal was to identify transcript-cluster, or gene-level inferential statistics
was be performed with a 2-factor Model I Analysis of Variance (ANOVA) with multi-
ple a postiori contrasts in order to provide a list of significant differentially expressed
transcript clusters.
An ANOVA was selected (with contrasts) instead of multiple t-tests for several
reasons. Firstly, performing multiple t-tests as opposed to an ANOVA immediately
exposes the inferential tests to a lowered confidence parameter, alpha[128]. The low-
ered alpha increases the chance of type I errors (false positives). Given an experimen-
tal model with 4 factors over 2 levels, it is possible to perform 6 separate t-tests. If
each t-test is given an alpha = 0.05 then the true alpha for the multiple t-tests is 0.26
or 1-((1-0.05)6) [128]. An advantage to performing multifactoral ANOVA models is
that both factors and interactions are measured. To use an ANOVAs model we must
meet several assumptions about the underlying data. The theory behind parametric
ANOVAs assumes a normal distribution, independent data, and homogeniety of pop-
ulation variances (homoscedasticity). With respect to a normal distribution of signal
intensity, most microarray algorithms (D-Chip [129], RMA [130], and GC-RMA [127])
transform the signal to log2 scale and further scale and normalize with methods like
locally weighted scatter plot smoothing (LOWESS) or quantile-quantile normaliza-
tion in order to produce a more nearly normal data space for tests of differential
expression. Despite these procedures, data are frequently not normal and two sample
classes often do not have the same distribution; this is particularly a problem when
sample numbers are low. An advantage of parametric 2-way ANOVAs is that they are
quite robust to departures from normality [131]. Homocedasticity also has potential
to be violated. If the expression of disease state is being measured in a microarray
experiment, homoscedasity would manifest as similar variance of gene expression. A
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number of studies have indicated that in some disease states it is the variance rather
than the mean of many genes that is most changed [132] so this characteristic cannot
be assumed. That is, although similar expression variance may occur in a disease
with a specific genetic change (for example cystic fibrosis), when comparing normal
tissues with cancer tissue with large amounts of disregulation, it would be very un-
usual for all genes in both tissues to have equal variance. In an experimental model
with similar sizes of levels of factors, 2-way ANOVAs are robust with respect to vari-
ance on both the main factors and their interactions [131]. The assumption of data
independence is more difficult to resolve. Genes are related and interact on many
levels, and indeed much of bioinformatics research is currently engaged in examining
regulatory networks that are interesting because the genes involved are not indepen-
dent. This is a chicken and egg problem that is generally handled by first assuming
independence and then iterating if significant results appear to be found in order
to take this into account. Departures from independence tend to reduce the power
of F-tests [131]. When working with a 1-way ANOVA, alternative, nonparametric
approaches are available (for example Kruskall-Wallis [133]) but an effective 2-way
nonparametric ANOVA model has not been developed [128].
The total ANOVA formula is expressed as follows.
Yijk = µ + PatientTumori + TissueTypej + PatientTumor ∗ TissueTypeij
+ǫijk (2.1)
Where Y is signal, µis a common effect for the experiment, Patient Tumor represents
the patient tumor experimental factor, Tissue Type is the tissue type experimental
factor, the Patient Tumor*Tissue Type is each experimental cohort, and ǫ is the
residual error. Iterators i, j, and k indicate each patient tumor type (benign or ma-
lignant)(i), tissue type (normal epithelium, tumor, distant stroma, or tumor-stroma
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Table 2.1: Planned a posteriori contrasts performed after the ANOVA.
Control Cohort Test Cohort Contextualization
Normal Epithelium Tumor Benign tumor
(Benign Sample) (Benign Sample) gene list
Normal Epithelium Tumor Malignant tumor
(Malignant Sample) (Malignant Sample) gene list
Normal Epithelium Normal Epithelium Differences in
(Malignant Sample) (Benign Sample) epithelial controls
Stroma Tumor-Stroma Effects to stroma
(Benign) Microenvironment of exposure
(Benign) to benign tumors
Stroma Tumor-Stroma Effects to stroma
(Malignant) Microenvironment of exposure to
(Malignant) malignant tumors
Stroma Stroma Differences in
(Benign) (Malignant) stromal controls
environment)(j), and tissue sample (k).
A posteriori comparisons were performed as shown in Table 2.1.
2.3.4 Inferential Statistics: Transcript-level
Transcript-level analysis will focus on using known gene models to discover specific
transcript expression. Similar to gene-level analysis, an ANOVA will be used. The
ANOVA performed was also a 2-factor Model 1 ANOVA, formulated to evaluate signal
at the exon level; this allows more accurate analysis, differentiating transcript clusters
into individual transcript activities. The total ANOVA is expressed by:
Yijklm = µ + PatientTumori + TissueTypej + ExonIDk +
Sample(PatientTumor ∗ TissueType)ijl + PatientTumor ∗ TissueTypeij +
PatientTumor ∗ TissueType ∗ ExonIDijk + ǫijklm (2.2)
Where Y is signal, µis a common effect for the experiment, Patient Tumor repre-
sents the patient tumor experimental factor, Tissue Type represents the tissue type
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experimental factor, Exon ID represents the exon-to-exon effect independent of ex-
perimental factor, Sample(Patient Tumor*Tissue Type) represents sample-to-sample
effect, Patient Tumor*TissueType represents the experimental model’s cohorts, Pa-
tient Tumor*Tissue Type*Exon ID represents exon effects within the cohorts, and ǫ
is the residual error. The same a posteriori contrasts performed in gene-level analysis
were performed in the transcript-level analysis (Table 2.1). Iterators i, j, k, l, and m
indicate each patient tumor type (benign or malignant)(i), tissue type (normal ep-
ithelium, tumor, distal stroma, or tumor-stroma environment)(j), exon through out
samples(k), specific tissue sample (l), and exon per sample (m).
2.3.5 Biological Interpretation
Once gene lists were generated, each was assessed for significant representation
in biological annotation hierarchies including gene ontology (GO) groups, biochem-
ical and protein-protein interaction pathways, and chromosomal location, using the
Database for Annotation, Visualization, and Integrated Discovery (DAVID), version
6.7, from the National Institute of Allergy and Infectious Diseases (NIAID) at the
National Institutes of Health (NIH) [134] [135]. DAVID itself accesses several exter-
nal databases including: Biocarta, KEGG, Panther, Reactome, BIND, DIP, MINT,
NCICB, and UCSC TFBS. These databases are used to evaluate annotative terms
relating to the following categories: disease associations, molecular functionality, bio-
logical process, cellular localization, genomic position, homology, literature citations,
molecular pathway, protein domain, and tissue expression. Single enrichment analy-
sis (SEA) was performed for benign and malignant DE transcript lists (All, Up, and
Down) separately, resulting in 6 result sets. All SEA was performed using Fischer’s
exact test, compensating for multiple comparisons with the Benjamini and Hochberg
(BH) false discovery rate modification [136].
To visualize relationships between terms the tool AmiGO was used to generate
a graph of relationships, and Photoshop (version 5.0) was used to better render the
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AMIGO graph (without changing details or context) [137].
Two tools were used to explore de novo pathway generation potential, STRING
8 [138] and Genes2Network [139]. STRING 8 is a comprehensive data warehouse
of protein-interactions and protein interaction prediction algorithms. STRING pulls
data from IntAct [140], BioGRID [141], the Molecular Interaction Database (MINT)
[142], Database of Interacting Proteins (DIP) [143], BIND [144], KEGG [145], Reac-
tome [146], HPRD [147], EcoCyc, the NCI-Nature Pathway Interaction Database, and
Gene Ontology databases [148]. Additionally STRING performs text mining of anno-
tation in SGD, OMIM, the Interactive Fly, and PubMed abstracts. STRING is a com-
prehensive source of protein-interaction and so was the base resource for uncovering a
gene network. Genes2Network reconstructs networks by drawing on a number of addi-
tional databases, including: BIND [144], DIP [143], IntAct [140], MINT [142], pdzbase
[149], SAVI, Stelzl [150], vidal [151], ncbi hprd [147], and KEGG (mammalian) [145].
The output includes a visualization network that codes the known relationships and
potential interactions reporting where z-scores are ≥ 2.5. Gene2Network interactions
were added to the STRING generated network if interactions were not represented
by the STRING network, or if the Genes2Network presented an interaction between
two genes with fewer intermediate connecting genes.
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Figure 2.3: Flow chart of wet lab protocols used in microarray sample preparation.
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Figure 2.4: Quality checks incorporated throughout the sample preparation protocols.
CHAPTER 3: RESULTS
3.1 Study Sample Details
Ovarian tumors are histopathologically a heterogeneous group, and, as described
in the first chapter; there is disagreement as to whether they derive from a common
progenitor type or pathway. Under such circumstances a meaningful experimental
design must focus narrowly if the study is to answer any meaningful question. In
addition, human polygenic diseases require a large number of samples to achieve real
statistical power, and the ability of any one clinical center to acquire that number
is limited. Thus, a public ovarian cancer consortium has been established [113] to
allow multiple centers to co-contribute. While CMC does not belong formally to
the consortium it may contribute data, through the Gene Expression Omnibus. The
bioinformatics challenge to such an endeavor is that the data are not all collected
on the same platform or prepared with the same reagents, so effort is required to
standardize and normalize the data before it can be combined in what are termed
meta-studies [152]. Our contribution focuses on serous tumors, the most frequent
ovarian tumors, both benign and malignant (type II). Malignant tumors were all
type II serous tumors exhibiting a high-grade pathology and/or with co-occurrence
of tumor in the fallopian tube. Tumor sample pathologies observed included simple
serous cysts, serous cysts, serous cystadenomas, serous cystadenofibroma, and serous
carcinomas (papillary and cuboid).
The design initially proposed had 10 samples per tissue category, as illustrated in
Table 3.1. However, patients arrive according the logic of their disease and time, not
ours. This explains the distribution and numbers of samples that were actually used,
as shown in Table 3.2, which details the count of collected and hybridized samples
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Table 3.1: Sampling model design.
Normal Epithelium Tumor Stroma Tumor-Stroma Environment
Benign 10 10 10 10
Malignant 10 10 10 10
before quality control filtering (including replicates). Paired samples are preferred,
to control for age, genotype and environment, but when adequate amounts of high-
quality cells of all 4 types could not be found, a minimal requirement for pairing of
control and test tissues was defined (that is, normal ovarian surface epithelium with
tumor and stroma with tumor-stroma environment). Lastly, since normal epithelial
cells are least frequent in number and most easily removed by basic handling, for
samples having well defined cells of the other types but no available normal epithelial
cells, samples from age matched patients were considered acceptable. Percentages of
sample pairings are shown for benign and malignant samples in Figure 3.1.
Figure 3.1: Percentages of pairing schemes for benign (left) and malignant (right)
samples. “4” or “2” indicate the number of tissue samples derived from age matched
patients. “4 Paired” or “2 Paired” indicate the number of tissue samples derived
from the same patient. Samples counts are reported after all quality control has been
performed (total count 50 samples).
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Table 3.2: Total of 75 samples, details include replicates, before quality control.
Normal Epithelium Tumor Stroma Tumor-Stroma Environment
Benign 8 8 10 9
Malignant 8 10 11 11
Table 3.3: Basic patient demographic and pathology details.
Patient Tumor Cohort Pathology Age of Patient
PN1 Non-tumorous Non-tumorous 47
PN2 Non-tumorous Non-tumorous 66
PN3 Non-tumorous Non-tumorous 79
PN4 Non-tumorous Non-tumorous 65
PB1 Benign Simple Serous Cysts 69
PB2 Benign Serous Cystadenoma 39
PB3 Benign Serous Cystadenofibroma 63
PB4 Benign Serous Cysts 66
PB5 Benign Serous Cystadenofibroma 43
PB6 Benign Serous Cysts 27
PB7 Benign Papillary Serous Cystadenofibroma 65
PB8 Benign Simple Cyst 65
PB9 Benign Serous Cystadenofibroma 69
PM1 Malignant Papillary Serous Carcinoma 75
PM2 Malignant Serous Carcinoma 54
PM3 Malignant Serous Carcinoma 74
PM4 Malignant Serous Carcinoma 64
PM5 Malignant Serous Carcinoma 80
PM6 Malignant Serous Carcinoma 54
PM7 Malignant Serous Carcinoma 49
PM8 Malignant Papillary Serous Carcinoma 70
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3.2 Laser Capture Microdissection
Laser capture microdissection (LCM) was performed on all samples used in this
study. Although enabling the study to be more specific to tissue type expression,
LCM is a technically challenging assay that requires considerable preparatory work
as well as the time to perform the cell collection, neither of which preserves RNA in
an intact form. Staining is necessary to allow visual confirmation of target tissues.
The provided kit (Histogene Staining Kit) is an RNAse-free variant of hemotoxylin
staining. Pre-LCM staining, however, did not provide the same degree of visual
discrimination as standard tissue staining techniques. There is a trade-off between
using sufficient dye to make definitive calls and minimal enough amounts to prevent
interference in subsequent manipulations. In our hands the optimal trade-off used
OCT embedded samples serially cryosectioned, with some of the sections stained
with Hemotoxylin and Eosin (H&E). The H&E stains were fixed to slides and used to
guide LCM performed on the remaining serial sections (which were minimally exposed
to staining). While it meant that not all cells in a sample were used, a time-limit
was imposed during which a section was put in the LCM. This was to control for
degradation of RNA as it is exposed to ambient temperatures and atmosphere. All
LCM manipulations of a section were performed within 1 hour (from staining to RNA
extraction buffer).
For the majority of samples, each step of LCM capture was documented with im-
ages (Appendix A). This is partly to verify that the expected cells were captured. To
illustrate the process, sample B05 is shown during capturing of normal epithelium in
Figure 3.2. (A reference H&E stained section of the captured area is shown in Figure
3.3.) The first panel of Figure 3.2 shows a single-layer lining of normal epithelium
on the edge of a tissue section. The second panel shows capturing sites, periodically
placed along the normal epithelium. The third panel was taken after capturing; ar-
eas of captured (and removed) normal epithelium and unaffected normal epithelium
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are shown, to illustrate the specificity and success of normal epithelium capturing.
Figure 3.4 shows the specificity of tumor and adjacent stroma collection. The first
panel shows the initial capture site, the second shows just tumor cells captured (on
the cap), and the third shows the section after both tumor and peripheral stroma
were separately captured. Other examples are shown in Appendix A.
Figure 3.2: An image progression, capturing normal epithelium (sample B05). Before
capture (left), intermittent capture (middle), after capture (right). Images adjusted
100% increased brightness, 75% increased contrast for image clarity.
3.3 In Silico Quality Control
3.3.1 Rudimentary Microarray Processing Quality Control
Quality control of samples was performed on .cel files (raw data) to determine if
microarrays successfully hybridized. This step determines if a GeneChip in combina-
tion with the sample performs to specifications. Although every effort was made to
perform quality control on the samples, uncontrolled variables are the hybridization
cocktail and the GeneChip lot and age (and performance of the hybridization station
and scanner). It is noted here that there currently is no validated standardization
method for quality control of exon microarrays. Affymetrix, Inc. does make available
the software tool “Expression Console” which enables researchers to perform rudi-
mentary quality control. Several metrics can be performed to compare samples to
each other and determine if the total microarray signal is significantly different from
others in the study [125]. All measures of signal in this rudimentary quality control
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Figure 3.3: Hemotoxylin and Eosin staining of sample B05.
Figure 3.4: An image progression, capturing tumor and adjacent stroma (paired
benign tumor and tumor-stroma environment samples B16 and B22).
are based on performing RMA Sketch, using only “Core” annotation type probes;
however, measurements with “Extended” annotation type probes produced similar
trends (data not shown).
Extracted intensity values are first displayed as box plots (Figure 3.5). Technical
replicates are paired, sharing a primary label and using the letter ‘R’ to distinguish
them (for example M06 and M06R). Inspection of the box plots shows considerable
variation in the sample signals. The distribution of signal is one of the criteria for
a quality array: failed chips have lower mean intensities and a smaller total signal
range. We did not attempt to retrieve partial data from these arrays since we could
not determine single probe quality criteria.
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Figure 3.5: Box plots of the intensities of each microarray. Samples are ordered as
follows: normal epithelial (benign samples) (B01-B05), stroma (benign samples) (B06-
B13), tumor (benign samples) (B14-B19), tumor-stroma environment (benign sam-
ples) (B20-B25), normal epithelium (malignant samples) (M01-M06), stroma (ma-
lignant samples) (M07-M13), tumor (malignant samples) (M14-M21), tumor-stroma
environment (malignant samples) (M22-M29), and failed chips (X B04-X M27). Dis-
tributions of failed chips show a clear difference in range and level of intensity.
A number of probes on the GeneChip were designed to report solely on back-
ground, whose mean signal is compared to that of the reporting probes, as shown in
Figure 3.6 (compare the red to blue lines, see Figure legend for details) [126]. Per
.cel file, the difference between the experiment and background signal is commonly
used to classify measurements as meaningful. For these data sets, as a quality control
metric, if the global mean of reporting and background probes was very similar the
arrays were categorized as failed. It was reassuring to note that those samples failing
this quality control check coincide with those that failed the intensity distribution
assessment.
Batch effects, based on global properties of the probe intensities, were character-
ized using correlation between means, variance and outliers of individual arrays.
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Figure 3.6: Line graph plotting the mean signal of experiment probes (red) and mean
signal of background probes (blue).
3.3.2 73 Samples
Of the 75 samples prepared for this study, 73 hybridizations generated .cel files
without primary errors and were subjected to the quality control stages. Samples
prepared with the same lots of reagents often show correlation based on this variable
rather than the clinical variable, usually called a ‘batch effect’. There are a number of
simple visual analytic approaches to test for such association, one of the best-known
being Principle Components Analysis (PCA). Examination of the first three compo-
nents across all 73 samples, including those that were called ‘failed’, was performed
on GCRMA calculated ProbeSet values. We note here that the samples from failed
arrays were retrieved, rehybridized to fresh GeneChips with newly prepared sample
and that those follow-up arrays were judged to have passed. In Figure 3.7, passed
samples are green, the technical replicates are in blue, those in red were first rated as
failed. The passed samples (study and technical replicates) clearly cluster together.
Rotation of the components shows that the failed samples occupy a broad area below
the others (Figure 3.7).
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Figure 3.7: All samples, visualized with principal components analysis. Green spheres
indicate samples that have passed initial quality control (QC), blue spheres represent
samples that passed QC and were technical replicates, and red spheres were samples
that failed QC.
Samples that initially failed and were resampled and subjected to a second round
of hybridization that lead to qualification are highlighted in Figure 3.8. This figure
demonstrates that the passed replicate samples now cluster with the other passed
samples and not their previous arrays in the failed group. The pass/fail pairs are
colored and labeled based on the specific patient number and tissue type from which
they are derived. One can also examine how the samples cluster with respect to the
clinical class. The closest distance is between samples M25 and M27, which came
from patient 42 (tumor-stroma environment sampling).
Technical replicates should cluster most tightly of all samples with LCM purified
samples. Figure 3.9 displays the clustering results, with replicates shown in the same
color. All pairs are in close proximity, and since they all qualified they all group in
the ‘pass’ cluster. One would expect that the variance between replicates would be
smaller than the mean for all sample pairs, and this is indeed the case, shown in
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Figure 3.8: Principle components analysis of samples that initially failed but were re-
sampled and analyzed. Related failed and passed samples are indicated with the same
color. White samples are not relevant but could not be removed without changing
the covariance structure of the PCA plot.
Figure 3.8. Since a rehybridized sample might be depleted in some components, we
examined the variance between pass/fail pairs are less than the general variance seen
between the passed sample and failed sample pairing in Figure 3.9. This illustrates
that technical replicates are more similar by this measure than pass/fail pairs, shown
in Figure 3.10 using a trio (Pass/Fail/Replicate) of samples from B04.
When more sophisticated quality controls were instituted the same general group-
ing of samples was observed, although specific pair-wise distances were not main-
tained. Thus all measures gave agreement on the removal of the samples listed,
specifically in the case of one batch.
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Figure 3.9: Principle components analysis of samples with their representative tech-
nical replicates. Color indicates passed samples and associated technical replicates.
White samples are not relevant but could not be removed without changing the co-
variance structure of the PCA plot.
Figure 3.10: Principle components analysis of sample B04 with its technical replicate,
and a failed sample (green, blue, and red respectively). White samples are not relevant
but could not be removed without changing the covariance structure of the PCA plot.
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3.3.3 Outlier Experimental Samples
Of the 75 samples eventually prepared, 54 samples were unique and had acceptable
quality for subsequent analysis. Basic PCA of this subset of samples is shown in
Figure 3.11. Color according to several classifiers was used to look for indications
of substructure in the clusters. Figure 3.11 (left) compares malignant and benign
samples without showing a distinct class separation. However four samples cluster
together away from the main group, 2 from each class. The samples are M04, M27,
B01, and B15, two are from normal epithelium, one is from tumor, and one is a
tumor-stroma microenvironment sample. Interestingly, these come from only two
patients: PM6 (M04 [NE] and M27 [TS]) and PB2 (B01 [NE] and B15 [T]). All but
the tumor sample were outliers on the right edge of the 3D-PCA plot. Checking
several of the batch factors for possible correlation with the structure did not uncover
anything significant. This observation is data-cleansing method dependent; when
RMA was used to to calculate sample signal the structure disappeared (data not
shown). The structure is not genotype-dependent as additional samples from these
patients, using the same preparative reagents, did not co-cluster with the outliers.
These samples were removed from the pool used in subsequent analyses since there
is a clear but undefined factor exerting considerable influence on the data. After the
preceding quality control steps were carried out, 50 samples remained for the analyses
described below, detailed in Table 3.4.
3.3.4 Sample Factors: Random and Experimental
Many factors affect processes this complex that might influence the sample strat-
ification, including: clinician involved in tissue harvesting, patient’s other known
conditions and demographics, tumor stage and origin (epithelial or mesenchymal),
experimental cohort, sample preparation conditions, and hybridization processing
batch. Examination of these factors for correlation with general data features showed
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Figure 3.11: Principle components analysis of experimental samples. Coloring is by
cohort (left) and coloring by patient (right) (with 4 outliers).
Table 3.4: Experiment sample count after completing all levels of quality control.
Normal Epithelium Tumor Stroma Tumor-Stroma Environment
Benign 4 5 8 6
Malignant 5 8 7 7
positive effects of varying degree for: the clinician, cohort, tissue type, tumor ori-
gin, sample preparation conditions, and hybridization processing batch. The patient
tumor, patient, and age factors were not significantly correlated with general data
features.
55
Figure 3.12: Principal components analysis of the final 50 samples, colored by tissue
type (left) and cohort (right). Tissue type is indicated as: tumor (red), normal
epithelium (green), stroma (blue) and tumor-stroma environment (purple). Cohorts
are indicated as: tumor (shades of red), normal epithelium (shades of green), stroma
(shades of blue), and tumor-stroma environment (shades of purple). The lighter
shades are benign and the darker shades are malignant.
Uncontrolled factors for which some substructure was revealed included clinician
(Figure 3.13), tissue origin (Figure 3.15), sample preparation (Figure 3.14), and hy-
bridization processing batches (Figure 3.14). Most of the samples were harvested by
clinicians C1 and C2 (clinician encoded as Cn, where n is 1-4); for C1 and C2 no
clustering is apparent while C3 and C4 collected 4 samples which do appear to show
substructure, but given the sample size this may not be significant. Since they remain
within the overall cluster and do not redefine the boundary they do not need to be
removed from the pool. Since the hybridization processing occurs after the sample
processing, it encompasses the cumulative variation (Figure 3.14). In general, both
images show a similar pattern. If samples are coded by image processing date (Figure
3.14, right) a trend is observed, in which samples appear higher in the cluster the
later the scan date. This trend is typical of practice effects.
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The controlled factors of interest in this study were the tissue type, patient tumor
and the interaction of these two factors, designated as “cohorts”. Tissue type specified
if the tissue was normal epithelium, stroma, tumor, or tumor-stroma environment.
Patient tumor is defined as the tumor type of the patient the tissue was removed from
(benign or malignant), no matter the malignancy of the tissue. The interaction of
the factors, or cohort, included the following distinctions: normal epithelium from a
patient exhibiting a benign tumor, tumor from a patient exhibiting a benign tumor,
and so on for all combinations of tissue type and patient tumor. Using PCA on
GCRMA intensities, the samples did not fall into clearly defined groups according to
a “patient tumor” variable (data not shown), however, using either tissue type (Figure
3.12, left) or cohort (Figure 3.12, right), similar groups emerged. In Figure 3.12, left,
the tumor sample group is distinct from the normal epithelium sample group, and
from the stroma and tumor-stroma environment sample groups. The most dispersed
sample groups are the normal epithelium and the tumor-stroma environment. The
stroma group falls into a distinct cluster, completely separate from the tumor samples
but overlapping the NE and TS groups. In Figure 3.12 right, we examine the four
interaction variables to determine whether local structure exists within the larger
tissue type clusters; no such structure can be observed. On the other hand, based
on tissue origin (epithelial Vs. mesenchymal) substructure becomes apparent (Figure
3.15), although some overlap occurs.
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Figure 3.13: Principal components analysis of the final 50 samples, colored by clini-
cian.
Figure 3.14: Principal components analysis of the final 50 samples, colored by sample
preparation batch (left) and chip scan date (right).
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Figure 3.15: Principal components analysis of the final 50 samples colored by tissue
of origin: epithelial (red) or mesenchymal (blue). Images show orthogonal views.
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3.4 Gene-level Analysis
In order to perform gene-level analysis, transcripts (232,496 core ProbeSets) were
collapsed into 22,027 transcript clusters (effectively genes) using a winsorized mean
[153]. A 2-way ANOVA was performed, for which factor 1 was patient tumor and
factor 2 the tissue type, so the interaction was patient tumor x tissue type. After
performing the ANOVA, a total of 6 contrasts were performed, in order to define lists
of significantly differentially expressed (DE) genes (Table 3.5). All such transcript
clusters were significant with a FDR of less than or equal to 0.05 and an absolute fold
change of 2 or greater.
For malignant tumors, the S x TS contrast detected no DE genes. Contrasting
NE and S in malignant tumor Vs benign tumor samples detected no DE genes. In
benign tumors the NE x T yielded 92 DE genes (the benign tumor cluster list) and,
in malignant tumors the NE x T contrast yielded 87 DE genes (the malignant tumor
cluster list) (Figure 3.16). In benign tumors the S x TS contrast revealed a single
DE gene, (NRCAM, a neuronal adhesion molecule in the immunoglobulin superfamily
that is involved in cell-cell adhesion and directional signaling, characterized by having
many isoforms) [154] (Figure 3.16). Further inspection of the benign tumor cluster
list showed the 78 of the 92 DE genes showed increased expression, while in the
malignant tumor cluster list 73 of the 87 DE genes showed increased expression. Of
the DE genes with increased expression, 21 were common to both lists. Both lists
had a total of 14 DE genes that decreased in expression, of which 2 were common to
both lists (Figure 3.17). Detailed transcript cluster lists can be found in Appendix B.
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Figure 3.16: Difference and intersection counts of transcript (left) and transcript
cluster (right) lists. NrCAM was found significant to both transcript and transcript
cluster benign tumor-stroma environment lists.
Figure 3.17: Difference and intersection counts of increasing (left) and decreasing
(right) transcript cluster lists produced from the gene-level analysis. NrCAM was
found significant in the increasing transcript cluster list commenting on the benign
tumor-stroma environment. GNG11 and END2 were found in common in both ma-
lignant and benign tumor decreasing transcript cluster lists.
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Table 3.5: A posteriori contrasts, performed at the transcript cluster (gene) level.
Control Cohort Test Cohort Gene Contextualization
Count
Normal Epithelium Tumor 92 Benign tumor
(Benign Sample) (Benign Sample) gene list
Normal Epithelium Tumor 87 Malignant tumor
(Malignant Sample) (Malignant Sample) gene list
Normal Epithelium Normal Epithelium 0 Differences in
(Malignant Sample) (Benign Sample) epithelial controls
Stroma Tumor-Stroma 1 Effects to stroma
(Benign) Microenvironment of exposure
(Benign) to benign tumors
Stroma Tumor-Stroma 0 Effects to stroma
(Malignant) Microenvironment of exposure to
(Malignant) malignant tumors
Stroma Stroma 0 Differences in
(Benign) (Malignant) stromal controls
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3.5 Transcript-level Analysis
We selected exon arrays as the platform because it allows us to further dissect DE
genes into component isoforms. Thus, after determining the DE genes, the ANOVA
step was extended to the transcript level, with the same FDR and significance cut-
offs. This expands the input to 221,985 ProbeSets. The same experimental factors
were used as in section 3.4, and some terms were added to allow us to model exons as
distinct factors (described in detail in the Inferential Statistics section of the Materials
and Methods). In the benign tumor samples, the NE x T contrast revealed 116 DE
transcripts (Figure 3.16, left) of which 95 were increased (Figure 3.18, left) and 21
decreased in expression (Figure 3.18, right); in the malignant tumors the NE x T
contrast revealed 107 DE transcripts (Figure 3.16) of which 85 increased (Figure
3.18, left) and 22 decreased in expression (Figure 3.18, right). Across the two lists, 31
increased (Figure 3.18, left) and 3 decreased transcripts were in common (Figure 3.18,
right). In the benign tumor S x TS contrast the same single DE transcript (NRCAM;
NM 001037132) was identified. No DE transcripts were found for the other contrasts.
All transcript DE list counts are shown in Table 3.6. Detailed transcript lists can be
found in Appendix B.
Within a transcript cluster some transcripts may vary when others do not, so a
second comparison was performed. The single DE gene identified in the benign tumor
S x TS contrast, NRCAM, maps to the same transcript form. Of the 92 DE genes in
the NE x T benign tumor list, 83 map to transcripts identified in the list of 116 DE
transcripts (Figure 3.19, left). Of the 87 DE genes in the NE x T malignant tumor
list, 86 mapped to the same transcript (Figure 3.19, right). The genes, transcripts
and differences are discussed in detail below.
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Figure 3.18: Difference and intersection counts of increasing (left) and decreasing
(right) transcript lists produced from the transcript-level analysis. NrCAM wass
the increasing transcript found significant to the benign tumor-stroma environment.
END2, GNG11, and MGP were the decreasing transcripts found significant to the
benign and malignant tumor environments.
Figure 3.19: Difference and intersection counts of transcript lists Vs transcript cluster
lists derived from benign tumors (left) and malignant tumors (right). KCTD1 was
the transcript cluster not found when modeling malignant tumor as transcripts.
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Table 3.6: A posteriori comparisons and contrasts, performed at the transcript level.
Control Cohort Test Cohort Gene Contextualization
Count
Normal Epithelium Tumor 116 Benign tumor
(Benign Sample) (Benign Sample) gene list
Normal Epithelium Tumor 107 Malignant tumor
(Malignant Sample) (Malignant Sample) gene list
Normal Epithelium Normal Epithelium 0 Differences in
(Malignant Sample) (Benign Sample) epithelial controls
Stroma Tumor-Stroma 1 Effects to stroma
(Benign) Microenvironment of exposure
(Benign) to benign tumors
Stroma Tumor-Stroma 0 Effects to stroma
(Malignant) Microenvironment of exposure to
(Malignant) malignant tumors
Stroma Stroma 0 Differences in
(Benign) (Malignant) stromal controls
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3.6 Biological Contextualization
Significant results were found for the NE x T contrasts in benign and malignant
tumors. These can be considered with respect to individual elements, or mapped in
sets to pathways and systems. For the latter approach there are a number of public
resources that facilitate different levels of interaction, from the genetic manipulation
of metabolic pathways to the yeast two-hybrid and cross-linking methods used in
protein-protein interaction studies. The results presented here used DAVID [134]
[135], which has the advantage that multiple databases are accessed and the asso-
ciations encompass a number of types of connections. Summary counts for results
from DAVID are recorded in Table 3.7 and Table 3.8 (detailed tables are given in
Appendix C). Databases are listed if significant terms resulted from them. Signifi-
cance was determined by an FDR of at least 0.05. The column label “exon” indicates
transcript-level results and the label “gene” indicates transcript-cluster based results.
A label ‘All’ means a complete list while a label “Up” indicates the subset whose
expression was increased in the direction of the contrast, while “Down” indicates the
opposite. The interpretation of these results are presented in Chapter 4.
3.6.1 Chromosomal Location
It is well known that there are gross chromosomal aberrations associated with
many cancers, and that there are long-range epigenetic effects in evidence. Thus co-
location can be an informative feature for genes that are mutually affected even when
functional roles do not overlap. DAVID reports on chromosomal location at two scales:
chromosome number and cytoband, and the genes themselves have start positions
relative to the reference genome build. Examination of the gene lists indicates one co-
location cluster occurs for the malignant tumor increased expression at the transcript
level. Chromosome 8 is significant (FDR = 0.024) with the gene set (RAD54B,
SOX17, AZIN1, CHMP4, C8orf62, ESRP1, FAM49B, GRHL2, MAL2, PRKDC, and
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Table 3.7: Summary of biological annotation for benign transcript and transcript-
cluster lists. Abbreviations include the following usage: SP for Superfamily (Protein),
PIR for Protein Information Resource, GOTerm CC for Gene Ontology Term Cellular
Component followed by a number indicating specificity of terms included (the larger
the more specific), FAT for Filtered Algorithm Tree, Panther MF for Protein Analysis
through evolutionary relationships molecular function, UCSC TFBS for University
California Santa Cruz Transcript Factor Binding Site, CGAP Sage for Cancer Genome
Anatomy Project Serial Analysis of Gene Expression, GNF U133A for Genomics
Institute of the Novartis Research Foundation U133A chip expression, and Est for
expressed sequence tag
Database Exon Exon Exon Gene Gene Gene
All Up Down All Up Down
SP Comment Type 1 0 0 1 0 0
SP PIR Keywords 2 3 0 0 0 0
GOTerm CC 2 3 3 0 0 0 0
GOTerm CC 3 5 6 0 0 0 0
GOTerm CC 4 5 3 0 0 0 0
GOTerm CC 5 5 7 0 0 0 0
GOTerm CC All 0 12 0 0 0 0
GOTerm CC FAT 0 12 0 0 0 0
Panther MF All 0 1 0 0 0 0
PIR Summary 2 0 0 0 0 0
PubMed 4 0 0 2 3 0
Biocarta 1 0 0 0 0 0
UCSC TFBS 75 64 0 48 57 0
CGAP Sage 4 2 0 2 1 0
GNF U133A 7 2 1 4 5 0
Unigene Est 12 7 0 9 12 0
Total 126 122 1 66 78 0
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Table 3.8: Summary of biological annotation for malignant transcript and transcript-
cluster lists. Abbreviations as stated in Table 3.7 with the addition of BP for biological
process and EC number for enzyme commission number.
Database Exon Exon Exon Gene Gene Gene
All Up Down All Up Down
SP Comment Type 6 10 0 12 10 0
SP PIR Keywords 0 5 0 2 4 0
GOTerm BP 2 1 0 0 0 0 0
GOTerm CC 2 0 1 1 0 0 0
GOTerm CC 3 1 0 3 2 1 1
GOTerm CC 4 0 1 1 2 2 1
GOTerm CC 5 5 3 0 4 8 1
GOTerm CC All 7 5 1 7 10 1
GOTerm CC FAT 7 15 1 7 14 1
Panther MF All 0 0 1 0 1 0
PubMed 3 7 1 3 9 0
EC Number 1 1 0 1 1 0
Reactome Pathway 0 0 0 1 1 0
UCSC TFBS 25 36 0 35 39 0
CGAP Sage 3 6 14 3 5 0
GNF U133A 8 10 7 8 8 1
Unigene Est 5 18 6 11 16 0
Total 72 119 36 98 129 6
68
SNTB1). Relevance to this finding to other reports is given in Chapter 4.
3.6.2 Gene Ontology Analysis
Functional roles are assigned to genes according to controlled vocabularies and the
curation of domain experts. The most widely used controlled vocabulary is the Gene
Ontology, or GO [148]. The hierarchy contains three independent branches, biologi-
cal process (BP), cellular component (CC), and molecular function (MF), providing
themes that link individual gene products. The significantly enriched CC terms in the
lists for both benign and malignant tumors include a number of expected categories:
plasma membrane, apical junctions, cell junctions, occluding junction, tight junctions,
cytoskeleton, extracellular matrix, as well as condensed chromosome centromeric re-
gion. Only one significant BP annotation was reported for malignant tumor, cellular
component organization, which was associated with a transcript list using all tran-
scripts (up and down). Significant enrichment of MF terms was reported for two of
the lists (increasing benign tumor transcripts ‘Up’ and malignant tumor transcripts
‘Down’); the terms were “Cell junction protein” and “Extracellular matrix”, respec-
tively. Gene and transcript mappings, their concordance with current models, and
other interpretations are given in Chapter 4.
3.6.3 Pathway Analysis
DAVID accesses several databases containing pathway and protein interaction
information, including: Biocarta, KEGG, Panther, Reactome, BIND, DIP, MINT,
NCICB, and UCSC TFBS. From these, significant interactions were reported based
on data in Biocarta, Reactome, and UCSC TFBS. In the benign tumor transcript list
(All) Biocarta reported significance for the SUMOylation pathway. Small Ubiquitin-
Like Modifiers (SUMOs) are proteins that post-translationally modify other proteins
over many processes like apoptosis, cell cycle progression, response to stress, tran-
scriptional stability and protein stabilization; the most common outcome is to modify
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localization or binding partners, and generally only a fraction of the total protein is
modified. For the malignant tumor transcript list (Up), Reactome reported signifi-
cant over-representation of cell division genes. Another form of interaction is the gene
regulatory network, which is connected by transcription factors that co-regulate spa-
tially distributed genes whose products are needed in a spatially and/or temporally
connected function. When reducing scope from known pathways to potential interac-
tions between elements in the lists, UCSC TFBS found many potential interactions
from all lists except the decreasing ‘transcript’ and ‘transcript cluster’ lists.
3.6.4 Gene Interaction Analysis
Differential gene lists from benign and malignant tumor samples were used to de-
rive networks of interaction. Two tools were used to search gene product interaction
databases for known interactions and build a network. Initially, STRING8 was used to
derive pathways for both the benign (Figure 3.20) and malignant (Figure 3.21) tran-
script lists. Only experimentally verified interactions were shown. Genes2Network
was then used to augment the STRING8-based network with inferred relationships
(Figure 3.22, benign, and Figure 3.23, malignant).
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Figure 3.20: Network of interactions between transcript products from the benign
transcript list (derived from STRING8).
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Figure 3.21: Network of interactions between transcript products from the malignant
transcript list (derived from STRING8).
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Figure 3.22: Network of interactions between transcript products from the benign
transcript list (derived from Gene2Network). Red indicates a seed node of the net-
work, yellow indicates significant nodes (z-scores > 2.5).
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Figure 3.23: Network of interactions between transcript products from the malig-
nant transcript list (derived from Gene2Network). Red indicates a seed node of the
network, yellow indicates significant nodes (z-scores > 2.5) which were not seeding
nodes, and grey indicates connecting nodes between seed or significant node.
CHAPTER 4: DISCUSSION
4.1 Notable Comparisons
Both transcript and gene (transcript cluster) lists were derived using ANOVA
models. Respectively, benign tumor, malignant tumor, and benign tumor-stroma
environment had 92, 87, and 1 significant DE genes and 116, 107, and 1 transcripts.
Global properties were evaluated using 3D-PCA of the 50 samples, in which the
most spatially distinct clusters were the tumors (benign and malignant). The other
categories clustered, but showed more overlap. Intuitively this separation makes
sense given the subsequent finding that a majority of DE genes and transcripts were
regulated in one direction (Up), rather than having equal numbers up and down. The
overlap in the benign and malignant samples at the global level is reasonable since a
number of DE genes were found in common.
The gene lists were somewhat shorter (∼10% fewer members) than the transcript
lists. This may be due to combining transcripts into one cluster. Since this data
set allows discrimination of exons, the primary focus in the following interpretation
of the results is on transcript-level analysis. That is, annotation was evaluated for
significance at both gene and transcript levels for gene networks, but pathway analyses
were performed and evaluated only with the transcript lists, except in the rare cases
where the network analysis only yielded results with gene input lists, in which case
that information was carried forward to the pathway analysis.
4.2 Control Sample Evaluations
In our opinion it is very significant that samples identified as normal epithelium
were very similar, regardless of the patient category. This observation is only possible
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for LCM isolated cells since this cell type occurs in such a small percent of the total;
thus the purification procedure was effective. When microdissected, care was taken
to identify epithelium that appeared histologically normal; this visual confirmation is
documented in Appendix A. In addition to confirming that the technical procedures
were correctly deployed, there is biological significance in this transcriptome profile
consistency: despite being in the neighborhood of abnormal cells, the epithelial cells
do not exhibit signs of significant perturbation. We infer from this stable baseline that
high confidence can be placed in those changes that are observed in other samples.
We identified no DE genes or transcripts in the profiles of distal stromal cells, re-
gardless of disease classification. While not biologically interesting, it again validates
the precision of the identification and sampling method, and increases our confidence
in the conclusions drawn from comparisons of tumor cells and their immediate neigh-
bors. Specifically, previous reports have shown that there is a change in stromal
cells adjacent to tumors, but the reports lacked specific distance information. This
study clarifies the relationship, showing that stromal cells immediately adjacent to
tumor cells are affected and more distant stromal cells are not detectably influenced
by the tumor with respect to transcripts. In fact, although we state that adjacent
stromal cells are affected by the presence of tumor, only one transcript was found to
be significantly different; this may reflect the need for more optimization in the cell
selection technique, or limits in the sample size of this study, or limits in the current
data cleansing methods, which are not very sensitive.
4.3 Ontology Enrichment
The complete results of the bioinformatics analyses that used Gene Ontology labels
as the core unit are given in Appendix C; the following paragraphs are focused on
those categories showing the greatest enrichment. In general the transcript and gene
lists yielded very similar terms and significance scores, as expected given the overlap
in the lists. When unique occurrences of a term were counted, the longer transcript
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Table 4.1: Summary of unique Cellular Component (Gene Ontology) term counts for
transcript and transcript-cluster lists associated with benign and malignant tumors.
Benign Malignant
Transcript (All) 8 8
Transcript (Increasing) 13 15
Transcript (Decreasing) 0 3
Transcript Cluster (All) 0 7
Transcript Cluster (Increasing) 0 13
Transcript Cluster (Decreasing) 0 3
lists yielded more terms. Not all lists yielded significantly enriched terms, including
benign tumor transcripts in the Cellular Component category, as shown in Table 4.1.
The relationship between these terms is visualized in Figure 4.1 (benign) and Figure
4.2 (malignant).
In Figure 4.1, there are two areas of primary enrichment, organelles and plasma
membrane, the first with more cytoskeletal terms and the second with more mem-
brane and junction terms. In Figure 4.2 a similar projection for the malignant tumor
set is shown. As in the benign tumor example, there is enrichment for organelles
and plasma membrane, and many of the subterms are shared. Interestingly, an addi-
tional category of terms referring to the extracellular region is found in the malignant
ontologies. The “Extracellular Region” term contains two significant terms “Extracel-
lular Matrix” and “Proteinaceous Extracellular Matrix”, both of which are associated
with decreased levels of transcripts. The only other Gene Ontology term associated
with transcripts present in lowered amounts is “Extrinsic to Membrane” which is
only found in the malignant ontology term set. Plasma membrane-linked terms are
most common between benign and malignant terms and differ only by the addition
of “Apical Plasma Membrane” to the malignant set. With respect to organelle-linked
terms, while the parent node is similar the leaves differ, with “Spindle” and “Con-
densed chromosome, centromeric region” dominating the malignant set rather than
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“Cell projection” and “Cilium”. Subsequent sections examine these categories and the
contributing transcripts in detail. The relationship between these terms is visualized
in Figure 4.1 (benign) and Figure 4.2 (malignant).
4.3.1 Cell Junctions
Cell junctions are a major theme in both benign and malignant transcript lists, and
many terms are shared: cell, cell-cell, occluding, tight, and apical junction (complex).
In the benign ontology set, it is the increased concentration of nine transcripts
that leads to the enrichment of these ‘junction’ terms: ARHGAP26, CDH1, CLDN4,
CLDN7, DSP, INADL, MPP7, PARD6B, PERP. Of these genes, ARHGAP26 is a rho
GTPase-activating kinase that binds to focal adhesion kinase, involved in organization
of the actin cytoskeleton. Defects in this gene are a cause of juvenile myelomonocytic
leukemia, and this gene was found to be down-regulated in other myeloid malignancies
[155]. It is regulated by Myb-b among other transcription factors. CDH1 (epithelial-
or E-cadherin) is a calcium dependent adhesion glycoprotein of the cell membrane,
and decreases have been correlated to the presence of gastric, breast, colorectal, thy-
roid and ovarian cancer. In contrast to our observations here, in which it has a higher
relative level in both benign and malignant tumors, a common observation is that
expression of CDH1 decreases proportionally to the severity of cancer stage [156]. It
has a proposed role in the mechanism of the important epithelial-mesenchymal tran-
sition [157]. It is the central element to the benign tumor network (shown graphically
in Figure 4.3), having confirmed interactions with 11 elements. It is regulated by
P53 and FOXD1 among other factors. CLDN4 and CLDN7 are both members of
the claudin family, integral membrane proteins that are part of the tight junction
complex, and regulate cell polarity and signal transduction through the paracellular
space. Claudin 4 and claudin 7 are commonly found to be over-expressed in pancre-
atic, prostate, breast and ovarian cancer (CLDN4) and in addition in hepatocellular,
urinary, lung, neck and head and thyroid cancers (CLDN7), and, in ovarian carci-
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noma, are among the most highly expressed genes [158][159]. CLDN7 has addition-
ally been identified as an independent predictor of poor survival in ovarian carcinoma
[159]. They are regulated by c-Jun, c-Fos, JunD (CLD4) and p53, MEF-2A and
NF-1 (CLDN7) among other transcription factors. Other transcripts are specifically
important to tight junction formation, including INADL [160], a protein important
to protein-protein interactions found in tight junctions and the apical membrane of
epithelial cells and with receptors that is regulated by AP-1, c-Fos, c-Jun and JunD
among others. Higher expression has been associated with progression of cervical
cancers associated with HPV infections [161]. MPP7 [162] is a membrane-associated
guanylate kinase -palmitoylated 7 adaptor protein that participates in assembling
protein complexes at the sites of cell-cell contact, such as tight junctions. It main-
tains epithelial cell polarity, and is regulated by FOXO3a,b and HNF-1A. PARD6B
[163], is a cytoplasmic protein involved in cell polarization processes as part of com-
plexes, serving as an adaptor, specifically in epithelial tight junctions; it is regulated
by the SRC-3 coactivator oncogene, and by Egr2,3, FOXL1 and E2F-3a,4,5 as well as
others. Desmosomes are also represented with DSP, desmoplakin, whose expression
increases. Desmoplakin is an obligate component of desmosomes, anchoring inter-
mediate filaments to plaques. They have been shown to gradually reduce in count
with tumorigenesis in both squamous epithelium and cervix uteri [164] [165]. More
specific to DSP expression, decreased expression in oral and pharyngeal squamous
cell carcinomas is associated with metastases [166] [167]. DSP is regulated by c-Jun,
c-Fos, NFkB, p53, c-Myc and GATA-1 among others. PERP, the TP53 apoptosis
effector gene, is a component of desmosome junctions, as well as the TP53-dependent
apoptotic pathway. The protein is localized to the plasma membrane, and is a tumor
suppressor gene down-regulated in metastatic melanoma and mammary carcinoma
[168] [169] [170].
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Figure 4.1: Graph of GO terms associated with the benign transcript lists. Terms are
placed in similar locations between the two ontology figures so relationships between
benign and malignant ontologies are clear. Border colors on ontological terms indicate
which transcript list yielded the term. Orange indicates the term arose from increasing
transcripts, blue indicates derivation from decreasing transcripts, and red indicates
significance emerged only when all transcripts were used. A black border indicates
no significance but give context in GO hierarchy. Green lines indicate an “is a part
of” relationship between terms while blue indicates an “is a” relationships between
terms. Originally, AmiGO was used to visualize the relationship between terms, the
resulting graph was redesigned in Photoshop, for clarity, without changing details or
context.
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Figure 4.2: Graph of GO terms associated with the malignant transcript lists. Figure
generated as stated in Figure 4.1.
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Of the above genes, three (ARHGAP26, PARD6B, and PERP) are not found
in the malignant transcript list. Both ARHGAP26 and PERP showed expression
changes consistent with a tumor which was not malignant (PARD6B has not been
tied to tumors). ARGHAP26 is expected to be decreasing in myeloid malignancies
but is increasing in this study; PERP is a tumor suppressor and is known to increase
in benign tumors. The expression levels in these samples may indicate that their
presence signals a block to the transition to malignant tumor.
The junction-related terms in malignant tumors were driven by transcripts of
the following genes: CALB2, CDH1, CLDN3, CLDN4, CLDN7, DSP, GABBR1,
HOMER1, INADL, MPP7, and SNTB1, of which six are common between the
benign and maligant junction terms (CDH1, CLDN4, CLDN7, DSP, INADL and
MPP7). The 5 uniquely associated with malignant samples are: CALB2, CLDN3,
GABBR1, HOMER1, SNTB1, of which CALB2, calbindin 2, and GABBR1, gamma-
aminobutryric acid B receptor 1, exhibit decreased levels. CALB2 is an intracellular
calcium-binding protein in the troponin C superfamily, and has been identified as a
marker in some cancers. It is regulated by Cart-1 and CREB among other factors.
Because of its other functions it also appears with the extracellular region terms and is
additionally discussed in that section. The additional claudin gene, CLDN4, is again
an integral membrane protein, with receptor capabilities and similarity to an apop-
tosis gene in rats. Of the other genes, SNTB1 (syntrophin, beta 1) is a cytoskeletal
protein of the peripheral membrane, responsible for organizing the subcellular local-
ization of many membrane proteins, linking receptors to the actin cytoskeleton. It is
regulated by p53, POU3F2 and STAT5A among factors. GABBR1 is a signal receptor
for the main inhibitory neurotransmitter of the mammalian CNS, in this case for the
state of prolonged inhibition, perhaps related to suppression of pain symptoms. It is
considered a therapeutic target for pancreatic cancer [171]. Activity is mediated by
many G-proteins that act by down-regulating activated calcium channels (of CALB2
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above). It is regulated by NFkB,1, Egr-1, CREB, FOXC1 and MEF-2A among other
factors. The homer homolog 1 (HOMER1) gene encodes a scaffolding protein that
binds and crosslinks the cytoplasmic regions of a number of proteins, and regulates
group 1 metabotrophic glutamate receptor function, which inhibits apoptosis [172],
coupling surface receptors to intracellular calcium release. There is evidence that
isoform 3 is involved in structural changes at synapses during neuronal development.
It is regulated by MEF-2A, POU3F2, CREB and other factors.
The tight junction figures prominently in the set above; tight junctions are one
type of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous
seals around the cells as barriers that prevent solutes and water from passing freely
through the paracellular space. They occlude movement in the plasma membrane,
segregating the apical (i.e. edge exposed to lumen) and basolateral (adjacent to cells
and basement membrane) regions of the plasma membrane. Claudins are integral to
tight junctions. Although a decrease in tight junctions is most frequently observed in
tumorigenesis, ovarian tumors do not fit this standard, and our results are in agree-
ment with those reports. Of the three claudins found to have significant expression
increase in this study, CLDN3 is the only transcript cluster containing a transcript
exclusively significant to malignant tumors. Given claudins hallmark over-expression
in malignant ovarian tumors, not benign tumors, this was initially contrary to lit-
erature. One study found CLDN3/4 overexpression in ovarian carcinomas but not
cystadenomas [173]. This would support our CLDN3 results, but does not explain
CLDN4 or, by inference, CLDN7. The assay in the study cited used immunohisto-
chemistry, and documented CLDN4 staining in up to 14% of serous cystadenomas.
When evaluated with RT-PCR, CLDN4 transcript was present at 10-fold the level of
CLDN3 transcript. A troubling aspect of the study is the absence of a positive con-
trol in the adenoma staining (negative result) group, although there was a negative
control for the carcinoma staining (positive result) group [173]. Thus the disparate
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CLDN4 results in benign tumors may reflect the more sensitive, quantitative nature
of oligonucleotide arrays over immunohistochemistry.
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Table 4.2: Summary of transcripts related to Cell Junctions, specifically “cell”, “cell-
cell”, “occluding”, “tight”, and “apical junction (complex)” terms. Listed are the
gene symbol associated with the transcript, the state of the tumor (specifically benign,
malignant, or both), the expression relative to the control tissue (given as increasing or
decreasing), and the associated ontological term/s. Terms in parentheses are related
to the transcripts but are not the direct subject matter of the table (1 of 3).
Gene Relative Tumor Term
Symbol Expression State
ARHGAP26 Increase Benign Cell junction
(Increase) (Benign) (Cytoskeleton)
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
CALB2 Decrease Malignant Cell junction
Decrease Malignant Cell-cell junction
(Decrease) (Malignant) (Plasma membrane)
(Decrease) (Malignant) (Plasma membrane part)
CDH1 Increase Both Cell junction
Increase Both Cell-cell junction
(Increase) (Both) (Apical part of cell)
(Increase) (Benign) (Cytoskeleton)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
CLDN3 Increase Malignant Apical junction complex
Increase Malignant Cell junction
Increase Malignant Cell-cell junction
Increase Malignant Occluding junction
Increase Malignant Tight junction
(Increase) (Malignant) (Apicolateral)
(plasma membrane)
(Increase) (Malignant) (Plasma membrane)
(Increase) (Malignant) (Plasma membrane part)
CLDN4 Increase Both Apical junction complex
Increase Both Cell junction
Increase Both Cell-cell junction
Increase Both Occluding junction
Increase Both Tight junction
(Increase) (Both) (Apicolateral)
(plasma membrane)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
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Table 4.3: (continued).
Gene Relative Tumor Term
Symbol Expression State
CLDN7 Increase Both Apical junction complex
Increase Both Cell junction
Increase Both Cell-cell junction
Increase Both Occluding junction
Increase Both Tight junction
(Increase) (Both) (Apicolateral)
(plasma membrane)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
DSP Increase Both Apical junction complex
Increase Both Cell junction
Increase Both Cell-cell junction
(Increase) (Malignant) (Apicolateral)
(plasma membrane)
(Increase) (Benign) (Cytoskeleton)
(Increase) (Malignant) (Plasma membrane)
(Increase) (Malignant) (Plasma membrane part)
GABBR1 Decrease Malignant Cell junction
(Decrease) (Malignant) (Plasma membrane)
(Decrease) (Malignant) (Plasma membrane part)
HOMER1 Increase Malignant Cell junction
(Increase) (Malignant) (Plasma membrane)
(Increase) (Malignant) (Plasma membrane part)
INADL Increase Both Apical junction complex
Increase Both Cell junction
Increase Both Cell-cell junction
Increase Both Occluding junction
Increase Both Tight junction
(Increase) (Both) (Apical part of cell)
(Increase) (Both) (Apicolateral)
(plasma membrane)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
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Table 4.4: (continued).
Gene Relative Tumor Term
Symbol Expression State
MPP7 Increase Both Apical junction complex
Increase Both Cell junction
Increase Both Cell-cell junction
Increase Both Occluding junction
Increase Both Tight junction
(Increase) (Both) (Apicolateral)
(plasma membrane)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
PARD6B Increase Benign Apical junction complex
Increase Benign Cell junction
Increase Benign Cell-cell junction
Increase Benign Occluding junction
Increase Benign Tight junction
(Increase) (Benign) (Apical part of cell)
(Increase) (Benign) (Apicolateral)
(plasma membrane)
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
PERP Increase Benign Apical junction complex
Increase Benign Cell junction
Increase Benign Cell-cell junction
(Increase) (Benign) (Apicolateral)
(plasma membrane)
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
SNTB1 Increase Malignant Cell junction
(Increase) (Malignant) (Plasma membrane)
(Increase) (Malignant) (Plasma membrane part)
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4.3.2 Spindle and Condensed Chromosomes
A unique set of terms was significantly enriched in the malignant tumor results,
relating to spindle functions, which are involved with cell cycle and mitosis. “Spin-
dle” term enrichment was due to the increased expression of 5 transcripts: NEK2,
BUB1B, CENPF, RCC2, and CBX3. The Never in Mitosis Gene a-related Kinase
2, NEK2, functions in mitotic regulation as an integral component of the mitotic
spindle-assembly checkpoint. It phosphorylates SGOL1, and isoforms have distinct
roles related to the cell-cycle. Increased expression has been confirmed in ovarian
cancer cell lines (SKOV3 and OVCAR5) as well as cervical, breast, prostate, and
leukemic cell lines. In breast tissue cell lines, increases of NEK2 cause cells to become
multinucleated with supernumerary centrosomes [174]. It is regulated by MIF-1,
PPAR1,2, Egr-3 and other factors. Budding uninhibited by benzimidazoles 1 ho-
molog beat (BUB1B) is a kinase involved in spindle checkpoint function, localized
to the kinetochore, that helps ensure proper chromosome segregation. It is disregu-
lated in many tumors: for example, in bladder carcinoma an increase in expression
of BUB1B was shown to be associated with variation in centromere count and, by
extrapolation to chromosomal instability (CIN) [175]. It has been implicated as an
apoptosis trigger in polyploid cells and may play a role in tumor suppression. It is
SUMOylated by SUMO2, and is regulated by PPAr-1,2, MEF-2A, GATA-2 factors,
among others. Centromere Protein F (CENPF) is known to be associated with CIN
in breast cancer and to be correlated with poor patient prognosis [176]. The gene
product associates with the centromere-kinetochore complex at the onset of mitosis
[177] and is part of the nuclear matrix in G2; it likely has a role in chromosome seg-
regation in mitosis. Autoantibodies to this protein are found in patients with cancer.
It regulates membrane recycling. It is regulated by GATA-1, RP58, δCREB, Pax-6
and other factors. Regulator of chromosome condensation 2 (RCC2) is required for
completion of mitosis and cytokinesis and may be a guanine nucleotide exchange fac-
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tor for RAC1. It has been shown to be involved in histone methylation [178], and it
interacts with microtubules. It is phosphorylated upon DNA damage. Additionally,
RCC2 was shown to be necessary for mitotic spindle formation in a siRNA experi-
ment where silencing RCC2 caused spindle assembly suppression, and activation of
the spindle cell-cycle checkpoint[179]. It is regulated by c-Fos, JunD, Junb and other
factors. Lastly, chromobox homolog 3 (CBX3) binds DNA and is a component of
heterochromatin, but also binds lamin B receptor (a nuclear membrane protein), so
it may explain the association of heterochromatin with the inner nuclear membrane
[180].
A subset of terms, “Condensed chromosome, centromeric region”, was significantly
enriched by 4 of the above transcripts (BUB1B, CENPF, RCC2, and CBX3) and one
that is unique, the Holliday junction recognition protein (HJURP). This protein plays
a primary role in the incorporation and maintenance of the Histone H3 variant called
CENPA. It is required for the incorporation of CENPA into nucleosomes at replicated
centromeres, perhaps by stabilizing it’s protein during late telophase/early G1 [181].
We note that this interaction was not placed in the gene network given that CENPF,
not CENPA, was found significant in this study.
Both increases in mitotic activity and associations with CIN would be expected
of malignant tumors so the association of the malignant tumor samples with these
terms is consistent with reports in the literature. Since the enrichment was absent in
the benign tumor samples the processes described are likely required in the steps by
which tumors progress to the malignant state.
4.3.3 Terms Related to Cell Projection
Benign tumor enriched terms are related to cell projection, cilia, and axonemes,
due to the increased presence of five transcripts for “Cilium” (CD24, DNAH11,
DNAH7, LRRC50, and SPAG17), 6 for “Cell projection part” (CD24, DNAH11,
DNAH7, LRRC50, SLC34A2, SPAG17) of which 5 are common to the previous
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Table 4.5: Summary of transcripts related to “Spindle” and “Condensed Chromo-
some Centromeric Region” terms. Listed are the gene symbol associated with the
transcript, the state of the tumor (specifically benign, malignant, or both), the ex-
pression relative to the control tissue (given as increasing or decreasing), and the
associated ontological term/s. Terms in parentheses are related to the transcripts
but are not the direct subject matter of the table.
Gene Relative Tumor Term
Symbol Expression State
BUB1B Increase Malignant Spindle
Increase Malignant Condensed chromosome
centromeric region
CBX3 Increase Malignant Spindle
Increase Malignant Condensed chromosome
centromeric region
CENPF Increase Malignant Spindle
Increase Malignant Condensed chromosome
centromeric region
HJURP Increase Malignant Condensed chromosome
centromeric region
NEK2 Increase Malignant Spindle
RCC2 Increase Malignant Spindle
Increase Malignant Condensed chromosome
centromeric region
(Increase) (Benign) (Cytoskeleton)
set, and 4 for “Axonemes” (DNAH11, DNAH7, ITLN1, LRRC50, and SPAG17),
all shared with the previous sets. ITLN1, Intelectin 1, is an adipokine normally ex-
pressed by visceral adipose tissue. Distiguishing itself as the only cell projection asso-
ciated transcript with decreased expression, reduction in ITLN1 expression is known
in polycystic ovary syndrome, obesity, and diabeties [182]. DNAH7 [183] is the heavy
chain of of axonemal dynein, the force-generating protein of respiratory cilia, as is
DNAH11 [184], and the leucine rich repeat cilium-stabilizing protein LRRC50 [185], is
associated with cilium structure and stability. None of these three genes have known
associations with carcinoma. DNAH7 is regulated by FOXC1, MIF-1, POU3F2,1 and
FOXD1, among others. DNAH11 is regulated by p53, Sp1, SRF, POU2F1 and Cart-1
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among other factors. LRRC50 is regulated by NFB1, Egr-1, CREB and SREBP-1a,b
among other factors. The sperm associated antigen 17, SPAG17, is involved in the
structural integrity of the central apparatus of the sperm axoneme, and is regulated
by POU2F1, FOXD3, Pax-6, Cdc5 among other factors. The solute carrier family 34
(Na phosphate) member 2 protein, SLC34A2, may be the main phosphate transport
protein for brush border membranes. It is regulated by c-Myb, NFB,1 among other
factors. CD24 antigen is a sialoglycoprotein expressed on mature granulocytes and in
many B cells, linked by a glycosyl phosphatidylinositol to the cell surface that may be
part of the signal transduction process. It promotes B cell proliferation but prevents
their terminal differentiation, and binds protein factors important in several cancer
cell lines and specifically with cell-type specific promoter activity in small cell lung
cancer. It is regulated by FOXO1a, POU3F2,1, FOXF2 among other factors. CD24
increases in expression have been associated with ovarian serous borderline tumor mi-
croinvasion [186]. Perhaps this increase corresponds to early stromal invasion, given
CD24s role association with borderline serous tumor microinvasion.
Cilia are a known ultrastructural feature of cells in serous cysts, but are not a
feature of ovarian surface epithelium or a consistent feature of high-grade serous car-
cinomas [187]. There are occasional reports associating cilia to tumorigenesis [188],
including a recent manuscript that cataloged a search for potential mechanisms com-
mon to primary cilium and tumorigenesis [189]. No specific mechanisms were found,
but there is evidence for a complex interaction of cilium and tumor development,
based on cell morphological and internal organization changes. In particular, centri-
oles, fundamental to separation in mitosis, are involved in the creation of cilia. In
actively dividing cells, centrioles flow between two states, centrosome and cilium, ac-
cording to the cell cycle stage [190]. As cells move to the S phase, cilia are reabsorbed
before progression to mitosis [191]. Ciliary membranes have been shown to contain
growth factors, morphogens, and hormone receptors [189]. Although mechanisms by
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which cilia use the receptors and signaling components are unclear [189], the poten-
tial for ciliated membranes to affect tissue architecure is considerable as connections
between the signaling and morphogens pathways (Wnt and Hedgehog signaling) are
better understood. Other aspects of cilia also seem related to cancer, such as the
occurrence of human inherited mutations in cilia that result in cell proliferation and
cysts (for example polycystic kidney disease). Loss of ciliated membranes leads to
the redistribution of receptors and consequent aberrant signaling [192] [193].
While cilium terms are enriched only for the benign tumors, spindle terms are
enriched only for the malignant samples. A possible explanation is the changing role
of centrioles, shuttling between the spindle and cilium as the time spent in a particular
part of the cell cycle changes. That is, given that cilium-related genes show increased
in expression in benign samples and spindle-related gene expression is increased in
malignant samples, this shift could be due to monopolization of centrioles by the
cell-cycle functions. Thus, this set of genes may be an indicator of malignancy. A
lack of cilia may reduce a cells sensitivity to external signals working to suppress the
tumor.
4.3.4 Terms Related to Plasma Membranes
Plasma membrane related terms were enriched and many were shared by both
benign and malignant transcript lists.
Excluding cell junction terms (discussed above in section 4.3.1, as a separate
group), benign plasma membrane terms are most specific for apical and apicolat-
eral plasma membranes. The term “Apicolateral plasma membrane” is related to
increased expression of the same transcripts as “Apical part of cell”, and has already
been discussed above. The benign related transcripts are: INADL, CDH1, EPCAM,
PARD6B, SCNN1A, and SLC34A2. Of these, INADL, CDH1, and PARD6B were
discussed above, under tight junction terms and SLC34A2 under the cell projection
ontology. SCNN1A is a sodium channel, non-voltage gated 1 alpha, and is not unique
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Table 4.6: Summary of transcripts related to “Axoneme”,“Cell Projection Part”,
and “Cilium” terms. Listed are the gene symbol associated with the transcript, the
state of the tumor (specifically benign, malignant, or both), the expression relative to
the control tissue (given as increasing or decreasing), and the associated ontological
term/s. Terms in parentheses are related to the transcripts but are not the direct
subject matter of the table.
Gene Relative Tumor Term
Symbol Expression State
CD24 Increase Benign Cell projection part
Increase Benign Cilium
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
DNAH7 Increase Benign Axoneme
Increase Benign Cell projection part
Increase Benign Cilium
(Increase) (Benign) (Cytoskeleton)
DNAH11 Increase Benign Axoneme
Increase Benign Cell projection part
Increase Benign Cilium
(Increase) (Benign) (Cytoskeleton)
ITLN1 Decrease Benign Cell projection part
(Decrease) (Benign) (Plasma membrane)
(Decrease) (Benign) (Plasma membrane part)
LRRC50 Increase Benign Axoneme
Increase Benign Cell projection part
Increase Benign Cilium
(Increase) (Benign) (Cytoskeleton)
SLC34A2 Increase Benign Cell projection part
(Increase) (Benign) (Apical part of cell)
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
SPAG17 Increase Benign Axoneme
Increase Benign Cell projection part
Increase Benign Cilium
(Increase) (Benign) (Cytoskeleton)
to plasma membrane as it is also associated with “Cytoskeleton”. It was included in
this group since it is epithelial membrane-associated but has no direct associations
to carcinoma [194]. It controls the re-adsorption of sodium in many of the gut or-
gans, and has a role in taste perception. It is regulated by c-Fos, c-Jun, NF-B,1, p53,
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PPAR-1,2 and other factors. EPCAM is the epithelial cell adhesion molecule, a mem-
brane protein found in most normal epithelial cells and gastrointestinal carcinomas.
It is calcium-independent. Although it appears only in this list because it fell below
the significance limit for the malignant samples, there was increased expression in
both benign and tumor samples, relative to normal epithelium, and it is central to a
number of interaction networks. EPCAM is considered to be one of the most widely
expressed tumor transcripts and there are multiple derived therapeutics that target
this gene product [195]. Several studies have evaluated EPCAM in ovarian surface
epithelial-stromal tumors, and while there is disagreement as to its effectiveness as
a marker for progression, all studies found increased EPCAM expression in tumors
[196] [197] [198] [199]. It is regulated by HNF-41,2 among other factors.
The ontological terms enriched in malignant samples are nested in a similar fash-
ion to the benign terms. Six transcripts lead to the appearance of this term “Apical
Part of Cell” including INADL, CDH1, EPCAM, MUC1, SCNN1A, and ERBB3. Of
these, 2 are unique (MUC1 and ERBB3) to this sample class. ERBB3/HER3/Erb1
is the v-erb erythroblastic leukemia oncogene homolog 3, an epidermal growth fac-
tor receptor (EGFR, tyrosine kinase family). It is membrane bound, and can bind
ligand, but requires heterodimerization with another EGFR member before signal
transduction occurs; the activated pathways lead to cell proliferation and differenti-
ation. Overexpression of this gene is reported in many cancers. One of its isoforms
is secreted and functions to modulate the activity of the membrane-bound form.
It is regulated by c-Jun, PPAR-1,2, c-Myb and MRF-2 among others. It belongs
to a family of 4 human growth factor receptors (HER), all which are under differ-
ent levels of investigation for therapeutics in multiple carcinomas including ovarian
types. Mucin 1, cell surface associated, MUC1, is a membrane-bound glycosylated
phsophoprotein. It binds to pathogens and also functions in cell signaling, including
modulation of signaling in the ERK, SRC, and NK-B pathways, while in activated T-
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cells it influences the Ras/MAPK pathway. Changes in expression, modification, and
aberrant localization are all associated with carcinomas. It is regulated by NF-B,1,
c-Jun, c-Fos, GR-, GATA-3 among other factors. Mucins as a group are commonly
expressed in carcinomas, including reports of association specifically with ovarian
surface epithelial-stromal tumors, including the serous subtype [200] [201].
Given the cross-over between plasma membrane terms and more specific terms (for
instance “Apical Junction Complex”), these plasma membrane terms are driven by
transcripts more specifically associated with other ontologies. Transcripts associated
with EPCAM, ERRB3, and MUC1 are uniquely associated with these terms; all have
well-documented associations with ovarian tumors.
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Table 4.7: Summary of transcripts related to “Plasma Membrane” and “Plasma
Membrane Part”. Listed are the gene symbol associated with the transcript, the
state of the tumor (specifically benign, malignant, or both), the expression relative to
the control tissue (given as increasing or decreasing), and the associated ontological
term/s. Terms in parentheses are related to the transcripts but are not the direct
subject matter of the table (1 of 7).
Gene Relative Tumor Term
Symbol Expression State
AMHR2 Decrease Benign Plasma membrane
Decrease Benign Plasma membrane part
ARHGAP26 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
(Increase) (Benign) (Cell junction)
(Increase) (Benign) (Cytoskeleton)
CALB2 Decrease Malignant Plasma membrane
Decrease Malignant Plasma membrane part
(Decrease) (Malignant) (Cell junction)
(Decrease) (Malignant) (Cell-cell junction)
CD24 Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Benign) (Cell projection part)
(Increase) (Benign) (Cilium)
CDH1 Increase Both Apical part of cell
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Cell junction)
(Increase) (Both) (Cell-cell junction)
(Increase) (Benign) (Cytoskeleton)
CDH6 Increase Both Plasma membrane
CLDN3 Increase Malignant Apicolateral
plasma membrane
Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
Increase Malignant (Apical junction complex)
Increase Malignant (Cell junction)
Increase Malignant (Cell-cell junction)
Increase Malignant (Occluding junction)
Increase Malignant (Tight junction)
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Table 4.8: (continued).
Gene Relative Tumor Term
Symbol Expression State
CLDN4 Increase Both Apicolateral
plasma membrane
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Apical junction complex)
(Increase) (Both) (Cell junction)
(Increase) (Both) (Cell-cell junction)
(Increase) (Both) (Occluding junction)
(Increase) (Both) (Tight junction)
CLDN7 Increase Both Apicolateral
plasma membrane
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Apical junction complex)
(Increase) (Both) (Cell junction)
(Increase) (Both) (Cell-cell junction)
(Increase) (Both) (Occluding junction)
(Increase) (Both) (Tight junction)
CLEC4M Decrease Benign Plasma membrane
Decrease Benign Plasma membrane part
COL6A1 Decrease Malignant Plasma membrane
(Decrease) (Malignant) (Extracellular matrix)
(Decrease) (Malignant) (Proteinaceous extracellular matrix)
COL6A2 Decrease Malignant Plasma membrane
(Decrease) (Malignant) (Extracellular matrix)
(Decrease) (Malignant) (Extrinsic to membrane)
(Decrease) (Malignant) (Proteinaceous extracellular matrix)
CP Increase Both Plasma membrane
Increase Both Plasma membrane part
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Table 4.9: (continued).
Gene Relative Tumor Term
Symbol Expression State
DSP Increase Both Apicolateral
plasma membrane
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Apical junction complex)
(Increase) (Malignant) (Cell junction)
(Increase) (Malignant) (Cell-cell junction)
(Increase) (Benign) (Cytoskeleton)
DYTN Increase Benign Plasma membrane
EHD2 Decrease Both Plasma membrane
Decrease Both Plasma membrane part
(Decrease) (Malignant) (Extrinsic to membrane)
EPCAM Increase Both Apical part of cell
Increase Both Plasma membrane
Increase Both Plasma membrane part
ERBB3 Increase Malignant Apical part of cell
Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
FOLR1 Increase Both Plasma membrane
Increase Both Plasma membrane part
GABBR1 Decrease Malignant Plasma membrane
Decrease Malignant Plasma membrane part
(Decrease) (Malignant) (Cell junction)
GNG11 Decrease Both Plasma membrane
Decrease Both Plasma membrane part
(Decrease) (Malignant) (Extrinsic to membrane)
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Table 4.10: (continued).
Gene Relative Tumor Term
Symbol Expression State
GPR39 Increase Both Plasma membrane
Increase Both Plasma membrane part
HOMER2 Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
(Increase) (Malignant) (Cell junction)
INADL Increase Both Apical part of cell
Increase Both Apicolateral
plasma membrane
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Apical junction complex)
(Increase) (Both) (Cell junction)
(Increase) (Both) (Cell-cell junction)
(Increase) (Both) (Occluding junction)
(Increase) (Both) (Tight junction)
ITLN1 Decrease Benign Plasma membrane
Decrease Benign Plasma membrane part
(Decrease) (Benign) (Cell projection part)
LAMC2 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
LPAR3 Increase Both Plasma membrane
Increase Both Plasma membrane part
LYPD1 Increase Both Plasma membrane
MAL2 Increase Both Plasma membrane
MAP7 Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
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Table 4.11: (continued).
Gene Relative Tumor Term
Symbol Expression State
MPP7 Increase Both Apicolateral
plasma membrane
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Both) (Apical junction complex)
(Increase) (Malignant) (Cell junction)
(Increase) (Malignant) (Cell-cell junction)
(Increase) (Malignant) (Occluding junction)
(Increase) (Malignant) (Tight junction)
MUC1 Increase Malignant Apical part of cell
Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
MYOF Increase Benign Plasma membrane
(Increase) (Benign) (Cytoskeleton)
PARD6B Increase Benign Apical part of cell
Increase Benign Apicolateral
plasma membrane
Increase Benign Plasma membrane
Increase Benign Plasma membrane part
(Increase) (Benign) (Apical junction complex)
(Increase) (Benign) (Cell junction)
(Increase) (Benign) (Cell-cell junction)
(Increase) (Benign) (Occluding junction)
(Increase) (Benign) (Tight junction)
PERP Increase Benign Apicolateral
plasma membrane
Increase Benign Plasma membrane
Increase Benign Plasma membrane part
(Increase) (Benign) (Apical junction complex)
(Increase) (Benign) (Cell junction)
(Increase) (Benign) (Cell-cell junction)
PTPN3 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
(Increase) (Benign) (Cytoskeleton)
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Table 4.12: (continued).
Gene Relative Tumor Term
Symbol Expression State
SCNN1A Increase Both Apical part of cell
Increase Both Plasma membrane
Increase Both Plasma membrane part
(Increase) (Benign) (Cytoskeleton)
SLC34A2 Increase Benign Apical part of cell
Increase Benign Plasma membrane
Increase Benign Plasma membrane part
(Increase) (Benign) (Cell projection part)
SKAP1 Increase Benign Plasma membrane
SLC1A1 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
SLC24A6 Decrease Benign Plasma membrane
Increase Benign Plasma membrane part
SNTB1 Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
(Increase) (Malignant) (Cell junction)
SORL1 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
SORT1 Increase Both Plasma membrane
Increase Both Plasma membrane part
SPINT2 Increase Malignant Plasma membrane
ST3GAL5 Decrease Malignant Plasma membrane
Decrease Malignant Plasma membrane part
TACSTD2 Increase Benign Plasma membrane
Increase Benign Plasma membrane part
TRPC1 Decrease Malignant Plasma membrane
Decrease Malignant Plasma membrane part
VTCN1 Increase Malignant Plasma membrane
XPR1 Increase Malignant Plasma membrane
Increase Malignant Plasma membrane part
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4.3.5 Cytoskeleton
Enrichment for the “Cytoskeleton” associated terms occurred only with benign
tumors, although it is a node to the “Spindle” term that was enriched in the ma-
lignant samples. The enrichment was due to increased expression of the following
transcripts: AGBL2, ARHGAP26, CDH1, DSP, DNAH11, DNAH7, LRRC50, MNS1,
MPZL2, MYOF, MYO5C, PTPN3, RCC2, SCNN1A, and SPAG17. Several of these
terms have been discussed under other headings, which is reasonable since this is a
combination of cell junction and plasma membrane terms. It includes 4 transcripts
not previously covered: AGBL2, MNS1, MPZL2, and MYO5C.
The ATP/GTP binding-protein like, AGPL2, may play a role in processing tubulin
but little is known about its functions. It is regulated by Nkx3-1(v1,2,3,4) and NF-B
among other factors. MNS1 is a meiosis-specific nuclear structural 1 gene, which may
function as a nuclear skeleton protein that regulates morphology during meiosis. It
is regulated by POU3F1,2, FOXL1 among other factors. The myelin protein zero-
like 2, MPZL2, is strongly regulated in thymus development and in several epithelial
structures in embryogenesis. It is regulated by c-Myc, PPAR-1,2, POU2F1,2 among
other factors. Myosib VC, MYO5C, is a myosin form involved in transferrin traf-
ficking and secretory granule transport [202], and alternative splicing determines its
associations with RAB10, but little else is known about its specific functions. It is
regulated by MEF-2A, HNF-1A, POU2F1,2,2B,2C, among other factors. Compared
to many of the other ontological terms, many transcripts exclusively associated with
“Cytoskeleton” are weakly characterized representing need for further investigation.
4.3.6 Extracellular Region
The extracellular region terms were only enriched with the malignant transcript
list and were also the only group whose phenotype was decreased expression instead
of increased expression. Specific terms included: “Extracellular Matrix”, “Proteina-
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Table 4.13: Summary of transcripts related to Cytoskeleton. Listed are the gene
symbol associated with the transcript, the state of the tumor (specifically benign,
malignant, or both), the expression relative to the control tissue (given as increasing or
decreasing), and the associated ontological term/s. Terms in parentheses are related
to the transcripts but are not the direct subject matter of the table (1 of 2).
Gene Relative Tumor Term
Symbol Expression State
AGBL2 Increase Benign Cytoskeleton
ARHGAP26 Increase Benign Cytoskeleton
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
(Increase) (Benign) (Cell junction)
CDH1 Increase Benign Cytoskeleton
(Increase) (Both) (Apical part of cell)
(Increase) (Both) (Cell junction)
(Increase) (Both) (Cell-cell junction)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
DSP Increase Benign Cytoskeleton
(Increase) (Both) (Apical junction complex)
(Increase) (Both) (Apicolateral)
(plasma membrane)
(Increase) (Malignant) (Cell junction)
(Increase) (Malignant) (Cell-cell junction)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
DNAH11 Increase Benign Cytoskeleton
(Increase) (Benign) (Axoneme)
(Increase) (Benign) (Cell projection part)
(Increase) (Benign) (Cilium)
DNAH7 Increase Benign Cytoskeleton
(Increase) (Benign) (Axoneme)
(Increase) (Benign) (Cell projection part)
(Increase) (Benign) (Cilium)
ceous Extracellular Matrix”, and “Extrinsic to Membrane”. For the first two terms
the same transcript group was responsible, including EFEMP1, COL6A1, COL6A2,
DCN, and MGP. These genes are a closely connected cluster of deregulation in the
malignant gene network (Figure 4.4). Many of these genes are reported to have tumor
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Table 4.14: (continued).
LRRC50 Increase Benign Cytoskeleton
(Increase) (Benign) (Axoneme)
(Increase) (Benign) (Cell projection part)
(Increase) (Benign) (Cilium)
MNS1 Increase Benign Cytoskeleton
MPZL2 Increase Benign Cytoskeleton
MYOF Increase Benign Cytoskeleton
(Increase) (Benign) (Plasma membrane)
MYO5C Increase Benign Cytoskeleton
PTPN3 Increase Benign Cytoskeleton
(Increase) (Benign) (Plasma membrane)
(Increase) (Benign) (Plasma membrane part)
RCC2 Increase Benign Cytoskeleton
(Increase) (Malignant) (Condensed chromosome)
(centromeric region)
(Increase) (Malignant) (Spindle)
SCNN1A Increase Benign Cytoskeleton
(Increase) (Both) (Apical part of cell)
(Increase) (Both) (Plasma membrane)
(Increase) (Both) (Plasma membrane part)
SPAG17 Increase Benign Cytoskeleton
(Increase) (Benign) (Axoneme)
(Increase) (Benign) (Cell projection part)
(Increase) (Benign) (Cilium)
suppression functions. COL6A1 and A2 are collagen type 6 variants, beaded filament
collagens found in most connective tissue that maintain structural integrity. They are
extracellular matrix proteins, this family is a component of microfibrils. COL6A1 is
regulated by c-Jun, c-Fos, Pax-2, Nkx2-2, RP58 and CREB, among other factors and
COL6A2 is regulated by SREBP-1, Elk-1, TBP and AP-1 amongst others. Decorin,
DCN, is a proteoglycan, a small cellular or pericellular matrix material, a component
of connective tissue that binds to collagen fibrils and contributes to matrix assembly.
DCN, is a known growth inhibitor to ovarian cancer cell lines SKOV and 2774 in vitro
[203]. When placed in an matrigel assay, DCN did not suppress tumor cells; the study
authors attributed this to collagen binding to DCN [203]. Interestingly, it is repressed
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by COL6A1, and COL6A2. It is regulated by c-Jun, c-Fos, HNF-1A, POU2F1m GR-
α,β among other factors. The matrix Gla protein, MGP, is found in the organic
matrix of bone and cartilage. It has been shown to bind, interact and be repressed
by DCN. MGP has been shown to be an important biological regulator through con-
trolling calcification [204]. It is regulated by AP-1, Sox9, c-Fos, c-Jun, PPAR-1,2 and
FOXl1, among other factors. The EGF-containing fibulin-like extracellular matrix
protein 1, EFEMP1, is an extracellular matrix glycoprotein, with tandemly repeated
EGF repeats. It is up-regulated in malignant gliomas, as well as down-regulated in
hepatocelluar carcinoma and sporadic breast cancer due to promoter hypermethyla-
tion [205] [206]. It is regulated by Cart-1, HNF-1A, PPAR-1,2, FOXJ2, POU2F1 and
other factors. Calbindin 2, CALB2 (or calretinin) is an intracellular calcium-binding
protein in the troponin C superfamily (discussed in section 4.3.1). It was not ex-
pressed in invasive serous tumor nests in the peritoneum as well the destruction of
surrounding calretinin+ mesothelial cells surrounding all metastases studied [207]. It
is regulated by Cart-1, CREB and other factors.
Presence of the more specific “Extrinsic to Membrane” term was due to 5 tran-
scripts with decreased expression: EHD2, NAPA, COL6A2, GNG11, and AKT3.
COL6A2 is part of the cluster described above. The N-ethylmaeimide-sensitive fac-
tor attachment protein alpha, NADA, is involved in the process of vesicle docking and
fusion processes of cells. It is part of the multi-subunit fusion apparatus, required for
vesicular transport between the endoplasmic reticulum and the Golgi apparatus. It is
implicated in the accurate transport of cadherins to adheren junctions of the plasma
membrane [208]. It is regulated by NF-B, TGIF, SREBP-1a,b,c, and HNF-1A among
other factors. This study results indicated increased expression of CDH1 (E-cadherin)
and CDH6 (H-cadherin) in both benign and malignant tumors. GNG11 is a guanine
nucleotide binding protein, gamma 11, that encodes a lipid-anchored cell membrane
protein that participates in transmembrane signaling. Decreased expression is asso-
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ciated with splenic marginal zone lymphomas. Several multimeric forms activate ion
channels. It is regulated by Sox9, FOXO1a, FOXO4, HSF1, POU3F2 among other
facors. EHD2, EH-domain containing 2, has been associated with membrane protein
trafficking. The v-akt murine thymoma viral oncogene homolog 3, (or protein kinase
B, gamma) protein, AKT3, belongs to the serine/threonine protein kinase family, reg-
ulators of cell signaling in response to insulin and growth factors. They are involved
in many processes from proliferation to differentiation , apoptosis, tumorigenesis, glu-
cose uptake, etc. It is a downstream mediator of the PI 3-K pathway, whereby Akt is
recruited to the plasma membrane, where it then phosphorylates many substrates, in-
cluding transcription factors (FOXO1), kinases (Raf-1, Chk1) and signaling pathway
factors (Bad, MDM2). It has been shown to be protective against apoptosis-based
therapeutics [209]; this may be associated with the G-M phase transition of the cell
cycle which is slowed by the repression of AKT3 in ovarian carcinoma [210]. It is
regulated by Sp1, FOXO1a, FOXC1, STAT3, c-Jun, CREB, FOXO3b among others.
4.4 Major Trends in Ontologies
On the whole, the enriched ontology terms shown here were consistent with lit-
erature reports. The strong enrichment of cilia terms in benign versus spindle terms
in malignant tumors is interesting, and reasonable. Benign serous tumors do indeed
show the same ultrastructural features of cilia that are found in serous cysts. The
significantly increased cell-cycle activity in rapidly growing malignant tumors should
lead to more spindle formation. Transcripts associated with centrioles, used in both
spindles and cilia, may be a barometer for the transition to a malignant state, as
increased mitotic activity would tend to monopolize available centrioles. We found
evidence for apoptotic signaling in benign tumors, through the enhanced presence of
PERP, a tumor-suppressor gene. Not only was PERP not increased in the malignant
cells, HOMER1 was increased, which is an apoptosis suppressor. In the malignant
tumor cells there was increased expression of cadherin, claudins, and other cell junc-
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Table 4.15: Summary of transcripts related to Extracellular Region. Listed are the
gene symbol associated with the transcript, the state of the tumor (specifically benign,
malignant, or both), the expression relative to the control tissue (given as increasing or
decreasing), and the associated ontological term/s. Terms in parentheses are related
to the transcripts but are not the direct subject matter of the table.
Gene Relative Tumor Term
Symbol Expression State
AKT3 Decrease Malignant Extrinsic to membrane
COL6A1 Decrease Malignant Extracellular matrix
Decrease Malignant Proteinaceous extracellular matrix
(Decrease) (Malignant) (Plasma Membrane)
COL6A2 Decrease Malignant Extracellular matrix
Decrease Malignant Extrinsic to membrane
Decrease Malignant Proteinaceous extracellular matrix
(Decrease) (Malignant) (Plasma Membrane)
DCN Decrease Malignant Extracellular matrix
Decrease Malignant Proteinaceous extracellular matrix
EFEMP1 Decrease Malignant Extracellular matrix
Decrease Malignant Proteinaceous extracellular matrix
EHD2 Decrease Malignant Extrinsic to membrane
(Decrease) (Malignant) (Plasma Membrane)
(Decrease) (Malignant) (Plasma Membrane Part)
GNG11 Decrease Malignant Extrinsic to membrane
(Decrease) (Malignant) (Plasma Membrane)
(Decrease) (Malignant) (Plasma Membrane Part)
MGP Decrease Malignant Extracellular matrix
Decrease Malignant Proteinaceous extracellular matrix
NAPA Decrease Malignant Extrinsic to membrane
tion gene products, and these form the hub of several of the in silico gene networks
developed in these cells. While increased expression of claudins is typical in malig-
nancies, expression was higher than corresponding normal cells in both tumor types
for E-cadherin (CDH1), a well studied gene that is usually lowered in expression in
malignancies. This led us to look more closely at the transcript cluster for CDH1
gene. With further evaluation, malignant CDH1 expression is measured at a 2.3 fold
increase in expression, which, while increased from normal expression, is only half
the signal increase measured in benign tissues (4.5 fold increase). For this transcript,
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then, we do see a trend of decreased expression from benign to malignant, as expected.
A decreased expression of CDH1 is an indicator of epithelial-mesenchymal transition-
ing essential to metastasis but not of malignancy. Since the target was malignant,
not metastastic, serous tumors, this observation is not a contradiction.
Other clues were found to position tumor cohorts in the tumorigenesis process.
Benign tumors in our data set showed elevated levels of genes associated with apopto-
sis, generally repressed in malignant cells, and with a known ultrastructural feature,
cilia. Cilia have been observed but are rare in serous malignancy, so they are not a
definite indicator of tumorigenesis either. The most precise evidence of progression
in the benign samples is the elevated expression of CD24, cited as an indicator of
borderline serous tumors. If this is a robust indicator, this would place our benign
tumor samples closer to the borderline malignant stage of progression.
Malignant tumors also fall within a progression line. Evidence of CIN, mitotic
activity, and loss of apoptotic tumor-suppressors all invoke known aspects of the ma-
lignant state. The epithelial-to-mesenchymal transition is considered the watershed
event for metastasis. Several observations indicate that this set of malignant tumors
has not completed this transition, and likely are not metastatic. This includes the
increased expression in CDH1 mentioned above, and also CD24, DSP and the set of
tight junction-related transcripts. Although negative data is not a reliable founda-
tion for conclusions, there are known up-regulated genes in the EMT that we looked
at; for example MPP7 is increased in malignant cells but was not found significantly
increased in our samples
In this context other trends from the ontologies make sense: the transition involves
restructuring of the apical junctions and membrane, and these terms are enriched.
The reduction in extracellular elements, particularly collagen, is typical of the de-
struction of the basement membrane, a necessary step before metastasis. Malignancy
often involves induction of fetal genes, and the observed increase in one of the isoforms
108
of the plasma membrane gene, ERBB3, which is active in embryonic development and
differentiation, is a commonly seen feature of malignant cells [211].
4.5 NrCAM Expression
When performing comparisons of the tumor-stroma environment, only one tran-
script was significant. In the benign tumor-stroma environment, NRCAM (Neuron
Cell Adhesion Molecule: NM 001037132) showed a 6.77 increase in benign adjacent
stromal expression over distal stroma, in contrast to a 1.31 increase in malignant
samples. NRCAM is a neuronal cell adhesion molecule that binds ankyrin and pro-
motes directional signaling during axonal cone growth. It likely has a general role in
cell-cell communication, signaling from its intracellular domain to the actin cytoskele-
ton during directional cell migration. It has a large number of allelic variants. It is
regulated by HNF-42, POU2F1, PPAR1,2, FOXD1,3 and other factors. Although
mostly studied in the context of the nervous system it has been implicated in tumor
biochemistry including thyroid and lung carcinomas [212] [213]. NRCAM has also
been shown to indoctrinate surrounding cells into tumorigenesis (survival and prolif-
eration) when expressed in NIH3T3 fibroblasts [214]. In that study the extracellular
region of NRCAM was shown to induce proliferation by stimulating the PI3K/AKT
pathway, indicating a paracrine function for NRCAM through integrin interaction
[215].
In our study slight NRCAM increases were observed in malignant cells, although
they did not meet the criteria for significance. It is not clear whether this is due to
a real drop in expression or because of the significant reduction in the presence of
material in the extracellular region overall; NRCAM as an extracellular agent may
have been destroyed with other proteins. This transcript, even though it may have
affected tumor tissue, was not expressed in tumor tissue. Indeed, we were only able
to observe it all because of the purification method used (LCM); since NRCAM can
act in both autocrine and paracrine signaling, a macrodissected sample would have
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given no reason to suspect paracrine signaling over autocrine signaling.
4.6 Chromosomal Location
By comparing the distribution of significant DE genes compared to a randomly
selected set one can determine whether a likely epigenetic or other large-scale aberra-
tion has occurred. Only one chromosome had significance: chromosome 8 contained
11 of the malignancy-associated increased-expression transcripts, although they are
not clustered on a single cytoband. The transcripts in chromosome 8 include from
PRKDC (8q11), C8orf62 (8q11.21), SOX17 (8q11.23), CHMP4C (8q21.13), RAD54B
(8q22.1), ESRP1 (8q22.1), AZIN1 (8q22.3), GRHL2 (8q22.3), MAL2 (8q23), SNTB1
(8q23-q24), and FAM49B (8q24.21). Of this set, two have previously known associa-
tions with ovarian cancer, including MAL2 and RAD54B [216] [217].
4.7 Deriving a Gene Network
There are many levels at which cellular networks can be considered, from regu-
latory circuits with transcription factors to protein localization and interaction com-
plexes. There are several tools that will accept a ‘significant gene list’ and search rel-
evant databases for known networks at each of these levels. Here we used STRING8
to derive pathways for both the benign (Figure 4.3) and malignant (Figure 4.4) tran-
script lists. The tool allows inclusion of connecting elements at varying levels of
evidence; in our case we restricted connections to experimentally verified interac-
tions. Single time-point sampling is likely to miss important nodes in any network,
and not all nodes need change for network output to change, so that an analysis based
on differential expression will not pick up all nodes; biological networks are particu-
larly fragile in this respect. Thus, after significant interacting genes were placed, a
second tool, Genes2Networks, was used to infer transcripts not in the list which may
be important.
Many of the trends reported in the ontological enrichment results are also apparent
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in the networks, including especially the decreased expression of extracellular region
genes, seen as a cluster of interconnected blue transcripts in the malignant network
(Figure 4.4). As well, the 2 core nodes in both networks networks, CDH1, and
CLDN4 are associated with tight junctions and apical membranes, highlighted in the
ontological enrichment outcomes.
The networks provide a better-integrated visualization of the connectivity of
ERBB3/4 modulation with other observations in the malignant data set. Also, even
though the benign transcript list was longer, the benign network is less connected,
with only 50 derived genes and 53 interactions compared to the malignant network,
with 73 and 97 respectively. This is mirrored by the GO enrichment lists, where the
benign list has 30 nodes (terms) and 44 edges compared to the malignant GO list,
with 37 and 54 respectively. This is expected if more and more disregulated genes
are expressed through the accumulation of mutations proceeding through the steps
of tumorigenesis.
Although it is not clear if this is a general feature, the benign gene network con-
tains ERBB4 while the malignant network contains ERBB3. As a reminder, these
are EGFR protein kinases; ERBB3 is the only HER/NEU protein that has an inac-
tive intracellular domain, relying entirely on trans-extracellular signalling [218]. Both
ERBB3 and ERBB4 bind to PI3-K and are associated with the PI3K/AKT pathway,
associated with apopotosis suppression and angiogenesis, but only ERBB3 is immune
to EGFR tyrosine kinase inhibitors [219].This may be why AKT3 significantly de-
creased in malignant tumors. Further study in this shift between two HER proteins
may uncover important therapeutic mechanisms.
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Figure 4.3: Graph of a predicted protein network derived from the benign transcript
list. Gene symbols are surrounded by red borders if they were increased relative to
normal, and blue if they were decreased. Double outlined boxes indicate those genes
common to both benign and malignant networks (see Figure 4.4). Gene symbols with
black dashed borders indicate DE transcripts with only inferred relationships. Gene
symbols with no border are Genes2Network-inferred relationships but were not found
to be a DE transcripts. Black lines indicate known interactions, grey lines indicate
inferred relationships. Known inhibiting and promoting relationships are respectively
given bars or arrows (for example CD24 inhibits CDH1).
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Figure 4.4: Graph of a predicted protein interaction network derived from the malig-
nant transcript list. Figure elements are represented as in Figure 4.3.
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4.8 Future Directions
The production of a high-quality genomics data set is cause for pride and also for
frustration. The experimental design must accommodate some sampling problems
and in some cases the ability to actually collect samples simply does not meet expec-
tations. The technical requirements of the assays are such that extended consistency
is extremely difficult to achieve. The choice of platform is subject to the vagaries
of fashion in both availability of similar data sets and the algorithms and methods
produced for their analysis. Frustration arises because the data set, once produced,
has such rich options for subsequent data mining that knowing where to start first
and acknowledging when additional efforts must be left to others is difficult. The
bioinformatics level achieved in this study was rudimentary, and primarily involved
sample cleansing and preliminary screening for the largest signals, to validate global
consistency with published studies. This establishes the suitability of the samples
for inclusion in in-depth data mining projects. While the sample numbers are quite
small, high quality and sound platform choice ensure that merging the data with
other studies, or extending this study, are both feasible approaches.
If study extension is considered several factors of interest immediately come to
mind. Given the heterogeneity of ovarian surface epithelial-stromal tumor histopathol-
ogy, the addition of other subtype cohorts would certainly be revealing if the LCM
method was used in cell collection. Currently ovarian serous tumorigenesis theory is
hotly debated, as there is a proposal that type II serous ovarian tumors may not rise
in situ but result from metastases of fallopian tube serous tumors. Thus, adding sam-
ples from fallopian tube fimbrae epithelium to this study would allow rapid evaluation
of the merits of the proposal, as well as other types of primary sites. A reasonable
common baseline would be the progenitor tissue, fetal coelemic epithelium, as well as
a comparison of that tissue with the OSE profiled here. Also, since the experimental
model focused on serous tumors, the stroma (although evaluated) was not extensively
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monitored (distance from tumor was either immediately proximal or distal but the
interval was not carefully measured).
With respect to data mining, the tools for exon signal analysis, rather than gene
signal analysis, and for transcript isoform enrichment discovery are both obvious
points for bioinformatics tool development, with the advantage that predictions can
be tested using wet-lab assays on the original samples. Meta-analyses, achieved by
merging external data sets, and integration, based on informatics tools that bring
in RNA-seq and other types of high-throughput assay data, are also clearly areas of
immediate interest.
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APPENDIX A: LCM IMAGES
Figure A.1: Image progression, capturing normal epithelial tissue sample M01 with
H&E stain. Before capture, during capture, after capture, and H&E stain (from left
to right).
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Figure A.2: Image progression, capturing stromal tissue sample M08 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.3: Image progression, capturing stromal tissue sample B07 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.4: Image progression, capturing tumor (B16) and adjacent stromal tissue
sample (B22). Images show before capturing (left), tumor captured on cap (middle),
and tissue after adjacent stromal has additionally been sampled (right).
138
Figure A.5: Images of H&E staining for tissue samples B16 and B22.
Figure A.6: Image progression, capturing stromal tissue sample M09 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.7: Image progression, capturing tumor tissue sample M16 with H&E stain.
(Left before, middle after, and right H&E staining).
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Figure A.8: Image progression, capturing normal epithelial tissue sample M03 with
H&E stain. The image on the right shows the captured normal epithelium on a cap
devoid of stroma
Figure A.9: Image progression, capturing stromal tissue sample M10. (Left before
and right after).
140
Figure A.10: Image progression, capturing tumor (M17) and adjacent stromal tissue
sample (M25). Images show before capturing (left), after tumor capture (middle),
and tissue after adjacent stromal has been captured (right).
Figure A.11: Image progression, capturing stromal tissue sample M11 with H&E
stain. (Left before, middle after, and right H&E staining).
Figure A.12: Image progression, capturing tumor tissue sample M18 with H&E stain.
(Left before, middle after, and right H&E staining).
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Figure A.13: Image progression, capturing adjacent stromal tissue sample M26 with
H&E stain. (Left before, middle after, and right H&E staining).
Figure A.14: Image progression, capturing normal epithelial tissue sample B03 with
H&E stain. (Left before, middle after, and right H&E staining).
Figure A.15: Image progression, capturing stromal tissue sample M12 with H&E
stain. (Left before, middle after, and right H&E staining).
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Figure A.16: Image progression, capturing stromal tissue sample B09 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.17: Image progression, capturing normal epithelial tissue sample B04 with
H&E stain. (Left before, middle after, and right H&E staining).
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Figure A.18: Image progression, capturing stromal tissue sample B10 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.19: Image progression, capturing tumor (B17) and adjacent stromal tissue
sample (B23). Images show before capturing (left), after tumor capture (middle),
and tissue after adjacent stromal has been captured (right).
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Figure A.20: Image progression, capturing normal epithelial tissue sample M05 with
H&E stain. (Left before, middle after, and right H&E staining).
Figure A.21: Image progression, capturing stromal tissue sample B11 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.22: Image progression, capturing normal epithelial tissue sample B05. Be-
fore capturing is shown in the left image, then periodic capturing (middle image),
and after periodic capturing to show specificity of capturing (right image)
Figure A.23: Image progression, capturing stromal tissue sample B12 with H&E stain.
(Left before, middle after, and right H&E staining).
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Figure A.24: Image progression, capturing normal epithelial tissue sample M06 with
H&E stain. (Left before, middle after, and right H&E staining).
Figure A.25: Image progression, capturing stromal tissue sample M13 with H&E
stain. (Left before, middle after, and right H&E staining).
Figure A.26: Image progression, capturing tumor (M20) and adjacent stromal tissue
sample (M28). Images show before capturing (left), after tumor capture (middle),
and tissue after adjacent stromal has been captured (right).
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Figure A.27: Image progression, capturing stromal tissue sample B13 with H&E stain.
(Left before, middle after, and right H&E staining).
Figure A.28: Image progression, capturing tumor tissue sample M21 with H&E stain.
(Left before, middle after, and right H&E staining).
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APPENDIX B: TRANSCRIPT / TRANSCRIPT CLUSTER LISTS
Table B.1: Complete transcript list representing significant expression in benign tu-
mors (1 of 4).
All Transcripts Increasing Only Decreasing Only
AGBL2 AGBL2 AMHR2
AHCYL1 AHCYL1 ANG
AIFM1 AIFM1 BNC1
AMHR2 ANKRD18A C18orf34
ANG ARHGAP26 CLEC4M
ANKRD18A ARMC3 EHD2
ARHGAP26 ASRGL1 GNG11
ARMC3 C10orf79 GPRASP1
ASRGL1 C3orf15 HTRA1
BNC1 C6orf108 ITLN1
C10orf79 C9orf68 ITLN2
C18orf34 CAPSL MGP
C3orf15 CASC1 MTMR11
C6orf108 CCDC11 PRG4
C9orf68 CCDC30 SHF
CAPSL CD24 SLC24A6
CASC1 CDH1 SPOCK1
CCDC11 CDH6 TBX3
CCDC30 CLDN4 YPEL4
CD24 CLDN7 ZEB1
CDH1 CP ZNF385B
CDH6 CXorf22 —
CLDN4 DCDC2 —
CLDN7 DNAH11 —
CLEC4M DNAH7 —
CP DSP —
CXorf22 EFHC2 —
DCDC2 EHF —
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Table B.2: (continued).
All Transcripts Increasing Only Decreasing Only
DNAH11 EPCAM —
DNAH7 ERBB4 —
DSP ERP27 —
EFHC2 ESRP1 —
EHD2 FAAH2 —
EHF FAIM —
EPCAM FOLR1 —
ERBB4 GALNT4 —
ERP27 GPR39 —
ESRP1 HNRNPF —
FAAH2 HYDIN —
FAIM INADL —
FOLR1 KIAA1712 —
GALNT4 LAMC2 —
GNG11 LOC100132319 —
GPR39 LPAR3 —
GPRASP1 LRRC50 —
HNRNPF LYPD1 —
HTRA1 MAL2 —
HYDIN MDH1B —
INADL MECOM —
ITLN1 MNS1 —
ITLN2 MPP7 —
KIAA1712 MPZL2 —
LAMC2 MYB —
LOC100132319 MYEF2 —
LPAR3 MYO5C —
LRRC50 MYOF —
LYPD1 OSBPL3 —
MAL2 OXR1 —
MDH1B PARD6B —
MECOM PAX8 —
MGP PERP —
MNS1 PGM2L1 —
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Table B.3: (continued).
All Transcripts Increasing Only Decreasing Only
MPP7 PIH1D2 —
MPZL2 PRKX —
MTMR11 PRUNE2 —
MYB PRUNE2 —
MYEF2 PTPN3 —
MYO5C RBBP8 —
MYOF RNASET2 —
OSBPL3 SCGB2A1 —
OXR1 SCNN1A —
PARD6B SKAP1 —
PAX8 SLC1A1 —
PERP SLC34A2 —
PGM2L1 SORL1 —
PIH1D2 SORT1 —
PRG4 SOX17 —
PRKX SPAG17 —
PRUNE2 SPEF2 —
PRUNE2 SRPK1 —
PTPN3 ST6GALNAC2 —
RBBP8 STX18 —
RNASET2 TACSTD2 —
SCGB2A1 TMC4 —
SCNN1A TOM1L1 —
SHF TPRG1 —
SKAP1 TSGA10 —
SLC1A1 VWA3A —
SLC24A6 WDR49 —
SLC34A2 WDR52 —
SORL1 WDR77 —
SORT1 WDR78 —
SOX17 WFDC2 —
SPAG17 ZBBX —
SPEF2 ZDHHC13 —
SPOCK1 — —
SRPK1 — —
150
Table B.4: (continued).
All Transcripts Increasing Only Decreasing Only
ST6GALNAC2 — —
STX18 — —
TACSTD2 — —
TBX3 — —
TMC4 — —
TOM1L1 — —
TPRG1 — —
TSGA10 — —
VWA3A — —
WDR49 — —
WDR52 — —
WDR77 — —
WDR78 — —
WFDC2 — —
YPEL4 — —
ZBBX — —
ZDHHC13 — —
ZEB1 — —
ZNF385B — —
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Table B.5: Complete transcript-cluster list representing significant expression in be-
nign tumors (1 of 3).
All Clusters Increasing Only Decreasing Only
AHCYL1 AHCYL1 AMHR2
AIFM1 AIFM1 BNC1
AMHR2 ARHGAP26 C4orf49
ARHGAP26 ARMC3 CLEC4M
ARMC3 ASRGL1 EHD2
ASRGL1 C10orf79 GNG11
BNC1 C3orf15 HTRA1
C10orf79 C9orf68 ITLN1
C3orf15 CAPSL PRG4
C4orf49 CASC1 SALL1
C9orf68 CCDC11 SLC24A6
CAPSL CCDC30 TBX3
CASC1 CD24 YPEL4
CCDC11 CDH1 ZEB1
CCDC30 CDH6 —
CD24 CLDN4 —
CDH1 CLGN —
CDH6 CMTM7 —
CLDN4 CP —
CLEC4M DCDC2 —
CLGN DNAH7 —
CMTM7 DSP —
CP EFHC2 —
DCDC2 EHF —
DNAH7 EPCAM —
DSP ERBB4 —
EFHC2 ERP27 —
EHD2 ESRP1 —
EHF FAAH2 —
EPCAM FAIM —
ERBB4 FOLR1 —
ERP27 GALNT4 —
ESRP1 GPR39 —
FAAH2 HNRNPF —
FAIM HYDIN —
FOLR1 KIAA1712 —
GALNT4 LOC100132319 —
GNG11 LRRC50 —
GPR39 LYPD1 —
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Table B.6: (continued).
All Clusters Increasing Only Decreasing Only
HNRNPF MAL2 —
HTRA1 MDH1B —
HYDIN MECOM —
ITLN1 MNS1 —
KIAA1712 MPP7 —
LOC100132319 MYB —
LRRC50 MYO5C —
LYPD1 MYOF —
MAL2 NUP62CL —
MDH1B OSBPL3 —
MECOM PAX8 —
MNS1 PERP —
MPP7 PIH1D2 —
MYB PRKX —
MYO5C PRUNE2 —
MYOF PRUNE2 —
NUP62CL RBBP8 —
OSBPL3 SAMD12 —
PAX8 SCGB1D2 —
PERP SCGB2A1 —
PIH1D2 SCNN1A —
PRG4 SKAP1 —
PRKX SLC1A1 —
PRUNE2 SLC34A2 —
PRUNE2 SORL1 —
RBBP8 SORT1 —
SALL1 SPAG17 —
SAMD12 SPEF2 —
SCGB1D2 ST6GALNAC2 —
SCGB2A1 STX18 —
SCNN1A STX19 —
SKAP1 TBC1D8 —
SLC1A1 TOM1L1 —
SLC24A6 TSGA10 —
SLC34A2 WDR49 —
SORL1 WDR52 —
SORT1 WDR77 —
SPAG17 WDR78 —
SPEF2 WFDC2 —
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Table B.7: (continued).
All Clusters Increasing Only Decreasing Only
ST6GALNAC2 — —
STX18 — —
STX19 — —
TBC1D8 — —
TBX3 — —
TOM1L1 — —
TSGA10 — —
WDR49 — —
WDR52 — —
WDR77 — —
WDR78 — —
WFDC2 — —
YPEL4 — —
ZEB1 — —
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Table B.8: Complete transcript list representing significant expression in malignant
tumors (1 of 3).
All Transcripts Increasing Only Decreasing Only
AFTPH AFTPH AKT3
AKT3 ASRGL1 C16orf62
ASRGL1 AZIN1 CALB2
AZIN1 BAIAP2L1 COL6A1
BAIAP2L1 BCL11A COL6A2
BCL11A BUB1B DAB2
BUB1B CBX3 DCN
C16orf62 CD24 EFEMP1
CALB2 CDC7 EHD2
CBX3 CDH1 FBXL7
CD24 CDH6 GABBR1
CDC7 CENPF GNG11
CDH1 CHMP4C IGFBP6
CDH6 CLDN3 LRRN4
CENPF CLDN4 MAPRE2
CHMP4C CLDN7 MGP
CLDN3 CP NAP
CLDN4 CPSF3 NBR1
CLDN7 CXXC5 PTGIS
COL6A1 DSP SP140L
COL6A2 DTL ST3GAL5
CP EHF TRPC1
CPSF3 EPCAM —
CXXC5 ERBB3 —
DAB2 ESRP1 —
DCN EYA2 —
DSP EZH2 —
DTL FAM49B —
EFEMP1 FOLR1 —
EHD2 GALNT3 —
EHF GPR39 —
EPCAM GRHL2 —
ERBB3 HEY2 —
ESRP1 HJURP —
EYA2 HMMR —
EZH2 HNRNPF —
FAM49B HOMER2 —
FBXL7 HOXB8 —
FOLR1 INADL —
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Table B.9: (continued).
All Transcripts Increasing Only Decreasing Only
GABBR1 KLF5 —
GALNT3 KLK7 —
GNG11 LPAR3 —
GPR39 LRBA —
GRHL2 LYPD1 —
HEY2 MAL2 —
HJURP MAP7 —
HMMR MECOM —
HNRNPF MECOM —
HOMER2 MELK —
HOXB8 MND1 —
IGFBP6 MPP7 —
INADL MTHFD2 —
KLF5 MTIF2 —
KLK7 MUC1 —
LPAR3 MUC20 —
LRBA MYB —
LRRN4 MYEF2 —
LYPD1 NEK2 —
MAL2 PGM2L1 —
MAP7 PRKDC —
MAPRE2 PRKX —
MECOM PSAT1 —
MECOM PTPN12 —
MELK PTTG1 —
MGP PUS7 —
MND1 RAD51AP1 —
MPP7 RAD54B —
MTHFD2 RRAGD —
MTIF2 S100A14 —
MUC1 SCNN1A —
MUC20 SNTB1 —
MYB SORT1 —
MYEF2 SOX17 —
NAPA SPINT2 —
NBR1 SRPK1 —
NEK2 ST6GALNAC2 —
PGM2L1 STYXL1 —
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Table B.10: (continued).
All Transcripts Increasing Only Decreasing Only
PRKDC TEC —
PRKX TNPO3 —
PSAT1 UBE2T —
PTGIS VTCN1 —
PTPN12 WFDC2 —
PTTG1 XPO5 —
PUS7 XPR1 —
RAD51AP1 ZDHHC13 —
RAD54B — —
RRAGD — —
S100A14 — —
SCNN1A — —
SNTB1 — —
SORT1 — —
SOX17 — —
SP140L — —
SPINT2 — —
SRPK1 — —
ST3GAL5 — —
ST6GALNAC2 — —
STYXL1 — —
TEC — —
TNPO3 — —
TRPC1 — —
UBE2T — —
VTCN1 — —
WFDC2 — —
XPO5 — —
XPR1 — —
ZDHHC13 — —
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Table B.11: Complete transcript-cluster list representing significant expression in
malignant tumors (1 of 3).
All Clusters Increasing Only Decreasing Only
AFTPH AFTPH AKT3
AKT3 ASRGL1 CALB2
ASRGL1 AZIN1 COL6A2
AZIN1 BAIAP2L1 EFEMP1
BAIAP2L1 BCL11A EHD2
BCL11A BUB1B FBXL7
BUB1B CBX3 GNG11
CALB2 CD24 IGFBP6
CBX3 CDC7 LRRN4
CD24 CDH6 NAPA
CDC7 CENPF NBR1
CDH6 CHMP4C SP140L
CENPF CLDN3 ST3GAL5
CHMP4C CLDN4 TRPC1
CLDN3 CLDN7 —
CLDN4 CP —
CLDN7 CPSF3 —
COL6A2 CXXC5 —
CP DSP —
CPSF3 DTL —
CXXC5 EHF —
DSP EPCAM —
DTL ERBB3 —
EFEMP1 ESRP1 —
EHD2 EZH2 —
EHF FOLR1 —
EPCAM GALNT3 —
ERBB3 GPR39 —
ESRP1 GRHL2 —
EZH2 HJURP —
FBXL7 HOMER2 —
FOLR1 HOXB8 —
GALNT3 INADL —
GNG11 KCTD1 —
GPR39 KLF5 —
GRHL2 KLK7 —
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Table B.12: (continued).
All Clusters Increasing Only Decreasing Only
HJURP LPAR3 —
HOMER2 LRBA —
HOXB8 LYPD1 —
IGFBP6 MAL2 —
INADL MAP7 —
KCTD1 MECOM —
KLF5 MECOM —
KLK7 MELK —
LPAR3 MND1 —
LRBA MPP7 —
LRRN4 MTHFD2 —
LYPD1 MTIF2 —
MAL2 MUC1 —
MAP7 MYB —
MECOM MYEF2 —
MECOM NEK2 —
MELK PGM2L1 —
MND1 PRKDC —
MPP7 PRKX —
MTHFD2 PSAT1 —
MTIF2 PTPN12 —
MUC1 PTTG1 —
MYB PUS7 —
MYEF2 RAD51AP1 —
NAPA RAD54B —
NBR1 SCNN1A —
NEK2 SNTB1 —
PGM2L1 SORT1 —
PRKDC SPINT2 —
PRKX SRPK1 —
PSAT1 ST6GALNAC2 —
PTPN12 STYXL1 —
PTTG1 UBE2T —
PUS7 VTCN1 —
RAD51AP1 WFDC2 —
RAD54B XPR1 —
SCNN1A ZDHHC13 —
SNTB1 — —
159
Table B.13: (continued).
All Clusters Increasing Only Decreasing Only
SORT1 — —
SP140L — —
SPINT2 — —
SRPK1 — —
ST3GAL5 — —
ST6GALNAC2 — —
STYXL1 — —
TRPC1 — —
UBE2T — —
VTCN1 — —
WFDC2 — —
XPR1 — —
ZDHHC13 — —
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Table B.14: RefSeq numbers and fold-changes for all gene symbols associated with
the significant benign tumor transcript list (1 of 4).
Gene Symbol RefSeq Number Fold-Change
AGBL2 NM 024783 2.8
AHCYL1 NM 006621 3.34
AIFM1 NM 001130847 5.24
AMHR2 NM 020547 -2.53
ANG NM 001145 -3.94
ANKRD18A NM 147195 2.07
ARHGAP26 NM 015071 7.36
ARMC3 NM 173081 3.95
ASRGL1 NM 001083926 9.91
BNC1 NM 001717 -2.86
C10orf79 NM 025145 8.76
C18orf34 NM 001105528 -2.08
C3orf15 NM 033364 3.84
C6orf108 NM 199184 2.88
C9orf68 NM 001039395 3.94
CAPSL NM 144647 3.53
CASC1 NM 001082972 4.99
CCDC11 NM 145020 9.63
CCDC30 NM 001080850 4.7
CD24 NM 013230 15.31
CDH1 NM 004360 4.51
CDH6 NM 004932 6.68
CLDN4 NM 001305 4.22
CLDN7 NM 001307 3.67
CLEC4M NR 026707 -6.35
CP NM 000096 37.89
CXorf22 NM 152632 3.2
DCDC2 NM 016356 8.2
DNAH11 NM 003777 3.46
DNAH7 NM 018897 3.17
DSP NM 004415 5.55
EFHC2 NM 025184 2.31
EHD2 NM 014601 -2.36
EHF NM 012153 7.26
EPCAM NM 002354 8.4
ERBB4 NM 005235 3.99
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Table B.15: (continued).
Gene Symbol RefSeq Number Fold-Change
ERP27 NM 152321 10.41
ESRP1 NM 017697 11.08
FAAH2 NM 174912 3.23
FAIM NM 001033030 3.23
FOLR1 NM 016724 4.07
GALNT4 NM 003774 3.56
GNG11 NM 004126 -4.97
GPR39 NM 001508 30.92
GPRASP1 NM 014710 -5.87
HNRNPF NM 004966 3.13
HTRA1 NM 002775 -3.02
HYDIN NM 032821 3.54
INADL NM 176877 3.03
ITLN1 NM 017625 -31.69
ITLN2 NM 080878 -2.21
KIAA1712 NM 001040157 2.21
LAMC2 NM 005562 2.71
LOC100132319 AF315716 5.38
LPAR3 NM 012152 5.92
LRRC50 NM 178452 2.83
LYPD1 NM 144586 26.23
MAL2 NM 052886 23.28
MDH1B NM 001039845 2.69
MECOM NM 001105077 9.35
MGP NM 000900 -9.28
MNS1 NM 018365 6.2
MPP7 NM 173496 3.23
MPZL2 NM 144765 5.67
MTMR11 NM 001145862 -2.02
MYB NM 001130173 3.05
MYEF2 NM 016132 4.67
MYO5C NM 018728 2.75
MYOF NM 013451 7.84
OSBPL3 NM 015550 3.51
OXR1 NM 018002 3.15
PARD6B NM 032521 2.98
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Table B.16: (continued).
Gene Symbol RefSeq Number Fold-Change
PAX8 NM 003466 4.2
PERP NM 022121 11.04
PGM2L1 NM 173582 2.58
PIH1D2 NM 138789 4.25
PRG4 NM 005807 -10.97
PRKX NM 005044 3.56
PRUNE2 NM 015225 3.21
PRUNE2 NM 015225 6.5
PTPN3 NM 002829 2.04
RBBP8 NM 002894 5.75
RNASET2 NM 003730 9.31
SCGB2A1 NM 002407 20.67
SCNN1A NM 001038 5.75
SHF NM 138356 -2.12
SKAP1 NM 003726 2.59
SLC1A1 NM 004170 2.6
SLC24A6 NM 024959 -2.05
SLC34A2 NM 001177999 19.13
SORL1 NM 003105 4.34
SORT1 NM 002959 3.85
SOX17 NM 022454 3.43
SPAG17 NM 206996 2.77
SPEF2 NM 024867 2.68
SPOCK1 NM 004598 -2.11
SRPK1 NM 003137 2.49
ST6GALNAC2 NM 006456 6.38
STX18 NM 016930 3.95
TACSTD2 NM 002353 3.76
TBX3 NM 016569 -2.19
TMC4 NM 001145303 2.5
TOM1L1 NM 005486 4.68
TPRG1 NM 198485 2.6
TSGA10 NM 182911 4.29
VWA3A NM 173615 2.02
WDR49 NM 178824 4.36
WDR52 NM 001164496 3.21
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Table B.17: (continued).
Gene Symbol RefSeq Number Fold-Change
WDR77 NM 024102 4.95
WDR78 NM 024763 3.42
WFDC2 NM 006103 11.45
YPEL4 NM 145008 -2.37
ZBBX NM 024687 5.76
ZDHHC13 NM 019028 2.55
ZEB1 NM 030751 -7.04
ZNF385B NM 152520 -2.79
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Table B.18: RefSeq numbers and fold-chagnes for all gene symbols associated with
the significant malignant tumor transcript list (1 of 3).
Gene Symbol RefSeq Number Fold-Change
AFTPH NM 203437 2.28
AKT3 NM 181690 -7.3
ASRGL1 NM 001083926 6.45
AZIN1 NM 015878 3.09
BAIAP2L1 NM 018842 2.6
BCL11A NM 022893 3.03
BUB1B NM 001211 3.02
C16orf62 BC050464 -2.61
CALB2 NM 001740 -12.23
CBX3 NM 016587 4.74
CD24 NM 013230 7.81
CDC7 NM 001134420 2.63
CDH1 NM 004360 2.34
CDH6 NM 004932 4.5
CENPF NM 016343 4.91
CHMP4C NM 152284 4.51
CLDN3 NM 001306 2.27
CLDN4 NM 001305 5.49
CLDN7 NM 001307 3.82
COL6A1 NM 001848 -2.44
COL6A2 NM 001849 -2.38
CP NM 000096 14.24
CPSF3 NM 016207 2.76
CXXC5 NM 016463 2.82
DAB2 NM 001343 -3.63
DCN NM 001920 -15.14
DSP NM 004415 4.37
DTL NM 016448 3
EFEMP1 NM 004105 -16.58
EHD2 NM 014601 -2.29
EHF NM 012153 3.8
EPCAM NM 002354 5.67
ERBB3 NM 001982 2.63
ESRP1 NM 017697 15.83
EYA2 NM 005244 2.37
EZH2 NM 004456 2.92
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Table B.19: (continued).
Gene Symbol RefSeq Number Fold-Change
FAM49B BC017297 3.07
FBXL7 NM 012304 -2.01
FOLR1 NM 016724 3.06
GABBR1 NM 001470 -2.09
GALNT3 NM 004482 2.69
GNG11 NM 004126 -6.22
GPR39 NM 001508 7.09
GRHL2 NM 024915 3.16
HEY2 NM 012259 3.36
HJURP NM 018410 2.4
HMMR NM 001142556 2.24
HNRNPF NM 004966 2.44
HOMER2 NM 199330 4.24
HOXB8 NM 024016 2.78
IGFBP6 NM 002178 -9.37
INADL NM 176877 2.94
KLF5 NM 001730 2.29
KLK7 NM 139277 3.9
LPAR3 NM 012152 12.98
LRBA NM 006726 2.9
LRRN4 NM 152611 -2.06
LYPD1 NM 144586 6.69
MAL2 NM 052886 8.73
MAP7 NM 003980 2.09
MAPRE2 NM 014268 -2.49
MECOM NM 004991 2.91
MECOM NM 001105077 9.92
MELK NM 014791 2.91
MGP NM 000900 -7.06
MND1 NM 032117 3.93
MPP7 NM 173496 2.94
MTHFD2 NR 027405 4.13
MTIF2 NM 002453 2.37
MUC1 NM 002456 4.94
MUC20 NM 001098516 2.47
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Table B.20: (continued).
Gene Symbol RefSeq Number Fold-Change
MYB NM 001130173 2.71
MYEF2 NM 016132 3.9
NAPA NM 003827 -2.21
NBR1 NM 031858 -3.01
NEK2 NM 002497 3.8
PGM2L1 NM 173582 2.53
PRKDC NM 006904 2.57
PRKX NM 005044 3.06
PSAT1 NM 058179 2.62
PTGIS NM 000961 -5.53
PTPN12 NM 002835 2.66
PTTG1 NM 004219 21.82
PUS7 NM 019042 2.02
RAD51AP1 NM 001130862 4.94
RAD54B NM 012415 2.36
RRAGD NM 021244 2.11
S100A14 NM 020672 2.34
SCNN1A NM 001038 5.37
SNTB1 NM 021021 2.28
SORT1 NM 002959 2.97
SOX17 NM 022454 2.18
SP140L NM 138402 -2.56
SPINT2 NM 021102 4.44
SRPK1 NM 003137 2.8
ST3GAL5 NM 003896 -2.62
ST6GALNAC2 NM 006456 3.29
STYXL1 NM 016086 2.43
TEC NM 003215 4.39
TNPO3 NM 012470 2.03
TRPC1 NM 003304 -3.46
UBE2T NM 014176 3.01
VTCN1 NM 024626 4.27
WFDC2 NM 006103 5.87
XPO5 NM 020750 2.17
XPR1 NM 004736 4.27
ZDHHC13 NM 019028 2.27
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Table B.21: Ref seq numbers and fold-changesfor all gene symbols associated with
the significant benign tumor-stromal environment transcript list.
Gene Symbol RefSeq Number Fold-Change
NRCAM NM 001037132 6.77
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APPENDIX C: BIOLOGICAL CONTEXT RESULTS DETAIL
Table C.1: Complete results from DAVID for the benign transcript lists (1 of 4).
Annotation Exon All Exon Up Exon Down
SP COMMENT Tissue — —
TYPE Specificity
SP PIR Polymorphism Polymorphism —
KEYWORDS
SP PIR Tight Tight —
KEYWORDS Junction Junction
SP PIR — Cell —
KEYWORDS Junction
GOTERM CC 2 Axoneme Axoneme —
GOTERM CC 2 Cell Projection Part Cell Projection Part —
GOTERM CC 2 Apical Part of cell Apical Part of cell —
GOTERM CC 3 Plasma Plasma —
Membrane Part Membrane Part
GOTERM CC 3 Plasma Membrane Axoneme —
GOTERM CC 3 Axoneme Apical Part of cell —
GOTERM CC 3 Cell Projection Part Plasma Membrane —
GOTERM CC 3 Apical Part of cell Cilium —
GOTERM CC 3 — Cell Projection Part —
GOTERM CC 4 Apicolateral Apicolateral —
Plasma Membrane Plasma Membrane
GOTERM CC 4 Plasma Plasma —
Membrane Part Membrane Part
GOTERM CC 4 Plasma Membrane Axoneme —
GOTERM CC 4 Axoneme — —
GOTERM CC 4 Cell Projection Part — —
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Table C.2: (continued.)
Annotation Exon All Exon Up Exon Down
GOTERM CC 5 Apical Junction Apical Junction —
Complex Complex
GOTERM CC 5 Plasma Apicolateral —
Membrane Part Plasma Membrane
GOTERM CC 5 Apicolateral Cell-Cell —
Plasma Membrane Junction
GOTERM CC 5 Cell-Cell Plasma Membrane —
Junction Part
GOTERM CC 5 Axoneme Axoneme —
GOTERM CC 5 — Cell Junction —
GOTERM CC 5 — Cytoskeleton —
GOTERM CC ALL — Apical Junction —
Complex
GOTERM CC ALL — Apicolateral —
Plasma Membrane
GOTERM CC ALL — Cell-Cell Junction —
GOTERM CC ALL — Plasma Membrane —
GOTERM CC ALL — Occluding Junction —
GOTERM CC ALL — Tight Junction —
GOTERM CC ALL — Axoneme —
GOTERM CC ALL — Apical Part of Cell —
GOTERM CC ALL — Cell Junction —
GOTERM CC ALL — Plasma Membrane —
GOTERM CC ALL — Cilium —
GOTERM CC ALL — Cytoskeleton —
GOTERM CC FAT — Apical Junction —
Complex
GOTERM CC FAT — Apicolateral —
Plasma Membrane
GOTERM CC FAT — Cell-Cell Junction —
GOTERM CC FAT — Plasma —
Membrane Part
GOTERM CC FAT — Tight Junction —
GOTERM CC FAT — Occluding Junction —
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Table C.3: (continued.)
Annotation Exon All Exon Up Exon Down
GOTERM CC FAT — Axoneme —
GOTERM CC FAT — Apical Part —
of Cell
GOTERM CC FAT — Cell Junction —
GOTERM CC FAT — Plasma Membrane —
GOTERM CC FAT — Cilium —
GOTERM CC FAT — Cytoskeleton —
PANTHER — Cell junction —
MF ALL — protein
PIR SUMMARY GA733 — —
PIR SUMMARY Tight Junction — —
Specific
Obliteration
of the
Intercellular
Space
PUBMED ID 12477932 — —
PUBMED ID 15489334 — —
PUBMED ID 14702039 — —
PUBMED ID 16344560 — —
BIOCARTA SUMOylation — —
UCSC TFBS 75 Entries 64 Entries —
CGAP SAGE Brain Brain —
QUARTILE Ependymoma 3rd Ependymoma 3rd
CGAP SAGE Brain Brain —
QUARTILE Ependymoma 3rd Ependymoma 3rd
CGAP SAGE Brain — —
QUARTILE Ependymoma 3rd
CGAP SAGE Thyroid 3rd — —
QUARTILE Thyroid 3rd
GNF U133A Trigeminal Trigeminal Adrenal
QUARTILE Ganglion 3rd Ganglion 3rd Cortex 3rd
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Table C.4: (continued.)
Annotation Exon All Exon Up Exon Down
GNF U133A Skin 3rd Skin 3rd —
QUARTILE
GNF U133A Pancreatic — —
QUARTILE Islets 3rd
GNF U133A Whole — —
QUARTILE Blood 3rd
GNF U133A Liver 3rd — —
QUARTILE
GNF U133A Fetalbrain 3rd — —
QUARTILE
GNF U133A Spinalcord 3rd — —
QUARTILE
UNIGENE EST Uterine Tumor Uterine Tumor —
QUARTILE Disease 3rd Disease 3rd
UNIGENE EST Trachea Trachea —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Uterus Uterus —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Bladder Throid —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Throid Bladder —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Thyroid Tumor Thyroid Tumor —
QUARTILE Disease 3rd Disease 3rd
UNIGENE EST Ovary Ovary —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Pituitary Gland — —
QUARTILE Normal 3rd
UNIGENE EST Urinary Bladder — —
QUARTILE Tumor Disease
UNIGENE EST Mammary Gland — —
QUARTILE Normal 3rd
UNIGENE EST Mixed (Normal and — —
QUARTILE Tumor) disease
UNIGENE EST Esophagus — —
QUARTILE Normal
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Table C.5: Complete results from DAVID for the malignant transcript lists (1 of 6).
Annotation Exon All Exon Up Exon Down
SP COMMENT Subunit Subunit —
TYPE
SP COMMENT Interaction Interaction —
TYPE
SP COMMENT PTM Development —
TYPE Stage
SP COMMENT Function PTM —
TYPE
SP COMMENT Subcellular Function Tissue —
TYPE Location Specificity
SP COMMENT Developmental Subcellular —
TYPE Stage Location
SP COMMENT — Catalytic —
TYPE Location
SP COMMENT — Induction —
TYPE
SP COMMENT — Disease —
TYPE
SP COMMENT — Domain —
TYPE
SP PIR — Phosphoprotein —
KEYWORDS
SP PIR — Nucleus —
KEYWORDS
SP PIR — Tight Junction —
KEYWORDS
SP PIR — Cell —
KEYWORDS Membrane
SP PIR — Cell —
KEYWORDS Junction
GOTERM Chromosome — —
BP 2 Segregation
GOTERM — Apical Part Extracellular
CC 2 of Cell Matrix
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Table C.6: (continued.)
Annotation Exon All Exon Up Exon Down
GOTERM Plasma — Proteinaceous
CC 3 Membrane Part Extracellular Matrix
GOTERM — — Extracellular
CC 3 Matrix
GOTERM — — Extrinsic to
CC 3 Membrane
GOTERM — Apicolateral Proteinaceous
CC 4 Plasma Membrane Extraceullular Matrix
GOTERM Cell-cell Apical Junction —
CC 5 Junction Complex
GOTERM Apical Junction Apicolateral —
CC 5 Complex Plasma Membrane
GOTERM Apicolateral Cell-cell —
CC 5 Plasma Membrane Junction
GOTERM Plasma — —
CC 5 Membrane Part
GOTERM Cell — —
CC 5 Junction
GOTERM Cell-cell Apical Junction —
CC ALL Junction Complex
GOTERM Apical Junction Apicolateral Extracellular
CC ALL Complex Plasma Membrane Matrix
GOTERM Apicolateral Cell-cell —
CC ALL Plasma Membrane Junction
GOTERM Plasma Tight —
CC ALL Membrane Part Junction
GOTERM Occluding Occluding —
CC ALL Junction Junction
GOTERM Tight — —
CC ALL Junction
GOTERM Cell — —
CC ALL Junction
174
Table C.7: (continued.)
Annotation Exon All Exon Up Exon Down
GOTERM Plasma Complex Extracellular
CC FAT Membrane Part Apical Junction Matrix
GOTERM Cell-cell Apicolateral —
CC FAT Junction Plasma Membrane
GOTERM Apical Junction Cell-cell —
CC FAT Complex Junction
GOTERM Apicolateral Occluding —
CC FAT Plasma Membrane Junction —
GOTERM Cell Tight —
CC FAT Junction Junction
GOTERM Occluding Plasma —
CC FAT Junction Membrane Part
GOTERM Tight Apical Part —
CC FAT Junction of Cell
GOTERM — Cell —
CC FAT Junction
GOTERM — Chromosome —
CC FAT — Centromeric region
GOTERM — Condensed —
CC FAT Chromsome
GOTERM — Apical —
CC FAT Plasma Membrane
GOTERM — Condensed Chromosome —
CC FAT Centromeric Region
GOTERM — Spindle —
CC FAT
GOTERM — Plasma —
CC FAT Membrane
PANTHER — — Extracellular
MF ALL Matrix
CHROMOSOME — 8 —
PUBMED ID 15489334 15489334 1544908
PUBMED ID 12477932 12477932
PUBMED ID 19019843 18691976 —
PUBMED ID — 18669648 —
PUBMED ID — 19019843 —
PUBMED ID — 17418912 —
PUBMED ID — 18550469 —
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Table C.8: (continued.)
Annotation Exon All Exon Up Exon Down
EC NUMBER 2.7.11.1 2.7.11.1 —
UCSC TFBS 25 36 —
CGAP SAGE Stem Cell Stem Cell Mammary Gland
QUARTILE Null 3rd Null 3rd Normal Breast
Tissue From
a Breast Cancer
Patient
(Corresponding
to IDC7) 3rd
CGAP SAGE Uncharacterized Stem Cell 3rd Mammary gland
QUARTILE Tissue Mixture Breast Carcinoma
of Human Cancer Myoepithelium 3rd
Cell Lines 3rd
CGAP SAGE Stem Cell 3rd Retina Bilateral Mammary gland
QUARTILE Retinoblastoma, Null 3rd
Poorly Differentiated,
Left Orbit 3rd
CGAP SAGE — Uncharacterized Peritoneum
QUARTILE Tissue Mixture Malignant
of Human Cancer Peritoneal
Cell Lines 3rd Mesothelioma 3rd
CGAP SAGE — Brain 3rd Mammary gland
QUARTILE Normal Breast
Stroma 3rd
CGAP SAGE — Stomach Gastric Peritoneum
QUARTILE Cancer 3rd Normal 3rd
CGAP SAGE — — Brain glioblastoma
QUARTILE Infected With
Mutant EGFR
CGAP SAGE — — Mammary Gland
QUARTILE Grade II
CGAP SAGE — — Mammary Gland
QUARTILE Grade I ER+
PR+ Her2-
Invasive Ductal
Carcinoma 3rd
176
Table C.9: (continued.)
Annotation Exon All Exon Up Exon Down
CGAP SAGE — — Cartilage
QUARTILE Dedifferentiated
Chondrosarcoma
Lung Metastasis 3rd
CGAP SAGE — — Mammary Gland
QUARTILE Ductal Carcinoma In
Situ Extensive Grade
III Her2+ 3rd
CGAP SAGE — — Mammary Gland
QUARTILE Null 3rd
CGAP SAGE — — Mammary Gland
QUARTILE ER+ PR+ HER2-
QUARTILE Grade II 3rd
CGAP SAGE — — Skin Null 3rd
QUARTILE
GNF U133A Trigeminal Skin 3rd PB-BDCA4+
QUARTILE Ganglion 3rd Dentric Cells 3rd
GNF U133A Skin 3rd Pancreatic Fetabrain 3rd
QUARTILE Islets 3rd
GNF U133A Pancreatic Trigeminal Adrenal
QUARTILE Islets 3rd Ganglion 3rd Cortex 3rd
GNF U133A Fetalbrain 3rd Caudatenucleus Uterus
QUARTILE 3rd Corpus 3rd
GNF U133A Heart 3rd Heart 3rd Atrioventricular
QUARTILE Node 3rd
GNF U133A Caudatenucleus Trachea 3rd Trigeminal
QUARTILE 3rd Ganglion 3rd
GNF U133A Parietal Lymphnode 3rd Subthalamicnucleus
QUARTILE Lobe 3rd Lymphnode 3rd 3rd
GNF U133A Trachae 3rd Leukemialymphoblastic —
QUARTILE (Molt4) 3rd —
GNF U133A — Parietal —
QUARTILE Lobe 3rd —
GNF U133A — Fetallung 3rd —
QUARTILE —
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Table C.10: (continued.)
Annotation Exon All Exon Up Exon Down
UNIGENE EST Uterine Tumor Uterine Tumor Adrenal gland
QUARTILE Disease 3rd Disease 3rd normal 3rd
UNIGENE EST Esophageal Tumor Esophageal Tumor Kidney Tumor
QUARTILE Disease 3rd Disease 3rd Disease 3rd
UNIGENE EST Esophagus Esophagus Connective Tissue
QUARTILE Normal 3rd Normal 3rd Normal 3rd
UNIGENE EST Ovarian Tumor Colorectal Tumor Umbilical Cord
QUARTILE Disease 3rd Disease 3rd Normal 3rd
UNIGENE EST — Ovarian Tumor Adipose Tissue
QUARTILE Disease 3rd Normal 3rd
UNIGENE EST — Urinary Bladder Adrenal Tumor
QUARTILE Tumor Disease 3rd Disease 3rd
UNIGENE EST — Abdominal Cavity —
QUARTILE Normal 3rd
UNIGENE EST — Gastrointestinal —
QUARTILE Tumor Disease 3rd
UNIGENE EST — Stomach —
QUARTILE Normal 3rd
UNIGENE EST — Disease 3rd —
QUARTILE Disease 3rd
UNIGENE EST — Bladder —
QUARTILE Normal 3rd
UNIGENE EST — Mixed (normal and —
QUARTILE tumor) Disease 3rd
UNIGENE EST — Tongue Normal 3rd —
QUARTILE
UNIGENE EST — Larynx Normal 3rd —
QUARTILE
UNIGENE EST — Trachea Normal 3rd —
QUARTILE
UNIGENE EST — Laryngeal Cancer —
QUARTILE Disease 3rd
UNIGENE EST — Small Intestine —
QUARTILE Normal 3rd
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Table C.11: Complete results from DAVID for the benign transcript cluster lists (1
of 2).
Annotation Gene All Gene Up Gene Down
SP COMMENT Tissue — —
TYPE Specificity
PUBMED ID 12477932 12477932 —
PUBMED ID 15489334 15489334 —
PUBMED ID — 16344560 —
UCSC TFBS 48 Entries 57 Entries —
CGAP SAGE Brain Brain —
QUARTILE Ependymoma 3rd Ependymoma 3rd
CGAP SAGE Brain — —
QUARTILE Ependymoma 3rd
GNF U133A Trigeminal Skin 3rd —
QUARTILE Ganglion 3rd
GNF U133A Skin 3rd Trigeminal —
QUARTILE Ganglion 3rd
GNF U133A Whole Pancreatic —
QUARTILE Blood 3rd Islets 3rd
GNF U133A Pancreatic Whole —
QUARTILE Islets 3rd Blood 3rd
GNF U133A — Parietal —
QUARTILE Lobe 3rd
UNIGENE EST Uterine Tumor Uterine Tumor —
QUARTILE Disease 3rd Disease 3rd
UNIGENE EST Trachea Trachea —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Uterus Thyroid —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Throid Uterus —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Thyroid Tumor Thyroid Tumor —
QUARTILE Disease 3rd Disease 3rd
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Table C.12: (continued.)
Annotation Gene All Gene Up Gene Down
UNIGENE EST Bladder Bladder —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Mammary Gland Mammary —
QUARTILE Normal 3rd Gland Normal
UNIGENE EST Pituitary Gland Breast (Mammary Gland) —
QUARTILE Normal 3rd Cancer Disease 3rd
UNIGENE EST Ovary Ovary —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST — Esophagus —
QUARTILE Normal 3rd
UNIGENE EST — Pituitary Gland —
QUARTILE Normal 3rd
UNIGENE EST — Esophageal Tumor —
QUARTILE Disease 3rd
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Table C.13: Complete results from DAVID for the malignant transcript cluster lists
(1 of 6).
Annotation Gene All Gene Up Gene Down
SP COMMENT PTM PTM —
TYPE
SP COMMENT Subunit Subunit —
TYPE
SP COMMENT Interaction Induction —
TYPE
SP COMMENT Function Developmental —
TYPE Stage
SP COMMENT Domain Function —
TYPE
SP COMMENT Developmental Interaction —
TYPE Stage
SP COMMENT Induction Catalytic —
TYPE Activity
SP COMMENT Catalytic Domain —
TYPE Activity
SP COMMENT Tissue Tissue —
TYPE Specificity Specificity
SP COMMENT Alternative Subcellular —
TYPE Products Location
SP COMMENT Disease — —
TYPE
SP COMMENT Subcellular — —
TYPE Location
SP PIR Tight Tight —
KEYWORDS Junction Junction
SP PIR Cell Cell —
KEYWORDS Membrane Membrane
SP PIR — Phosphoprotein —
KEYWORDS
SP PIR — Cell —
KEYWORDS Junction
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Table C.14: (continued.)
Annotation Gene All Gene Up Gene Down
GOTERM Plasma Plasma Plasma
CC 3 Membrane Part Membrane Part Membrane Part
GOTERM Plasma — —
CC 3 Membrane
GOTERM Plasma Apicolateral Extrinsic to
CC 4 Membrane Part Plasma Membrane Membrane
GOTERM Apicolateal Plasma —
CC 4 Plasma Membrane Membrane Part —
GOTERM Plasma Apical Extrinsic
CC 5 Membrane Part Junction Complex to Membrane
GOTERM Apical Apicolateral —
CC 5 AJunction Complex Plasma Membrane
GOTERM Apicolateral Plasma —
CC 5 Plasma Membrane Membrane Part
GOTERM Cell-Cell Cell-Cell —
CC 5 Junction Junction
GOTERM — Chromosome, —
CC 5 Centromeric
Region
GOTERM — Condensed —
CC 5 Chromsome
GOTERM — Apical —
CC 5 Plasma Membrane
GOTERM — Condensed —
CC 5 Chromosome,
Centromeric
Region
GOTERM Plasma Apical Junction Extrinsic
CC ALL Membrane Part Complex to Membrane
GOTERM Apical Junction Apicolateral —
CC ALL Complex Plasma Membrane
GOTERM Apicolateral Tight —
CC ALL Plasma Membrane Junction
GOTERM Cell-Cell Occluding —
CC ALL Junction Junction
GOTERM Occluding Plasma —
CC ALL Junction Membrane Part
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Table C.15: (continued.)
Annotation Gene All Gene Up Gene Down
GOTERM Tight Cell-cell —
CC ALL Junction Junction
GOTERM Plasma Chromsome, —
CC ALL Membrane Centromeric
Region
GOTERM — Condensed —
CC ALL Chromosome
GOTERM — Apical —
CC ALL Plasma Membrane
GOTERM — Condensed —
CC ALL Chromosome
Centromeric
Region
GOTERM Plasma Apical Junction Extrinsic
CC FAT Membrane Part Complex to Membrane
GOTERM Apical Junction Apicolateral —
CC FAT Complex Plasma Membrane
GOTERM Apicolateral Plasmal —
CC FAT Plasma Membrane Membrane Part —
GOTERM Cell-Cell Occluding —
CC FAT Junction Junction
GOTERM Plasma Tight —
CC FAT Membrane Junction —
GOTERM Occluding Cell-cell —
CC FAT Junction Junction
GOTERM Tight Chromosome —
CC FAT Junction Centromeric
Region
GOTERM — Plasma —
CC FAT Membrane
GOTERM — Condensed —
CC FAT Chromosome
GOTERM — Apical Plasma —
CC FAT Membrane
GOTERM — Condensed —
CC FAT Chromosome,
Centromeric
Region
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Table C.16: (continued.)
Annotation Gene All Gene Up Gene Down
GOTERM — Spindle —
CC FAT
GOTERM — Anchored to —
CC FAT Plasma
Membrane
GOTERM — Cell —
CC FAT Junction
Panther — Cell Junction —
MF ALL Protein
PUBMED ID 15489334 15489334 —
PUBMED ID 12477932 12477932 —
PUBMED ID 18669648 18669648 —
PUBMED ID — 18691976 —
PUBMED ID — 17418912 —
PUBMED ID — 18550469 —
PUBMED ID — 19008095 —
PUBMED ID — 16964243 —
PUBMED ID — 9892664 —
EC NUMBER 2.7.11.1 2.7.11.1 —
REACTOME Cell-Cycle Cell-Cycle —
PATHWAY Mitotic Mitotic
UCSC TFBS 35 39 —
CGAP SAGE Stem Stem —
QUARTILE Cell 3rd Cell 3rd —
CGAP SAGE Stem Cell Stem Cell —
QUARTILE Null 3rd Null 3rd
CGAP SAGE Uncharacterized Retina Bilateral —
QUARTILE Tissue Mixture Retinoblastoma
of Human Cancer Poorly Differentiated —
Cell Lines 3rd Left Orbit 3rd —
CGAP SAGE — Uncharacterized —
QUARTILE Tissue Mixture
of Human Cancer
Cell Lines 3rd
CGAP SAGE — Liver Poorly —
QUARTILE Differentiated
Adenocarcinoma 3rd
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Table C.17: (continued.)
Annotation Gene All Gene Up Gene Down
GNF U133A Trigeminal Pancreatic Fetalbrain 3rd
QUARTILE Ganglion 3rd Islets 3rd
GNF U133A Pancreatic Skin 3rd —
QUARTILE Islets 3rd
GNF U133A Skin 3rd Trigeminal —
QUARTILE Ganglion 3rd
GNF U133A Heart 3rd Heart 3rd —
QUARTILE
GNF U133A Fetalbrain 3rd Caudatenucleus —
QUARTILE 3rd
GNF U133A Parietal Trachea —
QUARTILE Lobe 3rd 3rd
GNF U133A Caudatenucleus Parietal —
QUARTILE 3rd Lobe 3rd
GNF U133A Trachea 3rd Lymphnode —
QUARTILE 3rd
UNIGENE EST Uterine Tumor Uterine Tumor —
QUARTILE Disease 3rd Disease 3rd
UNIGENE EST Esophageal Tumor Esophageal Tumor —
QUARTILE Disease 3rd Disease 3rd
UNIGENE EST Esophagus Esophagus —
QUARTILE Normal 3rd Normal 3rd
UNIGENE EST Ovarian Tumor Urinary Bladder —
QUARTILE Disease 3rd Tumor 3rd
UNIGENE EST Urinary Bladder Ovarian Tumor —
QUARTILE Tumor Disease 3rd Disease 3rd
UNIGENE EST Gastrointestinal Oral Tumor —
QUARTILE Tumor Disease 3rd Disease 3rd
UNIGENE EST Abdominal Cavity Abdominal Cavity —
QUARTILE Normal 3rd Normal 3rd —
UNIGENE EST Colorectal Tumor Gastrointestinal —
QUARTILE Disease 3rd Tumor Disease 3rd —
UNIGENE EST Oral Tumor Colorectal Tumor —
QUARTILE Disease 3rd Disease 3rd —
UNIGENE EST Mixed (Normal and Bladder —
QUARTILE Tumor) Disease 3rd Normal 3rd —
UNIGENE EST Bladder Mixed (Normal and —
QUARTILE Normal 3rd Tumor) Disease 3rd —
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Table C.18: (continued.)
Annotation Gene All Gene Up Gene Down
UNIGENE EST — Stomach Normal —
QUARTILE 3rd
UNIGENE EST — Small Intestine —
QUARTILE Normal 3rd
UNIGENE EST — Tongue Normal —
QUARTILE 3rd
UNIGENE EST — Ovary Normal —
QUARTILE 3rd
UNIGENE EST — Trachea Normal —
QUARTILE 3rd
